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Introduction 
Avery and Mead showed in 1959 that pulmonary surfactant deficiency is a major factor in 
the pathophysiology of respiratory distress syndrome (RDS) (1). In 1980 Fujiwara et al. 
administered exogenous surfactant for the first time successfully to preterm infants with 
RDS (2). This was followed by numerous clinical trials that demonstrated a decrease in 
death rates and complications (3, 4). There are now accumulating data which suggest that 
a disturbed surfactant metabolism plays a role in several other neonatal lung diseases, 
such as congenital diaphragmatic hernia (CDH), meconium aspiration syndrome (MAS), sur-
factant protein-B (SP-B) deficiency, and neonatal pneumonia and/or sepsis. Also in adult 
respiratory distress syndrome, asthma, infectious lung diseases, and interstitial lung dis-
eases (5-9). Insufficient surfactant function could be due to a disturbance in surfactant ki-
netics or secondary to an inactivation of surfactant by several components. Surfactant 
therapy possibly plays a therapeutical role in the management of these clinical conditions.  
This review will focus on the surfactant metabolism in term neonatal lung diseases. We 
will discuss the role of surfactant in CDH, MAS, SP-B deficiency, and neonatal pneumonia 
and/or sepsis. First, we will briefly review the functions and composition of surfactant 
and the normal cellular metabolism of surfactant. 
 
 
Surfactant function and composition 
The primary function of surfactant is to decrease the surface tension at the air-liquid in-
terface in the alveoli and distal bronchioli, to promote lung expansion during inspiration 
and to prevent alveolar collapse at expiration. Besides these biophysical properties, sur-
factant plays also an important role in pulmonary host defense (10, 11). 
Surfactant is composed of a complex mixture of lipids (~90%) and proteins (~10%), which 
is strikingly comparable across species including human (12, 13). Of the surfactant lipids, 
80 to 90% are phospholipids, from which phosphatidylcholine (PC) is the major phosphol-
ipid, accounting for 70-80% (13). Other lipids are phosphatidylglycerol (PG), 
phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylserine (PS), 
sphingomyelin, cholesterol, triacylglycerols and free fatty acids (14). The PC molecule 
comprises a glycerol backbone, two fatty acids, phosphate, and a choline moiety. 
Approximately 60% of the PC contains two saturated fatty acids (sat PC, DSPC) of which 
most is dipalmitoyl (16:0/16:0) (DPPC). DPPC is the principal surface tension lowering 
component of surfactant. Most other PC molecules have a fatty acid with one double 
bound in the 2 position of the glycerol molecule.  
Four surfactant proteins have been identified (15, 16). SP-A and SP-D are hydrophilic, 
and SP-B and SP-C are hydrophobic. They are either exclusively lung-associated or pre-
dominately found in the lung. SP-A is the most abundant surfactant protein and is essen-
tial for the formation of tubular myelin, it functions as a regulator of phospholipid inser-
tion into the monolayer, and modulates the uptake and secretion of phospholipids by type 
II cells (17). However, mice that lack SP-A have indeed no tubular myelin but have normal 
lung function and surfactant metabolism even when exercised (18). Furthermore, together 
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with SP-D, SP-A has an important role in the lung defense. SP-A can both depress and acti-
vate macrophage function, it binds to multiple pathogens and facilitates phagocytosis of 
pathogens by macrophages and clearance from the airspace (10). SP-D also binds patho-
gens and facilitates their clearance (10). The absence of SP-D results in increased surfac-
tant lipid pools in the airspaces and emphysema in lungs of mice (19). SP-B also plays a 
role in the formation of tubular myelin, it promotes together with SP-C the rapid phos-
pholipid insertion into the air-liquid interface (20, 21), and SP-B influences the molecular 
ordering of the phospholipid layer (22, 23). Infants with a genetic absence of SP-B develop 
lethal respiratory distress after birth, which can only be overcome by a lung transplanta-
tion (24). The lack of SP-B cause a loss of lamellar bodies, tubular myelin, and an incom-
pletely processed SP-C (25). SP-C regulates the phospholipid ordering in the monolayer, 
enhances the reuptake of surfactant lipids in vitro, and may have a role in surfactant ca-
tabolism (20, 26). Mice that lack SP-C have a normal surfactant and lung function, and 
have no abnormalities in SP-B processing (27). However, the stability of surfactant at low 
lung volumes is decreased. On the other hand, overexpression of SP-C mature peptide in 
type II cells of transgenic mice results in lethal, neonatal RDS (28). 
 
 
 
 
Figure 1. Schematic illustration of surfactant phosphatidylcholine metabolism 
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Surfactant synthesis, secretion and clearance 
The synthesis, secretion and clearance of surfactant is a complex sequence of biochemical 
synthetic events, subcellular organelle growth, and maturational events which take place 
in the alveolar type II cell of the lung (Figure 1). Surfactant PC is synthesized from phos-
pholipid precursors (eg, fatty acids, glycerol, choline, glucose) in the Golgi apparatus (29, 
30). The CDP-choline pathway is the principle pathway involved in the de novo synthesis 
of surfactant PC (31). Shortly, choline is brought into the cell and is phosphorylated by 
choline kinase. The synthesis of the activated intermediate, CDP-choline is catalyzed by 
phosphocholine cytidyltransferase (CT). Finally, the phosphocholine is transferred via di-
acylglycerol to phosphocholine by the CDP-choline: 1,2-diacylglycerol phosphocholine-
transferase. The enzyme CT plays an important regulatory role in de novo synthesis of PC 
(32, 33). In the fetal type II cell intracellular glycogen stores appear to be a major source 
of the glycerol backbone of PC (34), whereas in the adult lung glucose from the circulation 
is a major substrate for the glycerol backbone of PC. Choline is mainly derived from the 
diet (35). The fatty acids of surfactant phospholipids are synthesized de novo in the type II 
cell, or taken up from the blood, or are derived from recycling of alveolar surfactant 
phospholipids (29). The exact relative contribution of the fatty acids supplied by the cir-
culation, those synthesized de novo, and those supplied by recycling of alveolar phosphol-
ipids to the formation of surfactant lipids by the type II cell is still unknown. Lipogenesis 
from glucose and lactate among other substrates, is probably of particular importance to 
supply fatty acids for surfactant phospholipid synthesis in the prenatal lung (36, 37). In 
the more mature lung, fatty acids of surfactant PC are derived mainly from uptake of 
fatty acids from plasma (38). The composition of the newly formed PC is modified to 
achieve high levels of DPPC, by acyl remodeling, mainly involving sequential actions of 
phospholipase and acyltransferase enzymes (39). 
Lamellar bodies are condensed, highly structured lipoprotein packages, that serve as 
the intracellular storage form of surfactant. Lamellar bodies are secreted into the alveolar 
space by fusing of their limiting membrane with the plasma membrane (40). This can be 
stimulated by stretch of the type II cell, by beta agonists, by purinergic agonists, such as 
ATP, and various other agents (41, 42). After secretion the lamellar bodies unravel to form 
loose membranous arrays and lattice-like structures, the tubular myelin. At alveolar sur-
face expansion during inspiration, surfactant components insert from the hypophase 
(epithelial lining fluid (ELF)) into the monolayer. At expiration the alveolar surface re-
duces and the monolayer is compressed, thereby squeezing out some surfactant proteins, 
unsaturated PC, and other lipids. By this mechanism, the monolayer comprises mainly the 
most surface tension lowering component DPPC during compression (43).  
Due to the cyclic changes during respiration the surfactant monolayer is degraded to 
small aggregates, representing ‘inactive surfactant’ or ‘used surfactant’. By differential 
centrifugation these small aggregates can be separated from the lamellar bodies and tu-
bular myelin, the ‘large aggregates’ (active surfactant) (44-46). 
The alveolar surfactant can be cleared by different pathways. Surfactant components 
can be reutilized through uptake by the type II cell, incorporated into the lamellar bodies 
and then directly resecreted (47, 48). Another way is by degradation and utilization of 
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surfactant components to synthesize new surfactant lipids or proteins. Finally, surfactant 
can be removed from the lung, either as intact molecules or as degraded products (41). 
The efficiency of recycling is age-dependent, and was calculated to be 90% in young pigs 
(38), >90% in the newborn rabbit and 50% in adult rabbits (47, 49). 
 
 
Surfactant kinetics 
The time required for de novo PC synthesis, secretion, and significant alveolar accumula-
tion has been studied in animals using radioactive labeled substrates. Following the in-
travascular injection of radiolabeled palmitic acid into newborn rabbits or sheep, maximal 
incorporation of the labeled precursors into lung PC occurs within ~10 minutes (50, 51). 
However, recovery of labeled alveolar surfactant PC does not reach its peak until about 35 
to 45 hours. Compared to adult animals the time to reach peak specific activity is longer 
in term newborns (52). Preterm ventilated lambs show similar to the term ventilated 
lambs a slow movement of surfactant PC from the synthetic sites to the alveolus (53).  
In preterm infants with RDS that received a 24 hour intravenous infusion of the stable 
isotope [U-13C]glucose, the palmitic acid became labeled after ~19 hours and was maxi-
mally labeled after ~70 hours (Table 1) (54). By using [U-13C]palmitic acid or [U-
13C]linoleic acid as precursors in preterm infants with RDS, surfactant PC became labeled 
after ~20 hours and ~16 hours, respectively, after start of infusion, and was maximally la-
beled after ~71 hours and ~85 hours, respectively (55). Recently, Bohlin et al. measured 
[1-13C]acetate incorporation in surfactant DPPC of preterm infants with RDS and term in-
fants without lung disease (56). The preterm infants showed first incorporation of label af-
ter ~13 hours, and reached maximal enrichment after ~82 hours, whereas term infants 
reached first enrichment of label at ~7 hours and maximal enrichment at ~35 hours. Term 
infants without significant lung disease who received [U-13C]palmitic acid had a first ap-
pearance of label in surfactant DPPC after ~9 hours, and a maximal incorporation of label 
at ~51 hours (57). Kinetic parameters in human infants studied with different precursors 
are depicted in Table 1. As in animal studies, these results of human stable isotopes stu-
dies show slower surfactant kinetics in preterm infants compared to term infants. The 
kind of precursor used is of no difference to the results. 
The fractional synthesis rate (FSR) of surfactant after infusion of labeled glucose ren-
ders the percentage of surfactant that is synthesized from glucose per day. In premature 
infants who received a 24 hour 13C-glucose infusion, the FSR was calculated to be ∼3%/day 
(54). Preterm infants who received labeled palmitic acid and linoleic acid had a FSR of 
∼12%/day and ∼25%/day, respectively (55). FSR in preterm and term infants after infusion 
of labeled acetate was ~2%/day and ~15%/day, respectively (56). When term infants re-
ceived labeled palmitic acid, the FSR was found to be ~17%/day (57) (Table 1). These data 
show a lower FSR in preterm infants compared to term infants. When [U-13C]palmitic acid 
was used as precursor, a higher FSR was found.  
The slow secretion and alveolar accumulation of surfactant are balanced in the term 
and preterm lungs by slow catabolism and clearance. For example, the half-life of radio-
labeled surfactant phospholipid given endotracheally to term lambs is about 6 days (58). 
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However, in premature baboons using the same method the half-life is about 30 hours 
(59), which may be due to more recycling in premature animals, and to species differ-
ence. Half-lives calculated in animal studies differ depending on gestational age, postna-
tal age, the labeled substrate used and the surfactant pool studied. 
Half-life measurements in human infants have been performed mainly in preterm infants 
with RDS. Using different markers such as PG, 2H-DPPC, [U-13C]palmitic acid labeled DPPC 
which were given endotracheally, the half-life of PG, respectively surfactant PC was about 
30 to 50 hours (60-62). The half-life of 13C-labeled PC-palmitate measured in tracheal as-
pirates of preterm infants with RDS after labeled glucose infusion was ~113 hours (54, 63). 
In preterm infants the surfactant half-life after infusion of [U-13C]palmitic acid and [U-
13C]linoleic acid was ~98 hours and ~47 hours, respectively (64). The half-life of preterm 
infants with RDS who received intravenous [1-13C]acetate was ~106 hours, whereas term 
infants with normal lungs had a half-life of ~28 hours (Table 1) (56). Thus, surfactant half-
live is different between preterm and term infants, with a slower disappearance of label 
in the preterm infants. 
 
 
Table 1. Surfactant kinetic parameters in infants studied with different precursors 
 
Premature Infants 
Term Infants  
without lung  
disease 
Term infants with severe 
lung disease 
precursors 13C-GLU 13C-PA 13C-LA 13C-AC 13C-PA 13C-AC 13C-PA 13C-LA 13C-AC 
Tapp (h) 19 20 16 13 9 7 9 10 11 
Tmax (h) 70 71 85 82 51 35 51 46 53 
T½ (h) 113 98 47 106 43 28 64 59 68 
FSR (%/d) 3 12 25 2 17 15 28 50 3 
13C-GLU, [U-13C]glucose; 13C-PA, [U-13C]palmitic acid; 13C-LA, [U-13C]linoleid acid; 13C-AC, [1-13C1]-
acetate. All labels were administered via intravenous infusion during 24 hours. 
 
 
In two reports, term critically ill patients were studied using different precursors for 
surfactant metabolism (56, 64). After infusing labeled fatty acids in a group of critically ill 
patients with various diagnoses, marked differences in PC kinetics among infants were no-
ticed (64). Term infants with primary respiratory failure had a surfactant metabolism simi-
lar to preterm infants with RDS, suggesting either delayed maturity of the surfactant sys-
tem or disruption from the underlying disease (56). 
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With stable isotopes, apparent differences in surfactant metabolism could result from 
differences in tracer metabolism, from true differences in surfactant synthesis and clear-
ance, or from differences in the size of the unlabeled surfactant pool. That is, a small 
unlabeled pool would result in an apparent increase of FSR by an unchanged absolute syn-
thesis of surfactant. 
In summary, animal studies show a slower surfactant turnover in newborns compared to 
adults. In human studies using stable isotopes the surfactant PC metabolism is even slower 
in preterm infants with RDS compared to term infants without lung disease. Moreover, 
term infants with respiratory failure have abnormal surfactant metabolism that is similar 
to that of preterm infants with RDS. 
 
 
Surfactant pool sizes 
In most species studied, phosphatidylcholine, DPPC in particular, increases in the last tri-
mester of the pregnancy (65-67). Lamellar bodies containing PC are first identified in hu-
man lung at 24 weeks of gestation and at 19 days of a 22-day gestation in the rat (68). In 
amniotic fluid, surfactant concentrations increase, reflecting accumulation of alveolar 
surfactant. This increase is also reflected in an increasing lecithin/sphingomyelin (L/S) ra-
tio (69). During and shortly after birth large amounts of surfactant are released into the 
alveolar space (70, 71). Since there is no depletion of the intracellular surfactant pool, 
this increase in alveolar pool shortly after birth is accompagnied by an increase in the de 
novo surfactant synthesis (72, 73). However, incorporation studies as mentioned above, 
showed a slow surfactant metabolism, which means that it takes a long time before de 
novo synthesized surfactant is detectable in the alveolar space. Increased lung tissue and 
alveolar surfactant pools can only be explained by the rapid mobilization of surfactant 
from other pools (lamellar bodies, small vesicles) within type II cells.  
The amount of lung tissue and alveolar surfactant changes with age. Surfactant pools 
are very high in the newborn period in all species studied to date, and decrease subse-
quently with lung maturity. In the rat, alveolar and lung tissue pools of both saturated PC 
and SP-A decrease with age (74, 75). Surfactant pool size/kg body weight decreases to 
adult value by 12 days of age (76). In humans total amounts of saturated PC in alveolar 
washes at autopsy also decreases with age (77, 78). Saturated PC in lung tissue was similar 
in all age groups (78). 
Animal studies showed a 10-fold higher surfactant pool size in term neonates compared 
to adults (79). Newborns from all animal species have from 30 to 100 µmol/kg (23-76 
mg/kg) surfactant in alveolar washes (80). In preterm infants with RDS, surfactant pool 
sizes in the alveolus are low (2-10 mg/kg) (52, 80), due to immaturity of the lungs, espe-
cially of the type II cells. In adults pool sizes are smaller because the lung structure, al-
veolar lining fluid, and surfactant film have adapted maximally to optimal function. The 
mean amount of total lung saturated PC/kg for the adult human was ~22 mg/kg, and ~2 
mg/kg in alveolar wash at autopsy (78).  
Hallman et al. showed an apparent pool size of ~15 mg/kg in human preterm neonates 
with RDS (61). They used PG as label to measure surfactant pool size. With the same 
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method Griese et al. calculated an apparent pool size of ~17 mg/kg sat PC in preterm 
neonates with RDS (81). Pool size measurements in preterm infants with RDS using en-
dotracheal administered stable isotope (13C-DPPC) in combination with a treatment dose 
of surfactant (100 mg/kg) showed an endogenous surfactant PC pool size (before treat-
ment) of ~10 mg/kg (62). 
In conclusion, surfactant pool size increases in late pregnancy, followed by a gradually 
decrease after birth to adult values. Among species, humans have the smallest alveolar 
pool sizes, whereas the amount of saturated PC in lung tissue is similar across species. The 
lower alveolar surfactant pool sizes make the human lung particularly vulnerable to sur-
factant dysfunction in case of lung injury. 
 
 
Congenital diaphragmatic hernia 
Although CDH lungs are immature (82) and show morphologically some resemblance to 
lungs of preterm infants with RDS, it is still unclear whether a primary surfactant defi-
ciency is present in human CDH. Several animal models have been developed to study the 
pathogenesis of CDH (83).  
The classical model of CDH consists of creating CDH by surgical intervention at the 80th 
day of gestation in lambs. By thoracotomy of the fetus the left diaphragm is opened and 
the stomach, omentum and small intestines are gently pulled into the chest. Then the 
gestation is allowed to progress to term. In bronchoalveolar lavage fluid of these surgically 
created CDH lambs the amount of phospholipids, PC, SP-A and SP-B is decreased compared 
to controls (84-87). However, the amniotic L/S ratio is not different in CDH lambs com-
pared to control lambs (84). In vitro studies in isolated type II cells of CDH lamb show a 
decreased incorporation of choline into PC (85, 87), suggesting decreased surfactant syn-
thesis in CDH (Table 2). 
In rodents (rats and mice) CDH can be created using a toxicological approach by giving 
nitrofen (2,4-dichlorophenyl-p-nitrophenyl ether) to pregnant rats on days 9 or 10 of ges-
tation (88, 89). In the nitrofen-induced CDH rat model, total phospholipids, sat PC, and 
SP-A in lung tissue are lower compared to control rats (Table 2) (90-94). By using antibo-
dies towards sphingomyelin and disaturated PC, the lungs of the nitrofen-exposed rats 
demonstrated an impaired secretion of sat PC into the alveoli by accumulation of antibo-
dies in the type II cells (93). In controls antibodies to sat PC were distributed on the sur-
face of the alveoli, showing secretion of surfactant. 
Human studies show contradictionary results about the presence of a surfactant defi-
ciency in CDH. L/S ratios in amniotic fluid have been reported to be both normal and de-
creased (95, 96). SP-A and sat PC concentrations in amniotic fluid were lower in fetuses 
with CDH who died or required extracorporeal membrane oxygenation (ECMO) (97). Au-
topsy studies in CDH patients who died at birth or within the first days of life showed de-
creased SP-A in lung tissue (98, 99). However, we reported earlier that the L/S ratio, PC 
and, phosphatidylglycerol concentrations in bronchoalveolar lavage fluid from CDH infants 
were not different from age-matched control patients (100). In this study we found a PC 
concentration of ~3 mg/ml and ~6 mg/ml ELF in ventilated and ECMO treated CDH pa-
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tients, respectively. Cogo et al. measured lower amounts of DSPC and SP-A in tracheal as-
pirates of CDH patients who did not required ECMO compared to control subjects (∼2 ver-
sus ∼5 mg DSPC/ml ELF) (57). After a 24 hour infusion of [U-13C]palmitic acid, the label 
was incorporated into surfactant PC after ∼8 hours, and reached a maximum enrichment 
after ∼50 hours. Fractional synthesis was ∼20% per day, and half-life of DSPC was ~59 
hours in CDH patients. Moreover, no significant difference was observed in these kinetics 
parameters of surfactant between the CDH and control subjects (Table 2) (57).  
The use of surfactant therapy in the CDH animal models is still contorversial. In the ex-
perimental lamb model prophylactic exogenous surfactant therapy caused an improve-
ment in gas exchange, lung mechanics, and hemodynamics (101-103). In the nitrofen-
induced rat model exogenous surfactant administration only had a transient effect on lung 
volume (104). However, surfactant treatment was not given prophylactically in these rats.  
There are only a few reports about surfactant treatment in human CDH patients (105-108). 
In all these reports the groups of infants studied were small. Already in the early nineties, 
a study performed by Bos et al. showed an improvement of oxygenation in three of the 
five infants with CDH after surfactant administration (106). In another study in which sur-
factant was given prophylactically to high-risk neonates with CDH, all three infants sur-
vived (105). Surfactant treatment in nine infants with CDH who required ECMO had no 
beneficial effect on the lungs, morbidity, and survival (108). 
Other treatments that could influence the surfactant status in CDH are the administra-
tion of corticosteroids or thyroid hormones. Corticosteroids give an increase in synthesis of 
sat PC and surfactant proteins in the lung. This is predominately induced by stimulation of 
various key enzymes involved in the synthesis of surfactant (109). The administration of 
antenatal glucocorticoid treatment is nowadays an established therapy for all fetuses be-
tween 24 and 34 weeks of gestation at risk for preterm delivery (110). The effect of pre-
natal hormonal therapy in CDH patients is not clear yet. Animal studies showed an in-
crease of DSPC, surfactant proteins, oxygenation and survival after antenatal corticoste-
roids (111-115). Combined use of antenatal corticosteroids with antenatal thyrotropin-
releasing hormone (TRH) acts synergistically in lung maturation (116, 117). However, 
clinical trials showed no beneficial effects or even adverse maternal and neonatal effects 
when TRH was added to antenatal corticosteroid treatment in premature labor (118, 119). 
Only one report is available about the use of antenatal corticosteroids in human CDH 
(120). This study describes three high-risk CDH patients who survived, and were extubated 
within 10 days after up to 7 or 8 doses of antenatal corticosteroids (120). But with the in-
creasing evidence of adverse perinatal and long-term effects of prenatal corticosteroids 
(121), this treatment option should be used with caution.  
Tracheal occlusion is another antenatal therapeutic strategy which enhances pulmonary 
arterial and alveolar developmental growth (122-124). It has been hypothesized that the 
elevated intrapulmonary distending force from the increased volume of fetal lung fluid 
accounts for the increase in lung mass. However, some animal studies have demonstrated 
a profound decrease in type II cells and a deficiency of surfactant due to the tracheal oc-
clusion (125-128). Especially timing and duration of tracheal occlusion are key factors de-
termining outcome. 
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Until today, the presence of a primary surfactant deficiency in CDH is still not clear. We 
suggest an inactivation of surfactant function due to the intensive ventilation with nega-
tive side effects (129), which is often necessary in CDH patients. Although, a decreased 
surfactant synthesis due to severe hypoplasia of the lungs (especially in the more severe 
cases of CDH) cannot be excluded.  
 
 
Table 2. Review of literature about surfactant parameters in animal and human neonates 
with severe lung disease 
 (DS)PC in 
BAL or TAS 
(DS)PC in 
lung tissue
surfactant  
proteins 
L/S 
ratio 
precursor  
incorporation 
references 
Congenital diaphragmatic hernia  
lambs ↓  ↓ SP-A/B BAL = ↓ 83-86 
rats  ↓ ↓ SP-A tissue =  89-93 
human 
  
↓ SP-A tissue, 
TAS, amnion fluid
↓/= = 57, 94-99 
Meconium aspiration syndrome 
rats = = ↓ SP-A/B BAL =  141 
piglets =     142 
human =  = SP-A BAL   143 
Pneumonia 
rats     ↑ 227 
human ↓  ↓ SP-A 
= SP-B BAL 
  209, 211 
SP-B deficiency 
mice 
 = 
no SP-B 
pro SP-C 
 = 189,190 
human ↑  no SP-B 
pro SP-C 
 ↑/= 194 
 
 
Meconium aspiration syndrome 
Aspiration of meconium directly inhibits surfactant function and induces an inflammatory 
response in the lung with possible detrimental effects to the type II cell function and 
thereby surfactant metabolism. Surfactant function is inhibited by meconium in a concen-
tration dependent way (130-132). Meconium increases the minimum and maximum surface 
tensions, and lowers the surface spreading rate of surfactant (130, 131, 133, 134). Separa-
tion of the lipid fraction from the water fraction of meconium by organic extraction exhi-
bited a stronger inhibitory activity of meconium in the chloroform fraction (lipid fraction) 
which contains free fatty acids, triglycerides, and cholesterol, compared to the water-
methanol fraction which contains proteins and bilirubin (130). Besides an effect on the 
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physical surface properties, meconium also changes the morphology of surfactant (133, 
134).  
Several mechanism are involved in the inactivation by meconium. One of these mecha-
nisms is the infiltration of phospholipids other than DPPC, or other lipids (e.g. free fatty 
acids) in the surface film (135). This forms an unstable surface monolayer that easily col-
lapses at high surface tension. Secondly, the formation of aggregates between surfactant 
and meconium constituents (usually proteins) may delay the formation of the surface film 
by competitive inhibition of phospholipid entry into the surface monolayer (136, 137). A 
third mechanism is degradation of surfactant lipids and proteins by enzymes (lipases, pro-
teases) (138-140). 
Studies about the surfactant concentration and composition in MAS are scarce. Cleary et 
al. found decreased SP-A and SP-B levels in the large aggregates of surfactant in a rat 
model of MAS (141). However, phospholipid and DPPC levels did not change significantly 
after meconium installation in either the lung tissue or BAL. In a newborn piglet model 
with MAS also no differences in phospholipids levels in BAL were found compared to con-
trols (142). Analyses of BAL fluid from 8 infants with MAS receiving mechanical ventilation 
revealed no difference in phospholipid and SP-A content compared to control subjects 
(143). However, concentrations of non-surfactant protein and albumin were >3 times 
those found in normal lung. In MAS patients who required ECMO surfactant phospholipids, 
PC, and SP-A in tracheal aspirates increased during the ECMO treatment (144-146). To our 
knowledge, only one study investigated the surfactant kinetics in the presence of me-
conium (147). This in vitro study in type II cells of adult rats showed that meconium in low 
concentrations (1%) increases the PC secretion by type II cells, but had no effect on sur-
factant PC synthesis. Higher meconium concentrations were toxic to the cultured type II 
cells, though the effect of these higher concentrations on surfactant synthesis is not 
known (Table 2). 
Exogenous administration of surfactant in animal models of MAS improves lung function 
and morphology, especially when surfactant is given at a high dose (200 mg/kg) (148-151). 
The clinical efficacy of surfactant therapy in MAS has been suggested by several nonran-
domized studies (6, 8, 152, 153). These studies showed an improvement in oxygenation, 
although most infants required two or more doses of exogenous surfactant. Two random-
ized controlled trials have been reported (154, 155). Findlay et al. administered three 
doses of bovine surfactant in a higher than standard dose (150 mg/kg per dose) to 20 in-
fants with MAS. Surfactant treated infants had improved oxygenation, a reduction in se-
verity of pulmonary morbidity, a decrease in ECMO requirement, and a decrease in hospi-
talization time compared to the control group (n=20) (154). In the latter trial surfactant 
was not given as a bolus, but was continuously infused over a period of 20 minutes, 
started within 6 hours after birth. In a larger trial performed by Lotze et al. term infants 
with severe respiratory distress received four doses of bovine surfactant (100 mg/kg per 
dose) at ~30 hours after birth. Half of these patients had MAS as the cause of their respi-
ratory failure. These authors were unable to demonstrate a difference in oxygenation, 
pulmonary morbidity, or hospitalization, although the need for ECMO in the surfactant 
treated group was decreased (155). From these studies it can be suggested that surfactant 
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therapy in MAS is most effective when given in the early phase of the respiratory failure, 
and at a high dose. 
Moreover, the type of surfactant may play a role in the degree of benefit (156). Natural 
lavage surfactant containing SP-A is most resistant to meconium. Followed by recombinant 
surfactant protein-C and leucine/lysine polypeptide surfactant (KL4-surfactant), and the 
modified natural surfactants (Curosurf, Alveofact, Survanta). These data suggest that the 
surfactant used for treatment of MAS requires another composition than the surfactant 
used for treatment of RDS.  
The optimal method of administration of surfactant in MAS is still a point of discussion. 
Paranka et al. first described a surfactant lavage of MAS in piglets (157). A lavage with 
surfactant could remove meconium, inflammatory cells, edema fluid, proteins, and other 
debris from the lungs, leaving behind a layer of functional exogenous surfactant. Similar 
studies were performed in an adult rabbit model and in newborn rhesus monkeys (158-
160). All these animal studies showed a beneficial effect from surfactant lavage on pul-
monary function, radiographic and histological appearance. There are a few reports about 
lavage therapy in human neonates with MAS (161-164). Two studies performed first a lav-
age with saline followed by standard surfactant administration, to overcome the airway 
obstruction and prevent non-homogenous distribution of surfactant (161, 162). Improve-
ment in saturation and oxygen index were noticed, however, the patients groups were 
small and no control group was included. Lam et al. treated 6 infants with MAS with a sur-
factant lavage (15 ml/kg surfactant solution with a concentration of 5 mg phospholi-
pids/ml) (163). They found a more rapid improvement in oxygenation and a shorter dura-
tion of ventilation in the lavaged group compared to historic controls. Recently, a multi-
center, randomized controlled trial comparing surfactant lavage with standard treatment 
of MAS has been reported (164). In lavaged infants, diluted Surfaxin (KL4-surfactant, 2.5 
mg/ml in a volume of 8 ml/kg) was instilled twice, followed by third, more concentrated 
(10 mg/ml) surfactant lavage. A shorter duration of ventilation and a persisting improve-
ment in oxygenation were noted, but the differences were not significant.  
Combinations of surfactant therapy with other approaches to treatment in MAS have 
been investigated (165, 166). These studies suggest that surfactant treatment in combina-
tion with high frequency ventilation or partial liquid ventilation had better effects on oxy-
genation and lung function than conventional ventilation alone. However, the relative ef-
ficacy of these combination therapies remains to be tested. 
A variety of substances are found to play a preventive role in the inactivation of surfac-
tant. (136, 167-169). Polymers (such as polyethylene glycol and dextran) added to surfac-
tant and instilled into the trachea of rats with MAS improves gas exchange, pulmonary 
mechanics, and histological appearance of the lungs (170, 171). The effect of polymers is 
not limited to a single inhibitor, or even a single mode of inhibition. This makes it possible 
to use polymers in the treatment of all kinds of lung injury where inactivation of surfac-
tant plays a role (172). However, also contradictionary results have been reported (173). 
Polyethylene glycol added to surfactant attenuated surfactant responses in adult rabbits 
with lung injury. The exact mechanism of overcoming the surfactant inhibition with poly-
mers has yet to be elucidated. Also the safety and efficacy of the use of polymers in hu-
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mans with lung disease have to be considered. Almaas et al. found that by the addition of 
ferric chloride, copper chloride, or acetic acid the inhibitory effect of meconium on sur-
factant could be abolished (136). They suggested that the contra-inhibition was caused by 
lowering the pH, and that meconium inhibition of surfactant is pH-dependent. 
In conclusion, surfactant inactivation seems to play a more important role in the patho-
physiology of MAS than does a surfactant deficiency. However, surfactant metabolism in 
MAS has not been studied yet. Surfactant therapy seem to be effective in MAS, and should 
probably be given at a high dose and at an early stage in the development of the disease. 
The usefulness of surfactant lavages, polymers and combination with other treatment op-
tions in MAS have to be further investigated. 
 
 
Congenital SP-B deficiency 
Congenital SP-B deficiency is a lethal inherited disease of the term neonate. It was first 
recognized in 1993 by Nogee et al. (24), and it is characterized by the absence of SP-B, an 
aberrant form of SP-C (174), altered phospholipid composition, and disorganized lamellar 
bodies and tubular myelin (175). Clinically, the neonate with SP-B deficiency presents 
with severe progressive respiratory distress which does not respond to surfactant therapy, 
corticosteroid administration, and ECMO (176, 177). The infants will die in the first few 
weeks of life, unless they undergo a lung transplantation (178).  
SP-B is a hydrophobic peptide with several functions related to surface tension reduc-
tion and metabolism of pulmonary surfactant (21, 23). It enhances the rate of absorption 
and surface spreading of the phospholipids, it maintains the surface active layer of surfac-
tant, and plays a role in the organization and turnover of pulmonary phospholipids. Fur-
thermore, SP-B counteracts the inhibition of surfactant function by plasma proteins, and 
contributes to the recycling of surfactant from the alveolar space (22). In humans the SP-B 
is encoded by a 9.5 kb gene that contains 11 exons on chromosome 2, and is expressed ex-
clusively in the epithelium of the lung (23). Mature SP-B is detectable in the human lung 
after 19 weeks of gestation, and is found in the amniotic fluid after 31 to 33 weeks of 
gestation (179). 
The most common mutation described to date is a net 2 base-pair insertion at codon 121 
in exon 4 of the SP-B gene (121ins2), causing a frameshift and premature stop signal for 
the termination of the translation (180). Affected patients are homozygous for this muta-
tion, their parents heterozygous carriers. But also other mutations have been identified 
resulting in total (181-185), partial (186, 187), or transient SP-B deficiency (188). 
Clark et al. described the creation of homozygous SP-B knockout mice (189). These mice 
die within minutes after birth, have poorly compliant lungs, and express the aberrant    
SP-C. Ultrastructural examination of the lungs revealed an absence of lamellar bodies and 
tubular myelin. However, phospholipid content in lungs from SP-B knockout mice was not 
altered compared to normal mice. Neither was the incorporation of labeled choline and 
labeled palmitic acid in lung saturated PC of SP-B deficient fetuses after injection of the 
labels in pregnant mice (190). Mice heterozygous for the disrupted gene express 50% of 
normal SP-B. These heterozygous mice show evidence of air trapping, abnormalities of 
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lung compliance, and are susceptible to hyperoxic lung injury (191, 192). No changes in 
the amount of lung PC and incorporation of choline and palmitate into saturated PC were 
found (190). Lung function studies in human subjects heterozygous for SP-B deficiency re-
vealed no abnormalities (193). 
Beers et al. investigated the phospholipid content, composition and synthesis in lung tis-
sue and lavage fluid acquired at transplantation or postmortem from SP-B deficient infants 
(194). They found elevated phosphatidylinositol and percent DSPC in lung tissue, and de-
creased levels of PG in both lavage and lung tissue compared to normal lungs. The incor-
poration rate of choline into PC, and acetate into phospholipids was increased in SP-B de-
ficient tissue compared to lung tissue of infants with chronic lung disease (194). The in-
corporation of glycerol into PC was not different between groups. Infants with chronic 
lung disease who underwent lung transplantation were used as comparison, as they had 
undergone the same therapeutic interventions as the SP-B deficient patients. 
In summary, although the tremendous intracellular and functional changes in SP-B defi-
cient type II cells, surfactant PC synthesis and clearance seems not disturbed. The exact 
mechanisms which lead to these changes of pulmonary type II cells still have to be eluci-
dated. By studying the surfactant metabolism in SP-B deficiency a better insight of the 
general surfactant metabolism in normal and other disease states can be obtained. Func-
tions of certain surfactant structures can become more clear, and a possible way of 
treatment could be revealed. 
 
 
Neonatal pneumonia 
Pneumonia is an important source of morbidity and mortality in newborn infants. Group B 
streptococci (GBS) and Escheria Coli (E. Coli) are the most common pathogens causing 
neonatal pneumonia (195). There is evidence of an impaired surfactant system due to viral 
and bacterial pneumonia. In viral pneumonia surfactant function is reduced due to injury 
to the type II cells of the lungs (196, 197). The interaction of bacteria or endotoxin with 
surfactant results in functional changes of surfactant, which results in an abnormal con-
centration and composition of surfactant due to injury of type II cells (198). Additionally, 
surfactant function is further inactivated by plasma proteins due to the increased alveolar 
permeability. 
SP-A and SP-D are believed to be molecules of the innate immune system through their 
ability to recognize a broad spectrum of pathogens (10, 199). These surfactant proteins in-
teract with a number of viruses, bacteria and fungi (200, 201). By binding to components 
of bacteria and viral surfaces the uptake of pathogens by phagocytes of the innate im-
mune system (alveolar macrophages, neutrophils) is enhanced. Furthermore, SP-A and SP-
D also regulate the production of cytokines and free radicals by innate immune cells (202, 
203). SP-A and SP-D deficient mice show increased lung inflammation during bacterial in-
fection (204). Recently, a study in transgenic mice also suggested a role of SP-B in pro-
tecting against endotoxin-induced lung inflammation by enhancing surfactant function 
(205). 
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Lavage fluid of adult patients with bacterial pneumonia showed a decrease in concen-
tration of PC, PG, and SP-A, while PI and sphingomyelin were increased, and SP-B unal-
tered (206-208). The same results were found in tracheal aspirates of children with bacte-
rial pneumonia or viral pneumonitis (209). The fatty acid composition of surfactant phos-
pholipids had also changed in adult patients with pneumonia; palmitic acid being signifi-
cantly reduced (210). During nosocomial infection in ventilated preterm neonates a de-
crease in total phospholipids, especially the amount of PC in the “small aggregate” frac-
tion, was reported (211). There were no other changes in phospholipid composition. The 
surface activity of the surfactant recovered in the “large aggregate” fraction was reduced 
during the peak of the infection, and returned towards normal levels afterwards (212). In 
tracheal aspirates of 21 preterm neonates with pneumonia, minimal surface tension was 
increased, whereas L/S ratio was not decreased compared to healthy term infants (213). 
The authors suggested that surfactant inhibition has a more important role in causing the 
respiratory failure in congenital pneumonia than a surfactant deficiency. Unfortunately, 
surfactant composition and concentration were not measured. There are no data about 
the surfactant content and composition in term neonates with pneumonia. 
Exogenous surfactant therapy in experimental neonatal GBS pneumonia in near-term 
rabbits resulted in a decreased bacterial proliferation, and less prominent inflammatory 
changes of the lungs (214). The same results were found in immature ventilated rabbits 
with experimentally induced GBS pneumonia (215). By adding a specific immunoglobulin 
against GBS in the same experimental model bacterial proliferation was even more effec-
tively reduced than treatment with surfactant alone (216). Surfactant treatment in ex-
perimental E. Coli pneumonia in adult rats showed an improvement in oxygenation (217). 
However, the animals were only studied for 30 minutes, and total phospholipids and PC in 
lavage fluid were not different between the infectious group and the control group. More-
over, exogenous surfactant in E. Coli endotoxin-treated neonatal piglets had a detrimental 
effect on oxygenation and pulmonary function (218). Lung lavages with diluted surfactant 
had better effects (219). 
Herting et al. reviewed the clinical course and outcome of 118 mostly preterm infants 
who were treated with surfactant due to respiratory failure, but were also found to be in-
fected with GBS (220). Surfactant treatment in these neonates improved gas exchange. 
However, the response to surfactant in neonates with GBS was slower than in infants with 
RDS alone, and repeated surfactant doses were often needed. A study in seven full term 
neonates with pneumonia, who were treated with surfactant showed an improvement in 
oxygenation (8). In four newborns with respiratory insufficiency due to bacterial sepsis, 
surfactant treatment showed decreases in mean airway pressures and oxygen demands 
(221). In a randomized double-blind placebo-controlled trial, the use of surfactant signifi-
cantly decreased the need for ECMO (155). However, only about 30% of the patients in 
both groups had a respiratory failure due to sepsis, other diagnoses were MAS and persis-
tent pulmonary hypertension. 
Although the above mentioned studies suggest some effect of surfactant therapy in 
pneumonia, others suggested, however, that exogenous surfactant may impair host de-
fense (222-225). Furthermore, there are indications that exogenous surfactant compo-
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nents may serve as nutrients for bacteria (226). Bacterial growth in different surfactant 
preparations is influenced by the microbial species and the composition and the dose of 
surfactant. 
Incubation of isolated type II cells with lipopolysaccharide (LPS) increased the amount 
of choline incorporation into PC in vitro (227). LPS exposure in rats has been shown to de-
crease phospholipid levels in lung lavage as early as 2 hours after exposure in ex vivo ex-
periments (228). At 72 hours, rats exposed to LPS showed an increased intracellular sur-
factant phospholipid pool as well as a decreased extracellular surfactant phospholipid pool 
(229). Neutrophils and activated macrophages degrade surfactant lipids in vitro and con-
tribute to the alterations in lipid pool size (230). Clearance of large amounts of phospho-
lipids could lead to decreased phopholipid levels, which may result in smaller alveolar 
pools of functional surfactant. SP-A seems to play a role in the regulation of extracellular 
surfactant phospholipid pools after LPS induced lung injury in vivo (231). Absence of SP-A 
resulted in decreased clearance of surfactant from the alveolar space in vivo. In the same 
study no change was found in surfactant synthesis and secretion in normal mice exposed 
to LPS as well as in SP-A knock-out mice exposed to LPS.  
In conclusion, pneumonia seems to effect surfactant function by decreasing surfactant 
concentration. However, most studies have been performed in animals or adult human pa-
tients. Little is known about the effect of pneumonia on surfactant metabolism in human 
infants.  
 
 
Conclusions 
Surfactant metabolism has been studied thoroughly in preterm animals and neonates with 
RDS. In term infants with severe lung disease, such as CDH, MAS, SP-B deficiency and 
pneumonia, the role of a disturbed surfactant metabolism in the pathophysiology is not 
clear yet. There are a few studies about surfactant concentration and composition in hu-
man infants with severe lung disease. Also the effect of surfactant therapy has been 
evaluated in several groups of infants. However, the results are controversial and the 
studied groups are often small. Surfactant synthesis and catabolism have hardly been 
studied in these groups of human patients. An understanding of the surfactant metabolism 
in several lung diseases provides not only information about the pathophysiology of the 
concerning disease, but contributes also to a better understanding of the surfactant me-
tabolism in general. 
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Introduction to the thesis 
In the development of RDS in the preterm neonate a primary surfactant deficiency plays 
an important role, and exogenous surfactant has become a standard treatment of RDS. 
Since the introduction of surfactant therapy for the treatment of neonatal RDS, mortality 
and morbidity due to RDS have dramatically decreased. However, 20 years later (2) still 
discussion exists about the dosage, the timing, and the composition of exogenous surfac-
tant. Bunt et al. have developed a novel method to study surfactant metabolism in pre-
term infants. With the use of this method the influence of prenatal corticosteroids and 
surfactant therapy on the endogenous surfactant synthesis in preterm infants was studied 
(232). 
Another factor that could influence surfactant metabolism is the method of ventilation. 
Repetitive alveolar distension during conventional mechanical ventilation, stimulates sur-
factant synthesis and secretion. During high frequency oscillation (HFO), this alveolar ex-
cursion might be limited, which could decrease surfactant production. Studies evaluating 
the effect of HFO on surfactant metabolism have yielded conflicting results. 
Despite the progress in neonatal care and the introduction of surfactant therapy, many 
very preterm infants develop bronchopulmonary dysplasia (BPD), characterized by lung in-
jury, inflammation, and an arrest in alveolar development. It is presently unclear in what 
way the surfactant system is involved in the ‘natural history’ of BPD. Studies of surfactant 
metabolism have been performed during the first days of life. However, almost no infor-
mation about surfactant metabolism during the development of BPD is available. 
There are (controversial) indications of a disturbed surfactant metabolism in several 
neonatal lung diseases, such as CDH, MAS, sepsis/pneumonia, and inherited SP-B defi-
ciency. Surfactant therapy seems to be effective in some cases, but the effect is often of 
short duration and/or unpredictable. Occasionally, surfactant metabolism has been stud-
ied in animal models of the lung diseases in question. In human infants surfactant analyses 
of tracheal aspirates or broncheoalveolar lavages have been performed, and have pro-
vided data on the quality and the concentration of surfactant. However, these data give 
no information on the synthesis and catabolism of endogenous surfactant. 
 
 
Aim of the studies 
1. To determine if high frequency oscillation (HFO) decreases surfactant production 
in preterm infants with respiratory distress syndrome (chapter 3). 
2. To study the surfactant metabolism and surfactant pool size during the early de-
velopment of bronchopulmonary dysplasia (chapter 4) 
3. To study the apparent surfactant pool size in neonates with severe lung disease 
(chapter 5). 
4. To study the endogenous surfactant metabolism in neonates with congenital dia-
phragmatic hernia, neonates with meconium aspiration syndrome, and neonates 
with inherited surfactant protein-B deficiency (chapter 6,7 & 8). 
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Methods 
Stable isotopes 
The surfactant metabolism in this thesis was studied with the use of stable isotopes. Sta-
ble isotopes are non-radioactive and can therefore be safely used in neonates. In the stud-
ies presented in this thesis we used two stable isotopes: 2H (deuterium) and 13C. The sta-
ble isotope of the carbon atom (13C) has a natural occurrence (enrichment) (1.11%). Base-
line samples are taken prior to the isotope administration to account for the natural en-
richment. In the samples, the ratio of 13C/12C is measured directly, so sampling techniques 
and sample amount are of little influence.  
 
 
 
 
 
Figure 1. Methods of stable isotope administration 
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In this thesis two different methods of tracer administration were used. Dipalmitoyl-
phosphatidylcholine (DPPC), which is the most surface active compound of surfactant was 
labeled with 2H (2H-DPPC). After endotracheal administration of the tracer, the 2H-DPPC 
mixes with the endogenous alveolar surfactant, will be taken up by the type II cells and 
mix with the intracellular surfactant, and will gradually disappear from the lung (Figure 
1). From the disappearance of the label we can calculate the half-life of the exogenous 
tracer and the surfactant PC pool size.  
The other tracer used in this thesis was 13C-glucose, which was administered by intrave-
nous infusion during 24 hours. The stable isotopes are incorporated into the fatty acids in 
surfactant PC by endogenous synthesis of PC, which will be secreted into the alveolar 
space (Figure 1). The rate of incorporation is a measure for synthesis of surfactant PC. The 
disappearance of the stable isotope from surfactant PC is a reflection of the turnover (i.e. 
synthesis and clearance) of endogenous surfactant PC. 
 
Extracorporeal membrane oxygenation (ECMO) 
ECMO is a temporary support of heart and lung function using mechanical devices. The 
support is achieved by draining venous blood, removing carbon dioxide and adding oxygen 
through an artificial lung, and returning the blood to the circulation via a vein (venoven-
ous) or artery (venoarterial) (Figure 2). The patients of the studies in this thesis were 
treated with venous-arterial ECMO. The right internal jugular vein and common carotic ar-
tery were cannulated. 
 
 
Figure 2. ECMO treatment in a fullterm neonate 
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Abstract 
 
In the current study we determined if high frequency oscillatory ventilation (HFOV) de-
creases surfactant production in preterm infants with respiratory distress syndrome (RDS). 
We randomized 19 infants < 28 weeks of gestational to either HFOV (n=8) or conventional 
ventilation (CV, n=11) at 24 hours of life. After a 24-hour continuous infusion of uniformly 
labeled carbon 13 glucose( [U-13C6] glucose), we measured 
13C enrichment in surfactant 
phosphatidylcholine (PC) in tracheal aspirate samples using gas chromatography/mass 
spectrometry. We calculated fractional synthetic rate (FSR) of surfactant PC from labeled 
glucose and its half-life of clearance (T½). FSR did not differ between groups 
(4.7±2.7%/day CV versus 4.2±3.1%/day HFOV, p=0.7) Half-life was 79±18 hours in the CV 
group and 76±23 hours in the HFOV group (p=0.7). Neither degree of ventilatory support 
nor supplemental oxygen exposure correlated with surfactant metabolic indices. Three of 
4 infants who died from RDS within the first month of life had a shorter half-life than 14 of 
15 infants who survived. In conclusion, surfactant metabolism is similar in preterm infants 
ventilated with HFOV and CV. Shortened surfactant half-life may characterize a subset of 
preterm infants with lethal RDS. 
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Introduction 
Pulmonary surfactant, a mixture of phospholipids and proteins synthesized by alveolar 
Type II cells, maintains alveolar expansion at end expiration. The phospholipid and protein 
components of the pulmonary surfactant are synthesized, assembled, secreted, degraded, 
and recycled in a complex metabolic cycle (17). The most abundant phospholipid in the 
pulmonary surfactant, phosphatidylcholine (PC) consists of a glycerol backbone to which 
choline and two fatty acids are attached. The principle surface-active phospholipid is di-
palmitoylphosphatidylcholine (DPPC), which contains two palmitic acid chains. The palmi-
tate in DPPC is derived either from circulating free palmitate or from de novo synthesis 
from precursors such as glucose and acetate. Of the many factors that influence pulmo-
nary surfactant metabolism, physical stretch stimulates surfactant synthesis and secretion 
(233-235).  
Previously, we noted that infants genetically deficient in surfactant protein-B exhibited 
better gas exchange and had less histologic evidence of surfactant accumulation in the 
airspaces when they were ventilated with high-frequency oscillatory ventilation (HFOV) 
(236). Because repetitive alveolar distension, such as occurs with conventional mechanical 
ventilation, stimulates surfactant synthesis and secretion, we speculated that HFOV, dur-
ing which this alveolar excursion will be limited, decreased surfactant production in these 
surfactant protein-B-deficient infants. Studies evaluating the effect of HFOV on surfactant 
metabolism, however, have yielded conflicting results. Some have suggested no effect of 
HFOV on surfactant metabolism. For example, with intraperitoneal administation of radio-
labeled palmitate, surfactant turnover was similar in adult rats with normal lungs venti-
lated with HFOV or conventional ventilation (CV) for 90 minutes (237). In other studies, no 
differences in surfactant phospholipid quantity or composition were found in nonhuman 
primates ventilated for 7 hours and 16 hours with CV or HFOV (238, 239). In contrast, 
studies using radiolabeled exogenous surfactant in preterm lambs and intravenous radio-
labeled palmitate in adult rabbits suggested decreased surfactant secretion in response to 
HFOV (240, 241). Studies performed in preterm humans have also suggested that HFOV 
decreases surfactant production. For example, phospholipid and PC concentration in tra-
cheal aspirates increased as infants were changed from receiving HFOV to CV (242). In ad-
dition, infants receiving HFOV had lower concentrations of surfactant protein-A in tracheal 
aspirates than infants receiving CV (243). 
The studies in infants have been limited by techniques suitable for answering these 
questions. The composition of surfactant in tracheal aspirates reflects the steady state 
and cannot provide insights into the dynamic aspects of surfactant metabolism. Methods 
using stable isotope-labeled glucose of fatty acids have permitted evaluation of pulmonary 
surfactant phospholipid metabolism in humans in vivo (54, 55, 244). Therefore, to deter-
mine if HFOV decreased pulmonary surfactant production, we used stable isotope-labeled 
glucose to compare endogenous surfactant metabolism in premature infants with respira-
tory distress syndrome (RDS) who were ventilated with HFOV or CV. 
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Methods 
Subjects 
Infants <28 weeks gestational age admitted to the St Louis Children’s Hospital neonatal in-
tensive care unit (NICU) were eligible if they required mechanical ventilation from birth, 
had a chest radiograph consistent with RDS, and had indwelling arterial access as part of 
their routine clinical care. Exclusion criteria included known congenital infection, con-
genital anomalies, maternal diabetes mellitus, or imminent death. During the first 24 
hours of life, the NICU team determined clinical management, including exogenous surfac-
tant replacement. Exogenous surfactant replacement (Survanta, Abbott Laboratories, Chi-
cago, IL) was given at a dose of 4 mL/kg/dose every 12 hours if fractional concentration of 
oxygen in inspired gas (FiO2) was >0.3 to keep peripheral oxygen saturation >92%. Within 
the first 24 hours, after assent from the attending physician, the parents were approached 
for consent. We explained to the parents that available data did not show either HFOV or 
CV to be superior to one another, and that their infant would be randomized to one of 
these forms of ventilation. If the bedside team determined that the assigned mode of ven-
tilation was not appropriate, the study would be discontinued. Once consent was ob-
tained, the infant was randomly assigned to receive either CV (VIP Bird, Bird Products Co., 
Palm Springs, CA) or HFOV (Sensormedics Model 3100A, Sensormedics Critical Care Co, 
Yorba Linda, CA) starting at 24 hours of age. Infants who were already receiving HFOV as 
part of their routine care continued to receive it. Once an infant was randomly placed to 
treatment, the medical team determined medical care, including ventilatory and nutri-
tional management. The Washington University Human Studies Committee approved the 
study. 
 
Isotope infusion and sample collection 
Once the infant was placed on the selected mode of ventilation, baseline tracheal aspi-
rate and blood samples were collected. A 24-hour continuous intravenous infusion of [U-
13C6] glucose (20 mg/mL, Campro Scientific, Veenendaal, The Netherlands and Cambridge 
Isotope Laboratories, Inc. Andover, Massachusetts, USA) dissolved in 5% or 10% dextrose 
and water, was started at 0.5 mL/kg/h to deliver approximately 0.05 mmol/kg/h of la-
beled glucose. The start of the study was defined by the start of the infusion of the la-
beled glucose. Blood samples were obtained every 6 hours during the infusion period. 
Samples were collected in an EDTA tube, immediately placed on ice, and directly centri-
fuged at 2500 rpm for 10 minutes. The plasma was stored at -70 C° until it was analyzed. 
Tracheal aspirates were collected in a standardized fashion every 12 hours as per current 
NICU suctioning protocol. Samples were collected for the length of time the infant re-
ceived the assigned mode of ventilation of 14 days, whichever was shorter. The tracheal 
aspirates were frozen at –70 °C. Aspirates containing visible blood were not included. 
 
Sample preparation and analysis 
Details of the sample preparation and analysis were previously described (54, 55, 244). 
Briefly, plasma was delipidated and glucose was isolated and derivatized to an aldonitril 
pentacetate derivative (245). Lipids were extracted from tracheal aspirates according to 
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Bligh and Dyer (246) and surfactant PC was isolated using TLC. PC was derivatized and 
fatty acid methyl esters were extracted with hexane and stored at –20 °C. Enrichment of 
13C in palmitic acid, the most common fatty acid in surfactant PC, in tracheal aspirates 
and enrichment of 13C-glucose in plasma were measured by gas chromatography-
combustion interface-isotope ratio mass spectrometry (GC-CI-IRMS) (VG Isotech, Midle-
wich, Cheshire, UK) as previously described (54, 55, 244). The enrichment was expressed 
as atom percent excess (APE), which represents the increase in the percentage of 13C at-
oms in total carbon dioxide from the combusted compounds above baseline enrichment 
(before infusion). Enrichments were corrected for the contribution of unlabeled carbon 
atoms added during derivatization. 
 
Data collection and analysis 
Clinical data, including ventilatory support, blood gas analyses, surgical and pharmacol-
ogical interventions, and complications, were collected for the duration of the study. An 
integrated respiratory score was calculated for each infant as previously described (247). 
This score was determined by multiplying the average daily FiO2 by the average daily 
mean airway pressure (MAP) and integrating the area under the curve for the total number 
of days in the study using Sigma Plot 2000 software (SPSS, Inc, Chicago, IL). We norma-
lized the respiratory score for the study duration (range, 10-14 days) by dividing by the 
number of days each participant was in the study. Tissue-bound and alveolar surfactant 
were regarded as one pool. Time of appearance (Tapp) is the time delay between the start 
of the infusion and the first appearance of 13C enrichment in surfactant PC (reported in 
hours). Time of maximum enrichment (Tmax) is the time that 
13C reaches its maximum en-
richment (Emax). The half-life (T½, hours) of clearance of labeled endogenous PC was cal-
culated from the monoexponential fitting of the downslope of the enrichment versus time 
curve. Fractional synthetic rate (FSR), which represents the percentage of the endogenous 
surfactant PC pool synthesized de novo from plasma glucose per day (%/day), was calcu-
lated by dividing the slope of the linear increase of the 13C enrichment curve by the 
steady state enrichment of plasma glucose (54, 55, 244). 
The study was designed to have sufficient power (ß=0.8) to detect a 30% difference in 
FSR at a significance level of 0.05. Normally distributed data are presented as means ± SD 
and non-normally distributed data are presented as median and range. Two-tailed Stu-
dents’ t tests were used for normally distributed data, Wilcoxon rank-sum tests were used 
for non-normally distributed data, and Fisher’s exact tests were used for categorical data. 
All statistical analyses were performed using the SAS software, version 8.1 (SAS institute, 
Cary, NC). 
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Table 1. Patient characteristics 
 
CV 
n=11 
HFOV 
n=8 
p-value 
Birth weight (g) 779±125 726±175 0.4 
Gestational age (wk) 26 (24-28) 26 (24-27 1.0 
Sex (M/F) 8/3 5/3 1.0 
Race (white/black) 3/8 4/4 0.4 
Apgar score at 5 minutes 7±2 6±2 0.4 
Antenatal corticosteroids (n) 9 4 0.3 
Doses of exogenous surfactant 2 (1-3) 2 (2) 1.0 
FiO2* 0.32±0.13 0.54±0.18 0.008 
MAP* 6.9±1.3 9±1.5 0.005 
OI* 3 (1.7-6.4) 5 (3.6-10.1) 0.01 
Average daily respiratory severity score# 3.4±1.5 5.5±2.1 0.02 
*At study start. 
#Total restiratory score (integrated MAP x FiO2) divided by the number of days in the study. 
 
 
Results 
Of the 33 families approached, 20 infants ultimately participated, 10 in each group. One 
infant randomized to HFOV did not tolerate it and was immediately changed back to CV. 
One additional infant in the HFOV group developed severe interstitial emphysema, which 
precluded regular tracheal aspirate sampling, and therefore was excluded. The clinical 
characteristics of the 19 infants are presented in Table 1. Both groups were similar in 
their demographic characteristics at the study entry; all infants received a similar amount 
of surfactant replacement. No infants received exogenous surfactant after 24 hours of 
life, and no infant required neuromuscular blockade during the period. There were no 
other differences between the 2 groups with regard to other complications, such as pul-
monary or bloodstream infections, patent ductus arteriosus, surgical interventions, or cor-
ticosteroid, antibiotic, or vasopressor administration during the study period (Table 1).  
There were no significant differences in the metabolic indices of endogenous surfactant 
synthesized from glucose between infants receiving HFOV and CV (Table 2). Specifically, 
FSR and T½ were similar between the two groups, suggesting no decrease in surfactant 
production or turnover in infants receiving HFOV. There were no correlations between sur-
factant metabolic indices and any respiratory indices (data not shown).  
Four infants died from respiratory failure within 24 days of life (3 with HFOV, 1 with 
CV). Three of these infants had T½ shorter than 14 of the 15 survivors (Figure). These 4 
infants also had a significantly higher respiratory score than did the survivors (median 6.6 
[5-9.2] versus 3.6 [1.7-5.2] per day, p=0.01). 
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Table 2. Endogenous surfactant PC metabolism: CV vs HFOV 
 CV HFOV p-value 
Tapp (h) 13 (9-23) 15 (10-28) 0.2 
Tmax (h) 70±24 87±22 0.1 
Emax (APE) 0.19±0.08 0.23±0.07 0.2 
T½ (h) 79±18 76±23 0.7 
FSR (%/d) 4.7±2.7 4.2±3.1 0.7 
Plasma enrichment (APE) 2.0±0.9 2.7±0.8 0.09 
 
 
Discussion 
Because alveolar stretch increases surfactant synthesis and secretion, we thought HFOV 
might decrease surfactant production, which could be detrimental in premature infants 
already deficient in pulmonary surfactant. We reasoned that if HFOV decreased surfactant 
production or pool size, it would be evident as changes in FSR, T½, or Tmax . We found no 
differences in these tracer kinetic indices of surfactant metabolism, suggesting that the 
alveolar distension produced by HFOV did not decrease surfactant production. 
This observation contrasts with the only previous studies in humans that relied on dif-
ferences in surfactant composition to suggest differences in surfactant metabolism with 
HFOV and CV (242, 243). These studies are not comparable with ours in other respects. 
For example, Dargaville et al. (242) evaluated infants in the recovery phase of hyaline 
membrane disease from 1 to 77 days of age and 27 to 40 weeks of gestation, in contrast to 
our population of infants in the acute phase of illness. Gerdes et al. (243) evaluated the 
concentration of surfactant protein-A, which is under metabolic control separate from 
that of surfactant phospholipid (248). Ours is the first study to evaluate the dynamics of 
surfactant metabolism in premature infants receiving HFOV.  
There may be several reasons that we did not detect differences in surfactant metabo-
lism between the 2 groups of infants. First, we studied an extremely immature, critically 
ill population, in whom surfactant metabolism may already be sufficiently disrupted such 
that differences in metabolism might have been below the threshold of detection for this 
technique. Second, all infants received a similar amount of surfactant replacement, 
which, at 5 to 10 times the endogenous pool, could have masked small differences in me-
tabolism (80). However, the FSR of 4.5% we obtained is similar to that of an earlier study 
in which differences in FSR (8.9, 3.3, 2.5, and 1.7%/day) were detected in infants who re-
ceived 0, 1, 2, and 3 doses of exogenous surfactant, respectively (63). Thus, it is reason-
able to assume that surfactant pool sizes were similar in the 2 groups of infants and that it 
is unlikely that the surfactant replacement masked differences in metabolism between 
the 2 groups. A third reason we might have been unable to detect differences between 
HFOV and CV is that we started our study at 24 hours of life. It is possible that alveolar 
stretch is a more important stimulus to surfactant production in the immediate transition 
from fetal to extra-uterine life and is less critical beyond 24 hours of life. 
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Figure. The half-life of 13C PC clearance of the 19 infants in the study 
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Four who died of respiratory failure within 24 days of birth (nonsurvivors) and 15 who survived at 
least 6 months (survivors). 
 
 
In our study, infants in the HFOV group had more severe lung disease, which itself could 
result in differences in surfactant metabolism. For example, Martini et al. (249) using sta-
ble isotope techniques similar to those used in this study, demonstrated decreases in PC 
synthesis and pool size in adult pigs with experimental thermal injury. In addition, Soli-
mano et al. (240) found that MAP and alveolar surfactant pool size in preterm lambs were 
inversely related to severity of hyaline membrane disease. Finally, hyperoxia may disrupt 
PC synthesis and secretion as demonstrated in vitro in rabbit lung slices or cultured alveo-
lar type II cells (250, 251). In any event, we would expect that the changes in surfactant 
metabolism associated with lung injury, if significant, would be similar to those we ex-
pected to find with HFOV, which would thereby accentuate, rather than mask, differences 
in surfactant metabolism. Furthermore, the lack of correlation between indices of en-
dogenous surfactant metabolism with any of the ventilatory indices suggests that these 
differences in ventilatory support between the 2 groups did not influence our results. 
Although we assume that we are measuring the metabolic indices of endogenous surfac-
tant synthesized de novo from plasma glucose, we are actually measuring the net results 
of synthesis, secretion, catabolism, recycling, and the rate at which the surfactant as-
cends the tracheobronchial tree, the latter of which may be influenced by the mode of 
ventilation. Furthermore, our kinetic analysis makes no adjustment for 13C tracer recycling 
through the glycolytic or gluconeogenic pathway. Distinguishing the magnitude of the con-
tribution of specific steps is difficult in human infants because the tracheal aspirates are 
the only realistic samples that can be obtained. The recent development of stable iso-
tope-labeled exogenous surfactant for estimating surfactant pool size will greatly enhance 
the interpretation of these data (62). 
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The intriguing observation of a shorter half-life of endogenous surfactant in premature 
infants who died of refractory respiratory failure suggests that there may be fundamental 
differences in surfactant metabolism in premature infants who do not survive. Under-
standing these fundamental differences will then permit the development of therapeutic 
strategies that are specific to the mechanism of metabolic disruption. 
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Abstract 
 
Because minimal information is available about surfactant metabolism in bronchopulmo-
nary dysplasia (BPD), we measured half-lives and pool sizes of surfactant phosphatidylcho-
line in very preterm baboons recovering from respiratory distress syndrome (RDS) and de-
veloping BPD, using stable isotopes, radioactive isotopes, and direct pool size measure-
ments. Eight ventilated premature baboons received 2H-DPPC (dipalmitoylphosphatidyl-
choline) on d 5 of life, and radioactive 14C-DPPC with a treatment dose of surfactant on d 
8. After 14 d, lung pool sizes of saturated phosphatidylcholine (sat PC) were measured. 
Half-life of 2H-DPPC (d 5) in tracheal aspirates was 28±4 h (mean±SEM). Half-life of radio-
active DPPC (d 8) was 35±4 h. Sat PC pool size measured with stable isotopes on d 5 was 
129±14 µmol/kg, and 123±11 µmol/kg on d 14 at autopsy. Half-lives were comparable to 
those obtained at d 0 and d 6 in our previous baboon studies. We conclude that surfactant 
metabolism does not change during the early development of BPD. More specifically, the 
metabolism of exogenous surfactant on d 8 is similar to that on the day of birth. Surfac-
tant pool size is low at birth, increases after surfactant therapy, and is kept constant dur-
ing the first two weeks of life by endogenous surfactant synthesis. Measurements with 
stable isotopes are comparable to measurements with radioactive tracers and measure-
ments at autopsy.  
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Introduction 
Since the introduction of surfactant therapy for the treatment of neonatal RDS, mortality 
and morbidity due to RDS have dramatically decreased (3). Most studies of surfactant me-
tabolism have been performed in animals with radioactive tracers used to measure surfac-
tant synthesis, half-life of surfactant, pool sizes, and influences of hormonal treatments 
(52, 252). Surfactant metabolism changes with lung injury and with development. New-
born animals have less de novo synthesis and a longer biological half-life of phosphatidyl-
choline (PC) than adult animals, but newborns also have higher rates of surfactant recy-
cling (52). In adult animals, acute lung injury or oxygen exposure change surfactant com-
position and pool sizes (253).  
Despite the progress in neonatal care, many very preterm infants develop BPD charac-
terized by lung injury, inflammation, and an arrest in alveolar development (254). It is 
presently unclear whether the surfactant system is involved in the development of BPD. 
Most studies of surfactant metabolism in newborn animals and humans have been per-
formed during the first days of life, during the acute phase of RDS. Almost no information 
is available about surfactant metabolism beyond the first week during the development of 
BPD (255). Infants who develop BPD have an altered phospholipid composition of surfac-
tant (256, 257), and surfactant therapy in infants developing BPD resulted in a transient 
improvement of oxygenation (258). In ventilated preterm baboons developing BPD, the 
abnormal alveolar development and injury is similar to that found in humans (259). These 
very preterm baboons have a large increase in intracellular surfactant pool size during the 
first few days, but surfactant secretion to the alveolar space is very limited (59). Surfac-
tant lipid and protein composition and surfactant function is abnormal in baboons devel-
oping BPD (59, 260). However, there is no information about the metabolism of the sat PC 
component of surfactant as the animals develop BPD.  
We recently used stable isotopes to study the surfactant metabolism in premature hu-
man neonates (54, 62). However, a validation of the method using stable isotopes has not 
been performed because radioactive isotopes are medically and ethically not accepted in 
human newborns, and lung pool size of surfactant has only been measured in newborns 
who did not survive (261).  
In the present study, we evaluated surfactant metabolism in very preterm ventilated 
baboons during the acute phase of RDS (d 1-3), the phase of recovery from RDS, and the 
development of BPD. We measured surfactant half-lives and pool sizes in each individual 
baboon during the first 2 weeks of life. We were specifically interested in the changes of 
the surfactant metabolism in the second week of life during the development of BPD. Fur-
thermore, we compared the surfactant half-life and surfactant pool size measured with 
stable isotopes to measurements made with radioactive isotopes and direct measurements 
of pool size at autopsy. 
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Methods 
Study protocol 
The animal studies were performed at the Southwest Foundation for Biomedical Research 
(San Antonio, TX), as described before and conformed to the American Association for Ac-
creditation of Laboratory Animal Care guidelines (59). 
We studied surfactant metabolism in 8 baboons (gestational age (GA) 124-127 d; full 
term at 185 d) using stable isotopes and radioactive isotopes with surfactant treatment at 
different times over a 14-d period of ventilation (Figure 1). The baboons received un-
labeled surfactant at birth (100 mg/kg Survanta®, Abott Laboratories, Abott Park, IL, 
USA). At 120 h (d 5), they received a tracer dose of 5 mg/kg (6.8 µmol/kg) deuterium 
(stable isotope) labeled DPPC (2H-DPPC, where 3 deuterium labels are present in the 
palmitoyl-groups) (L-3-phosphatidylcholine dipalmitoyl-D6, Doosan Serdary Research Labo-
ratories, NJ, USA) intratracheally. The 2H-DPPC was used to measure the disappearance of 
labeled PC palmitate from the tracheal aspirates and to calculate surfactant pool size. 
Day 5 was chosen because a 3-d interval is needed to reliably calculate surfactant half-life 
and pool size. At 192 h (d 8), these eight baboons received a treatment dose of 100 mg/kg 
(68 µmol sat PC/kg) Survanta® labeled with radioactive [14C]choline-labeled DPPC (5 µCi 
14C-DPPC/kg birth weight). A 6-d interval from d 8 to d 14 was chosen to compare the sur-
factant half-life and pool size with our previous data (59). In that study, we measured the 
surfactant metabolism in the first 6 d of life. Over the interval from birth to d 6, most of 
the PC in the surfactant treatment given at birth was degraded. Tracheal aspirates were 
obtained every 12 h for 14 d as described before (59). At 336 h (d 14) the animals were 
killed with pentobarbital. Alveolar wash and lung homogenates were retrieved as de-
scribed before (59). 
 
 
Figure 1. Schematic representation of the study protocol. 
 
 
Eight baboons received unlabeled surfactant at birth, exogenous 2H-DPPC on d 5, and on d 8 
they received exogenous 14C-DPPC together with a treatment dose of Survanta®. After 14 d of 
ventilation, direct surfactant sat PC pool size measurements were performed at atopsy. 
 
Birth        day 5 day 8 day 14 
2H-DPPC
6.8 µmol 
sat PC/kg
14C-DPPC 
Survanta® 
68 µmol sat PC/kg
 
100 mg/kg Survanta® 
68 µmol 
sat PC/kg
 
 
Autopsy: 
Lung surfactant 
sat PC pool 
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Analytical procedures 
The tracheal aspirates, alveolar washes, and lung homogenates were processed as de-
scribed before (262). The PC fraction of the tracheal aspirates was isolated by thin-layer 
chromatography and derivatives of PC palmitate were formed during incubation with 
0.015 mL N-methyl-N-(tert-butyldimethylsilyl)-trifluoroacetamide (MTBSTFA, Pierce, On-
milabo, Breda, The Netherlands) and 0.015 mL pyridine, to measure 2H-enrichment. 
Analysis of radioactive isotopes in tracheal aspirates, alveolar washes, and lung homoge-
nates were performed as described before (59). Fatty acid composition of surfactant PC in 
tracheal aspirates was measured by gas-chromatography (GC) (5890 series II, Hewlett-
Packard, Amstelveen, The Netherlands (100). 
 
Determination of enrichment of stable isotope 
The 2H-enrichment of surfactant PC-palmitate was measured with a Carlo Erba GC8000 gas 
chromatograph coupled to a Fisons MD-800 mass spectrometer (Interscience BV, Breda, 
The Netherlands). One µL of the derivative was injected on a fused silica capillary column 
of 25m x 0.22mm, coated with 0.11m HT-5 (SGE, Victoria, Australia). The enrichment was 
expressed as mol percent excess (MPE), which represents the molar percent of the labeled 
molecule (m+3 palmitate), corrected for baseline enrichment (before isotope infusion) 
(263). 
 
Calculations 
Calculations were performed as described previously (54, 62). As palmitic acid is by far 
the most abundant fatty acid in surfactant PC, calculations were performed for palmitic 
acid only.  
The half-life of 2H-DPPC and 14C-DPPC was calculated by exponential curve fitting of the 
final monoexponential part (y=a∗e-kt) of the downslope of the curve of 2H-enrichment and 
specific activity of 14C versus time, respectively (t½=ln(2)/k).  
The apparent lung surfactant pool size was calculated by using the linear regression line 
representing the decay of the log-transformed 2H-enrichment over time. Extrapolation 
back to the time of administration (t=120 h) represents the 2H-enrichment at t=120, from 
which we calculate the dilution of the tracer. The endogenous apparent pool size was cal-
culated by multiplying the amount of exogenous DPPC with the dilution factor. The en-
dogenous apparent pool size was corrected for the amount of exogenous 2H-DPPC adminis-
tered, and expressed as µmol/kg sat PC by using the fatty acid composition of PC obtained 
by GC. 
 
Data Analysis 
Data are presented as mean±standard error of the mean (SEM). Differences between 
groups were analyzed by one-way ANOVA. Significance was accepted at p<0.05. 
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Results 
We studied 8 baboons with a 
mean birth weight of 386±11 g 
(4 females, 4 males).  
On d 5, the baboons received 
a trace dose of 2H-labeled 
DPPC (6.8 µmol/kg). The val-
ues of the 2H-enrichment of PC 
palmitate in sequential tra-
cheal aspirates versus time 
were used to calculate a half-
life of 28±4 h (Figure 2B, Table 
1). The half-life was calcu-
lated from the final mono-
exponential part of the de-
crease in 2H-enrichment in 
each baboon.  
On d 8, the baboons re-
ceived a therapeutic dose of 
radioactive surfactant (100 
mg/kg Survanta®, 68 µmol sat 
PC/kg). The half-life, calcu-
lated by exponential curve fit-
ting of the final mono-
exponential part of the 
downslope of the curve of the 
specific activity of 14C-DPPC in 
airway samples versus time 
curve, was 35±4 h (Figure 2A, 
Table 1).  
We compared the results of 
these 8 baboons with our pre-
vious data for surfactant me-
tabolism in similar premature 
baboons that were ventilated 
for 6 d (59, 262). The previous 
studies in very premature ba-
boons (GA 125±2 d) were per-
formed by the same investiga-
tors, using the same pre- and 
postnatal care. The half-life of 
14C-DPPC given on d 0 in the 
previous study is shown in   
Figure 2. Decay of the label in tracheal aspirates af-
ter endotracheal administration of labeled DPPC 
(A) Specific activities of sat PC from tracheal aspirates 
after treatment of baboons with 14C-DPPC labeled 100 
mg/kg Survanta on d 8. Specific activities as CPM/µmol 
sat PC were normalized to the specific activity of the sur-
factant used to treat the preterm baboons. (B) Mean ± 
SEM 2H-enrichment of surfactant PC-associated palmitate 
in sequential tracheal aspirates of eight baboons (125 GA) 
after 2H-DPPC (stable isotope) administration at d 5 
(t=120 h). 
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Table 1. The results show similar half-lives on d 0, d 5 and d 8 after birth.  
The apparent lung sat PC pool size on d 5 was 129±14 µmol/kg (Table 1). The pool size 
was calculated from the monoexponential decrease in 2H-enrichment, by using the linear 
regression line representing the decay of the log-transformed 2H-enrichment over time. 
On d 14, the pool size of sat PC measured for the total lung was 123±11 µmol/kg (Table 
1). Total lung pool size on d 0 and d 6 from previous experiments are shown for compari-
son (59). There was no significant difference between pool sizes on d 5, 6 and d 14 (one-
way ANOVA, p=0.065).  
 
 
Discussion 
BPD was initially described as severe injury of the preterm lung resulting from mechanical 
ventilation and oxygen exposure (264). With the introduction of surfactant therapy and 
prenatal corticosteroids, BPD now primarily develops in very preterm infants weighing <1 
kg, without severe RDS. This new BPD may be primarily caused by an arrest of lung devel-
opment (265). We report here surfactant metabolism during the early phase of BPD in very 
premature baboons. Half-life and apparent lung sat PC pool size were calculated after en-
dotracheal instillation of a tracer dose of deuterium labeled DPPC on d 5 after birth. On d 
8 of life, half-life was measured after endotracheal radiolabeled DPPC together with a 
treatment dose of surfactant, and pool size measurements from whole lung were made on 
d 14. We show that although the baboons recover from RDS and develop the early phase of 
BPD, surfactant sat PC half-life and surfactant sat PC pool size do not change. It remains 
presently unclear whether the surfactant metabolism plays a role in the pathogenesis of 
BPD. 
 
 
Table 1. Surfactant half-lives and sat PC pool sizes 
 Do* 
14C-DPPC/  
autopsy 
D5 
2H-DPPC
D6* 
autopsy 
D8 
14C-DPPC 
D14 
autopsy 
Half-life (h) 30 28±4 - 35±4 - 
Pool size (µmol/kg sat PC) 30 129±14 166±11 - 123±11 
Half-life and sat PC pool size expressed as mean±SEM. On d 5, the baboons received 2H-DPPC (stable 
isotope) endotracheally, on d 8 they received 14C-DPPC (radioactive) with Survanta® (100 mg/kg) en-
dotracheally, and on d 14 the baboons were killed. *The results are compared with results reported 
previously (59). 
 
 
Most studies of surfactant kinetics have been performed over a short time course. In the 
present study, we were able to evaluate surfactant metabolism during the first 2 weeks of 
life in the same animal. In our previous study, we measured surfactant synthesis in the 
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acute phase of RDS, and surfactant half-life and pool size were studied after treatment 
with surfactant at birth. By using a 14-d ventilated preterm baboon model, which shows 
abnormal alveolar development and injury similar to that found in humans (266), we were 
now able to measure surfactant kinetics during the development of BPD, more specifically 
on d 5, and after surfactant treatment on d 8. Our measurements in the preterm baboon 
are summarized in Figure 3. We measured a low sat PC pool size at birth, which was in-
creased at d 6 after surfactant treatment. As 84% of the 14C-DPPC given at birth was de-
graded by d 6 (59), the increase of the total sat PC pool size resulted from endogenous 
synthesis of surfactant. In the second week of life, the pattern of surfactant metabolism 
was similar: about 90% of the 14C-DPPC administered at d 8 was degraded by d 14 (267), 
whereas the total lung sat PC pool size did not change significantly.  
 
 
Figure 3. An overview of the surfactant metabolism during the first two weeks of life in 
the very premature ventilated baboon 
 
At birth the baboons received 68 µmol/kg sat PC Survanta®, from which 84% was degraded at d 6 (re-
sults reported previously (11)). Pool size at d 6 was 166 µmol/kg sat PC, which indicate an increase 
of pool size by endogenous surfactant synthesis. In the second week of life during the early devel-
opment of BPD, the endogenous surfactant pool size remains fairly constant and catabolism is similar 
to that in the first week after a gift of 68 µmol/kg sat PC Survanta®. 
 
 
Sat PC pool size on d 5, measured with stable isotopes was 129 µmol/kg and was compa-
rable to the total lung pool size measured at autopsy on d 14 (123 µmol/kg) in the same 
animal. The trend of a larger sat PC pool size at autopsy on d 6 in the previous study (166 
µmol/kg) (59) compared to the pool size on d 5 in the current study, may be explained by 
measurements in different animals. It is also unclear to what extent an abnormal surfac-
tant metabolism influences the measurements. In the previous study, we found very high 
tissue pools, but low alveolar pool sizes of surfactant, caused by a low secretion of de 
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novo synthesized sat PC into the alveolar space. No other studies have investigated the 
evolution of surfactant pool sizes in premature animals during a longer period. A study in 
term rats found a progressive decrease in total lung sat PC pool sizes corrected for weight 
during the first 100 days after birth (from ~125 µmol/sat PC/kg to ~5 µmol/sat PC/kg) 
(74). 
Jackson et al. measured a total lung pool size of sat PC of ~45 µmol/kg in preterm mon-
keys with RDS at birth (79). However, these monkeys were not as premature as the ba-
boons in the present study (83% versus 68% of the term gestational age) and they did not 
receive exogenous surfactant. Preterm lambs delivered at 132 days gestational age had 
total lung sat PC pool sizes of ~60 µmol/kg without surfactant treatment (268) and ~80 
µmol/kg sat PC when treated with surfactant (269). In preterm neonates, using stable iso-
topes, we previously measured an apparent sat PC pool size of ~8 µmol/kg and ~22 
µmol/kg before and after surfactant therapy, respectively (62). Hallman et al. showed an 
apparent pool size of ~12 µmol/kg in human preterm neonates with RDS (61). They used 
PG as label to measure surfactant pool size. With the same method Griese et al. calcu-
lated an apparent pool size of ~13 µmol/kg sat PC in preterm neonates with RDS (81). 
However, the pool size measurements in humans were made with a tracer together with 
one or more therapeutic doses of surfactant, whereas in the present study only a trace 
dose of surfactant was used on d 5. The pool sizes measured in the human studies proba-
bly represent the alveolar pool sizes. Their apparent pool size was comparable with the 
alveolar pool size found in other studies (~20 µmol/kg) (261). In the current study, the 
pool size measured with stable isotopes likely represents the total lung pool size as the 
small amount of tracer is quickly taken up by the lung cells in contrast to the large treat-
ment doses. 
The half-life of DPPC over the interval from d 5 to d 8, using stable isotopes, was 28±4 
h, which was similar to the half-life measured with radioactive DPPC from d 8 onwards. 
Similar results were found at d 0, using radioactive DPPC, in our previous study (59). Thus, 
the half-life of surfactant did not change during the first two weeks of life in the very 
premature baboon. The same half-life of 35 h was found in preterm lambs using PG as 
tracer in alveolar washes (270). In one study in term newborn lambs, endotracheally in-
jected 3H-PC had a very long half-life of 6 d (58). Possibly, variations of half-lives are due 
to differences in maturity. In premature infants treated with amniotic fluid-derived sur-
factant containing PG, the half-life was 30 h (61). In another study in premature infants 
using PG and sphingomyelin (Sp) as markers, half-live of PG was 43 h and 105 h after 
treatment with Alveofact® and Survanta®, respectively, and the half-life of Sp was 97 h af-
ter treatment with Survanta® (81). The differences in half-lives could be explained by the 
different composition of the two surfactants and the different doses given. Comparable 
results were found in human premature neonates using stable isotopes (62). Preterm in-
fants received two doses of surfactant labeled with 13C-atoms, 5 h and 32 h after birth, 
respectively. The calculated half-life was 34 h and 17 h, respectively. All these studies in 
human neonates calculated half-life from the disappearance of the label (PG, Sp, and 13C) 
from tracheal aspirates, as in the current study. The half-life of a trace amount of labeled 
DPPC (d 5) in the present study was not influenced by the administration of treatment 
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doses of surfactant (100 mg/kg) (d 8), which is in agreement with Hallman et al. (61), and 
with our previous results (63). However, in mice the half-life for 3H-DPPC in total lung in-
creased ~2-fold after the instillation of 45 µmol/kg sat PC compared with a trace dose 
(271). Nevertheless, further increase of the dose had no effect on the half-life. 
As a secondary goal, we compared the method of DPPC half-life and sat PC pool size 
measurements using stable isotopes with that of radioactive isotopes and surfactant pool 
size measurements at autopsy in very premature ventilated baboons. The results obtained 
with the use of stable isotopes were comparable to the results obtained with radioactive 
tracers and tissue measurements of pool size. Estimation of surfactant half-life and pool 
size by the isotope dilution method is based on several assumptions. The distribution of 
the exogenous surfactant and the endogenous surfactant has to be similar, the phospho-
lipid composition in the various surfactant compartments has to be uniform, the surfac-
tant system has to be pulse labeled, there should be no endogenous synthesis of the label, 
and the pool size after exogenous surfactant has to be constant. It is reasonable to assume 
that most of the assumptions have been fulfilled as has been extensively discussed by 
Hallman et al. and by Torresin et al. (61, 62). 
In conclusion, the metabolism of surfactant PC did not change during the recovery from 
RDS and the development of BPD. Very preterm baboons have low sat PC pool size at 
birth. Treatment with surfactant increased instantaneously the total lung sat PC pool size, 
which was kept relatively constant by endogenous surfactant synthesis. Half-lives of sur-
factant PC did not change during the first 2 weeks of life. We also showed that stable iso-
topes are a valid tool for studying surfactant metabolism in vivo. This method can be eas-
ily applied to human neonates, which will enable us to better understand the role of sur-
factant in different neonatal lung diseases. 
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Abstract 
 
We measured surfactant phosphatidylcholine (PC) pool size and half-life in human con-
genital diaphragmatic hernia (CDH) patients who required extracorporeal membrane oxy-
genation (ECMO). Surfactant PC pool size and half-life were measured by endotracheal 
administration of deuterium-labeled dipalmitoylphosphatidylcholine in 8 neonates with 
CDH on ECMO (CDH-ECMO), in 7 neonates with meconium aspiration syndrome on ECMO 
(MAS-ECMO), and in 6 ventilated infants (NON-ECMO). Lung PC pool size in the CDH-ECMO 
group was 73±17 mg/kg (mean±SEM), which was not significantly different from the MAS-
ECMO (50±18 mg/kg) and the NON-ECMO group (69±38 mg/kg). Surfactant PC concentra-
tion in tracheal aspirates was not different between groups (~6 mg/mL). However, the 
percentage of palmitic acid in surfactant PC was significantly lower in the MAS-ECMO 
(56.3%) and the NON-ECMO (55.8%) group compared to the CDH-ECMO (67.6%) group. Sur-
factant PC half-life (~24 hours) was not different between the groups. A correlation was 
found between the surfactant PC half-life and the duration of ECMO. In conclusion, these 
data show no decreased surfactant PC pool size in high risk CDH patients who require 
ECMO. A shorter half-life of surfactant PC, indicating a faster turnover, may result in a 
faster improvement of the pulmonary condition during ECMO. 
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Introduction 
Congenital diaphragmatic hernia (CDH) usually results in severe respiratory insufficiency 
that may lead to death because of pulmonary hypoplasia and persistent pulmonary hyper-
tension. CDH lungs show some resemblance morphologically to the lungs of preterm in-
fants with respiratory distress syndrome (RDS) (82). The lungs of neonates with RDS are 
surfactant-deficient and, in general, these patients respond to surfactant treatment.  
Studies in animal and human models report conflicting data; it is unclear whether a 
primary surfactant deficiency is present in human CDH (100). In nitrofen-induced CDH rats 
and lambs with surgically induced CDH phospholipid, disaturated phosphatidylcholine (PC), 
and surfactant protein A (SP-A) in lung tissue are lower compared with controls (85, 87, 
91-93). The scarce data in humans show no difference in amniotic leci-
thine:sphingomyeline ratio between CDH and control fetus (95). SP-A was lower in the 
amniotic fluid of fetuses with CDH who died or required extracorporeal membrane oxy-
genation (ECMO) (97). Autopsy studies in CDH infants showed a decrease of SP-A in the 
lungs (98, 99). Earlier, we showed that the concentration of surfactant PC in broncho-
alveolar lavage from CDH patients is not different from control patients (100). Direct pool 
size measurements have only been done in autopsy studies of patients without CDH (261), 
and not in term-born patients with CDH. As a consequence, no data are available about 
the surfactant pool size and surfactant metabolism in human CDH patients.  
We report on surfactant PC pool sizes and the half-life of surfactant PC in neonates with 
CDH who required ECMO. Surfactant PC pool size and half-life were measured in vivo with 
the use of stable isotopes. 
 
 
Patients and Methods 
Patients 
The study was performed in the pediatric surgical and neonatal intensive care units of the 
Sophia Children’s Hospital between October 1999 and April 2001. We studied 3 groups of 
neonates (Table 1): neonates with left-sided CDH who required veno-arterial ECMO (CDH-
ECMO) (n=8), neonates with meconium aspiration syndrome (MAS) on ECMO (MAS-ECMO) 
(n=7), and a mixed group of ventilated term neonates without ECMO (NON-ECMO) (n=6). 
The diagnosis of the neonates in the NON-ECMO group were: CDH (n=2, one right-sided de-
fect); MAS (n=2); right-sided cerebral medial infarction (ventilated because of apneic at-
tacks and convulsions) (n=1); spina bifida; and Arnold Chiari malformation (ventilated be-
cause of apneic attacks) (n=1). Six CDH patients (1 NON-ECMO CDH patient) were diag-
nosed prenatally and were born in our hospital; 4 were postnatal referrals. One CDH-ECMO 
patient had a chromosomal disorder, and none underwent surgical repair before or during 
the study. Ventilator and arterial blood gas data before the start of ECMO are presented in 
Table 2.  
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Table 1. Patients characteristics 
 CDH-ECMO 
n=8 
MAS-ECMO 
n=7 
NON-ECMO 
n=6 
Male/Female 5/3 2/5 5/1 
Gestational age (wk) 38.4±0.8 40.6±0.6 39.8±0.5 
Birth weight (g) 3058±200 3267±184 3347±121 
Apgar 5 min. 8.0 (5-9) 7.0 (1-8) 8.5 (5-10) 
Age at start ECMO (h) 17±4 33±10 - 
Age at start study (h) 38±5 59±12 100±30 
Pneumothorax 3 2 0 
Surfactant treatment none 5 / 7 none 
Duration of ECMO (h) 197±43 133±25 - 
Time of ventilation (d) 22.5±2.7* 12.4±1.9 13.8±4.2 
Supplemental O2 (d) 36.5±14.2 16.9±2.1 15.5±4.5 
Length of stay in ICU (d) 27±3 11±3 31±14 
Survivors 3/8 7/7 6/6 
Data are expressed as mean±sem, except Apgar score at 5 min., presented as median (range). 
*Significantly different from MAS-ECMO and NON-ECMO group (p=0.046). 
 
 
Our institution uses a standardized protocol for treatment of CDH patients, consisting 
of: cardiac ultrasonagraphy, moderate fluid restriction (40-60 mL/kg body weight), no 
muscle paralysis, sedation with midazolam (0.1 mg/kg/h) and morphine (5-15 µg/kg/h), 
support of systemic blood pressure by dopamine and eventually norepinephrine, and con-
tinuous suctioning of double lumen nasogastric tube (272). 
The entry criteria for ECMO were: gestational age of ≥34 weeks; birth weight of ≥2000 
g; mechanical ventilation for <7 days; and alveolar arterial oxygen difference (AaDO2) of 
>600 torr (>80 kPa) for 8 hours. A minimal partial pressure of oxygen in arterial blood 
(PaO2) of ≥75 torr (≥10 kPa) was an additional criterion for CDH patients. During ECMO, 
ventilatory settings were usually reduced to peak inspiratory pressure of 12 to 16 cm H2O, 
positive end-expiratory pressure of 5 to 6 cm H2O, respiratory rate of 10 to 15 
breaths/min, and fractional concentration of oxygen in inspired gas (FiO2) of 0.25 to 0.3. 
 
Study Protocol 
The study protocol was approved by the local medical ethics committee, and patients 
were included after informed consent. The patients received a tracer dose of 5 mg/kg    
(1 ml/kg) deuterium-labeled dipalmitoylphosphatidylcholine (2H-DPPC) (L-3-
phosphatidylcholine dipalmitoyl-D6, Doosan Serdary Research Laboratories, Englewood 
Cliffs, NJ) endotracheally at the start of the study (t=0). The start of the study was within 
24±3 hours after the onset of ECMO or after the onset of ventilation. The patient’s head 
was placed in the midline. A 6-Fr catheter was passed down the endotracheal tube and 
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placed at the end of the tube. The 2H-DPPC was administered through the catheter, and 
afterwards the neonate was immediately reconnected to the mechanical ventilator at pre-
treatment settings. Tracheal aspirates were obtained every 4 to 6 hours during the time 
the infant was intubated, and immediately placed at -20°C, until further processing. No 
tracheal suctioning was done within 6 hours after 2H-DPPC administration. 
 
Procedure and determination of enrichment 
The tracheal aspirates were processed as described before (54, 273). One µL of the de-
rivative of deuterated PC palmitate was injected into a GC8000 gas chromatograph cou-
pled to a Fisons MD-800 mass spectrometer (Interscience BV, Breda, The Netherlands). En-
richment was expressed as mol percent excess (MPE), representing the molar percent of 
the labeled molecule, corrected for baseline (natural) enrichment (before administration 
of the isotope). 
 
Determination of composition and concentration 
Fatty acid composition of surfactant PC and the amount of surfactant PC were analyzed on 
a gas-chromatograph (GC) (Hewlett-Packard, 5890 series II, Amstelveen, The Netherlands) 
(100). The concentration of surfactant PC in the epithelial lining fluid (ELF) was calculated 
by correcting for dilution of the ELF during endotracheal suction: dilution factor = 
[urea]serum/[urea]supernatant (257). 
 
Calculations 
Calculations were performed as described before (54, 62, 273). The half-life of 2H-DPPC 
was calculated by exponential curve fitting of the final mono-exponential part of the 
downslope of the curve of 2H-enrichment over time. The apparent lung PC pool size was 
calculated as before (273), by using the linear regression line representing the decay of 
the log-transformed 2H-enrichment over time, started at t=18 h till 4 times the half-life of 
each individual curve and expressed as mg/kg PC. We measured the enrichment of 
palmitic acid in surfactant PC. Palmitic acid accounts for ~70% of all fatty acids in surfac-
tant PC. To calculate total PC pool size we therefore divided the pool size by the mean 
fraction of palmitic acid, measured in tracheal aspirates of the individual patients in the 
first 4 days of the study. Pool size was corrected for the amount of exogenous 2H-DPPC 
administered. 
 
Data analysis 
Data are presented as mean±SEM. Differences between groups were analyzed by one-way 
analysis of variance, and correlation by Pearson correlation test. Significance was ac-
cepted at p<0.05. 
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Table 2. Ventilator and arterial blood gas data before start of ECMO or highest ventila-
tory parameters in the NON-ECMO group 
  
MAP 
(cm H2O) 
PIP or ∆P 
(cm H2O) 
PaO2 
(kPa) 
PaCO2 
(kPa) 
OI AaDO2 
(mmHg) 
CDH-ECMO CV (n=1) 10.6 25 11.3 3.5 
 HFO (n=7) 15.4±0.9 51.1±4.3 8.6±1.8 6.6±1.2
26.0±4.0 587±13 
MAS-ECMO CV (n=4) 16.7±1.0 32.5±3.0 7.6±3.3 6.3±1.6
 HFO (n=3) 21.7±2.0 40.3±9.3 7.4±1.9 5.4±1.0
41.8±9.7 597±17 
NON-ECMO CV (n=4) 9.3±2.0 19.1±3.6 11.7±3.6 6.1±0.7
 HFO (n=2) 15-16 32-56 10.3-21.4 5.1-5.6
8.3±2.0* 333±96* 
CV, conventional ventilation; HFO, high frequency oscillation; MAP, mean airway pressure; PIP, posi-
tive inspiratory pressure; ∆P, pressure amplitude on HFO; OI, oxygenation index (OI=(MAP x 
FiO2)/PaO2; Pa-aO2, alveolar-arterial oxygen tension difference (Pa-aO2 = PaO2 – [(713 x FiO2)-
(PaCO2/0.8)].  
Data are expressed as mean±SEM, except for the HFO ventilated NON-ECMO group where both values 
are given. In the NON-ECMO group, 1 MAS and 1 CDH patient received HFO.  
*Signigicantly different from CDH-ECMO and MAS-ECMO (p<0.05). 
 
 
Results  
The CDH-ECMO group was ventilated during a significantly longer time (p=0.046) compared 
with the MAS-ECMO and NON-ECMO group (Table 1). Oxygenation index (OI) and AaDO2 
were significantly different between the NON-ECMO group and the CDH-ECMO and MAS-
ECMO group (p=0.032 and p=0.0001, respectively) (Table 2). 
Surfactant PC pool sizes were not significantly different between the 3 groups (Table 3). 
The CDH-ECMO patients had a mean surfactant PC pool of 73±17 mg/kg, the NON-ECMO 
group had a surfactant PC pool of 69±38 mg/kg, and the MAS-ECMO group had a pool of 
50±18 mg/kg. The NON-ECMO patients without significant lung disease had a surfactant PC 
pool size of 90 mg/kg (range: 26-155), whereas the patients with lung disease in the NON-
ECMO group had a mean surfactant PC pool size of 59±46 mg/kg (no difference between 
groups). A correlation existed between the surfactant PC pool size and half-life 
(p=0.0001).  
The mean surfactant PC half-lives of the different groups were not significantly differ-
ent (Table 3). However, we found a correlation between the duration of ECMO and the 
half-life for both groups, the MAS-ECMO (p=0.046) and the CDH-ECMO (p=0.046) (Figure).  
No correlation was found between the surfactant PC pool size or half-life and the fol-
lowing parameters: gestational age, birth weight, Apgar score at 5 minutes, age at start of 
the study, age at start of the ECMO therapy, OI, AaDO2, time to extubation, and length of 
stay in the intensive care unit.  
Surfactant pool size measurements in human neonates 
61 
Survivors and nonsurvivors in the CDH-ECMO group were not different in surfactant PC 
pool sizes and half-life, as were the surfactant-treated and nonsurfactant-treated neo-
nates in the MAS-ECMO group.  
The mean surfactant PC concentration during the first 4 days of the study was the same 
for all groups. The CDH-ECMO group had a surfactant PC concentration of 6.5±2.3 mg/mL 
ELF, in the MAS-ECMO group the concentration was 6.4±3.8 mg/mL ELF, and 5.4±2.6 
mg/mL ELF in the NON-ECMO group (Table 3). Fatty acid composition of surfactant PC was 
measured in tracheal aspirates during the first 4 days of the study. In the CDH-ECMO 
group, the percentage of palmitate was significantly higher compared with the MAS-group 
and the NON-ECMO group (p=0.029) (Table 3). Conversely the percentage of other fatty 
acids in PC were not significantly different between groups (data not shown). 
 
 
Table 3. Surfactant PC parameters measured in the 3 patient groups 
 
Pool size 
(mg PC/kg) 
Half-life 
(h) 
PC concentration 
(mg/ml ELF) 
Palmitic acid 
(%) 
CDH-ECMO    (n=8) 73±17 31.0±5.2 6.5±2.3 67.6±2.6* 
MAS-ECMO    (n=7) 50±18 21.9±6.4 6.4±3.8 56.3±2.1 
NON-ECMO   (n=6) 69±38 21.0±4.3 5.4±2.6 55.8±5.2 
Data are expressed as mean±SEM.  
*Significantly different from the MAS-ECMO and the NON-ECMO group (p=0.029). 
 
 
Discussion 
We evaluated surfactant PC pool size in human neonates with CDH who require ECMO. En-
dotracheally administered 2H-DPPC was used to measure surfactant PC pool size and half-
life in human infants in vivo. The method was validated in premature baboons by compar-
ing it with pool size measurements at autopsy and with half-life measurements with the 
use of radio-active isotopes (273). CDH patients receiving ECMO did not have a decreased 
surfactant PC pool size. We measured a mean total lung PC pool size of ~73 mg/kg, which 
was not significantly different from the MAS-ECMO (~50 mg/kg) and the NON-ECMO group 
(~69 mg/kg). Surfactant PC half-life was also not different between the 3 groups, and was 
~31 hours for the CDH-ECMO patients. 
Surfactant PC pool size has never been measured in human neonates with CDH who re-
quire ECMO. Most studies that investigated a possible surfactant deficiency in CDH meas-
ured surfactant phospholipid composition and PC concentrations in the lungs of animals or 
humans. There are only a few reports about the metabolism of surfactant in vitro in ani-
mal models (85, 87, 93). We measured a mean pool size of ~73 mg/kg surfactant PC in 
CDH patients receiving ECMO. Saturated PC pool sizes measured in term baboons are ~97 
µmol/kg (59). Assuming that 60% of PC is saturated PC, this would become 162 mg/kg PC. 
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In 3-day-old rabbits, the surfactant PC pool size at autopsy in total lung homogenate was 
~180 mg/kg (274). However, it is not clear how much of this PC is surfactant-associated 
and how much is associated with lung membrane PC. Pool size measurements in preterm 
infants with RDS, who received the tracer in combination with a treatment dose of surfac-
tant (100 mg/kg) showed an endogenous surfactant PC pool size (before treatment) of ~10 
mg/kg, which is much lower than we found in CDH patients receiving ECMO (62). Although 
CDH patients who require ECMO have the sickest lungs but similar pool sizes to our control 
group (~73 versus ~69 mg/kg PC), we expect that CDH patients who do not need ECMO  
have similar or even higher surfactant PC pool sizes. Alternatively, it is also possible that 
ECMO protects endogenous surfactant. In that case, CDH patients not receiving ECMO have 
lower surfactant PC pool sizes. Indeed, SP-A in tracheal aspirates of CDH patients also in-
creases during ECMO, but the SP-A levels were still low compared to non-CDH patients re-
ceiving ECMO (108). Although our data suggest that surfactant PC pool size in CDH patients 
receiving ECMO is normal, a good comparison with an appropriate control group is very 
hard to make. Ideally, a control group would consist of nonventilated infants, but it is 
ethically not possible to obtain tracheal aspirates in these patients. However, from litera-
ture it is known that pool size of surfactant phospholipids in healthy term neonates is ~100 
mg/kg (80). Our data certainly show that the degree of surfactant deficiency did not cor-
relate with severity of disease, because patients receiving ECMO have similar surfactant 
PC pool size compared to NON-ECMO patients. 
The results of the current study are in agreement with our results of an earlier study, 
where we found no difference in surfactant PC concentration in bronchoalveolar lavage 
fluid between CDH patients and controls (100). Surfactant PC concentrations during the 
first 4 days of the study were also not different between the groups, and were ~6 mg/mL 
ELF. Using the same method in a study in preterm infants, we found a lower surfactant PC 
concentration of 2.4 mg/mL ELF (244). Cogo et al. showed reduced levels of disaturated 
PC in ELF of CDH patients not receiving ECMO (~2.3 mg/kg disaturated PC) compared to 
controls (~4.6 mg/kg disaturated PC) (57). However, surfactant synthesis was not different 
between CDH patients and controls. It is not clear yet if surfactant concentrations meas-
ured in tracheal aspirates correlate with lung surfactant pool size. We did not find any 
correlation between surfactant concentration in ELF and surfactant PC pool size in our pa-
tients. 
The results of surfactant PC half-life are comparable to the results in preterm humans 
with RDS (61, 62, 81) and preterm baboons (273). The half-life is also in agreement with 
that of CDH patients not requiring ECMO (~26 hours) (personal communication, P. Cogo, 
Padua, Italy).  
A positive correlation was found between surfactant PC half-life and the duration of 
ECMO. Based on equal pool size and severity of disease at the start of the study, a possible 
explanation could be that a lower endogenous synthesis of surfactant leads to a slower di-
lution of the labeled exogenous surfactant in patients who required a longer duration of 
ECMO. A lower PC synthesis was also found in isolated type II pneumocytes from the lungs 
of the lamb model of CDH compared with normal (85, 87). We speculate that a surfactant 
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pool that is replaced by newly synthesized surfactant more rapidly results in a faster im-
provement of the clinical condition and a shorter duration of ECMO.  
At the time of the study, our standard protocol did not include permissive hypercapnia 
before start of ECMO as was suggested by recent publications (275). Even so, using our ap-
proach of a more ‘vigorous’ ventilatory support, we did not find reduced surfactant PC 
pool sizes, rendering an additional argument against a primary surfactant deficiency in 
CDH cases in need for very intensive ventilatory support and ECMO. We believe that, 
taken into account, the discernible negative effects of artificial ventilation in the hy-
poplastic lungs of CDH (129), a secondary surfactant insufficiency is a common feature in 
CDH. This could possibly be avoided by protective ventilatory strategies such as permissive 
hypercapnia and high frequency ventilation. 
 
 
Figure. Correlation between the surfactant phosphatidylcholine (PC) half-life and the du-
ration of extracorporal membrane oxygenation (ECMO) 
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A positive correlation was found between surfactant PC half-life and the duration of ECMO 
(p=0.001). The correlation existed for both ECMO groups, CDH-ECMO (y=0.23x + 2.24, p=0.046) and 
MAS-ECMO (y=0.21x + 1.50, p=0.046). 
 
 
In this study we observed neonates with MAS who required ECMO for comparison. Sur-
factant PC pool sizes in the MAS-ECMO group were not significantly decreased (~50 
mg/kg). Surfactant inactivation seems to play a more important role in the pathophysiol-
ogy of MAS. In vitro studies show an inhibition of surfactant function by meconium in a 
concentration-dependent manner (131). Surfactant inhibitors such as total protein and al-
bumin, were elevated in lung lavage fluid of infants with MAS (143). We found a signifi-
cant lower percentage of palmitic acid in surfactant PC in tracheal aspirates of the MAS-
ECMO group compared with the CDH-group (56% versus 68%). This may indeed point to a 
less active surfactant that is also suggested by a decreased surfactant protein A and B in 
bronchoalveolar lavage fluid of rats with MAS (141). The percentage of surfactant PC 
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palmitate was also significantly lower in the NON-ECMO group compared with the CDH-
ECMO group, which is because of the 2 MAS patients in the NON-ECMO group. 
We used 2 groups for comparison with CDH patients in the current study. One group of 
neonates with developmentally normal lungs who require ECMO (MAS-ECMO group), and a 
NON-ECMO control group, consisting of infants with several diagnoses who did not require 
ECMO. It is difficult to include control patients without significant lung disease who are 
ventilated for at least 3 days to study surfactant metabolism. 
In conclusion, surfactant PC pool size and half-life are not decreased in neonates with CDH 
who required ECMO compared with neonates with MAS who required ECMO and NON-ECMO 
patients. However, patients who needed a longer ECMO treatment had a longer surfactant 
PC half-life. Our results suggest no surfactant deficiency in CDH patients requiring ECMO, 
but does not exclude a surfactant inactivation secondary to the treatment. 
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Abstract 
 
Congenital diaphragmatic hernia (CDH) may result in severe respiratory insufficiency with 
a high morbidity despite recent advances in respiratory support and the use of extracorpo-
real membrane oxygenation (ECMO). The role of a disturbed surfactant metabolism in the 
pathogenesis of CDH is not clear yet. We therefore studied endogenous surfactant me-
tabolism in the most severe CDH patients who require ECMO. Eleven neonates with CDH 
who required ECMO treatment (CDH-ECMO), and ten ventilated neonates without signifi-
cant lung disease (controls) were studied. All infants received a 24-hr infusion with the 
stable isotope [U-13C]glucose. The 13C-incorporation into palmitic acid in surfactant phos-
phatidylcholine (PC) isolated from serial tracheal aspirates was measured. Mean PC con-
centration in epithelial lining fluid (ELF) was measured during the first four days of the 
study. Surfactant PC synthesis was decreased in CDH-ECMO patients compared to controls 
(2.4±0.33 versus 8.0±2.4 %/day, p=0.04). The control group had a higher maximal enrich-
ment (0.18±0.03 versus 0.09±0.02 APE, p=0.04), and an earlier time of maximal enrich-
ment (46.7±3.0 versus 69.4±6.6 hours, p=0.004) compared to the CDH-ECMO group, which 
reflects more and faster precursor incorporation in the control group. Surfactant PC con-
centration in ELF was similar in both groups. In conclusion, these results show that CDH 
patients who require ECMO have a decreased surfactant PC synthesis, which could serve as 
a rationale for the need for ECMO in this particular group of patients.  
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Introduction 
Congenital diaphragmatic hernia (CDH) may result in severe neonatal lung ‘disease’ due to 
lung hypoplasia, pulmonary hypertension, and the sequelae of ventilatory support (129). 
Despite advances in respiratory support and the use of extracorporeal membrane oxygena-
tion (ECMO), the morbidity of CDH remains high (276).  
The presence of a surfactant deficiency in CDH is subject to ongoing debate. The scarce 
data in humans show no difference in amniotic lecithine/sphingomyelin ratio between 
CDH and control fetuses (95), but amniotic SP-A was reported to be lower in CDH fetuses 
who died or required ECMO (97). Moreover, autopsy studies in CDH infants showed de-
creased SP-A levels in the lungs (98, 99). Earlier, we showed that the concentration of sur-
factant PC in bronchoalveolar lavage from CDH patients was not different from control pa-
tients (100). And more recently, in a study using stable isotopes, we found no decreased 
surfactant PC pool size in high risk CDH patients who required ECMO (277). 
In a previous study of our group, Cogo et al. studied the surfactant disaturated PC 
(DSPC) kinetics in CDH patients who did not require ECMO by using stable isotopes (57). 
Although the amounts of DSPC and SP-A in the tracheal aspirates of CDH patients were re-
duced, these patients had rates of endogenous surfactant DSPC synthesis comparable to 
control patients. 
Several animal models, such as the surgically created CDH lamb model and the nitrofen-
induced CDH rat model suggest decreased surfactant parameters in lung tissue (85, 87, 91-
93). In vitro studies in isolated type II cells of the CDH lamb model show decreased incor-
poration of precursor in surfactant phosphatidylcholine (PC), suggesting decreased surfac-
tant synthesis (85, 87). 
The purpose of our present study was to study the surfactant PC kinetics in vivo in CDH 
patients who required ECMO with the use of stable isotopes. We hypothesized that the 
surfactant synthesis in these CDH patients on ECMO, who have “sicker” lungs compared to 
CDH patients who do not require ECMO, is decreased.  
 
 
Patients and Methods 
Patients 
The study was performed in the pediatric surgical and neonatal intensive care units of the 
Sophia Children’s Hospital between October 1999 and April 2001. We studied two groups 
of neonates (table 1): neonates with left sided CDH who required veno-arterial ECMO 
(CDH-ECMO) (n=11), and a group of ventilated term neonates without significant lung dis-
ease (control) (n=10). The diagnoses of the 10 ventilated control patients were varied and 
overall no primary pulmonary anomaly or sign of abnormal lung development was present: 
gastroschisis, cerebral infarction, small to moderate omphalocele (n=2), anal atresia, 
thymic cyst, spina bifida, pentalogy of Cantrell, and hypoxic ischemic encephalopathy 
(n=2). Apart from the two study groups, we studied two male CDH patients who did not 
require ECMO. The study was approved by the local medical ethics committee, and all pa-
tients were studied after written informed consent of parents. 
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Our institution uses a standardized protocol for treatment of CDH patients, consisting 
of: immediate endotracheal intubation at birth and insertion of a nasogastric tube for de-
compression of the stomach, cardiac ultrasound, fluid restriction (40-60 ml/kg body 
weight), no muscle paralysis, sedation with midazolam (0.1 mg/kg/h) and morphine (5-15 
µg/kg/h), support of systemic blood pressure by dopamine and eventually norepinephrine, 
and continuous suctioning of double lumen nasogastric tube (272). 
The entry criteria for ECMO were: gestational age of ≥34 weeks; birth weight of ≥2000 
g; mechanical ventilation for <7 days; AaDO2 of >600 torr (>80 kPa) for 8 hours; and OI> 25 
for 4 hours. A minimal PaO2 of ≥75 torr (≥10 kPa) was an additional entry criterium for 
CDH patients. During ECMO, ventilatory settings were routinely reduced to peak inspira-
tory pressure of 9-12 mm Hg (12-16 cm H2O), positive end-expiratory pressure of ∼4 mm 
Hg (5-6 cm H2O), respiratory rate of 10 to 15 breaths/min, and FiO2 of 0.25 to 0.3. 
 
Isotope infusion and sample collection 
All included patients received a 24-hour continuous intravenous infusion of [U-13C]glucose 
(0.17 mg/kg/min, Campro Scientific, Veenendaal, The Netherlands and Cambridge Isotope 
Laboratories, Inc, Andover, Mass). The start of the isotope infusion was defined as the 
start of the study (t=0). Before and during the label infusion, 1 ml blood was drawn every 
6 h for determination of 13C-enrichment of plasma glucose. Samples were collected in an 
EDTA tube, immediately placed on ice, and centrifuged at 2500 rpm for 10 minutes. The 
plasma was stored at -70ºC until it was analyzed. Tracheal aspirates were obtained every 
4 to 6 h during the time the infant was intubated, with a maximum of 2 weeks. The tra-
cheal suctioning was performed during routine patient care and did not deviate form the 
normal clinical care. Tracheal aspirates were immediately placed at -20°C, until further 
processing.  
 
Analytical procedure 
The plasma and tracheal aspirates were processed as described before (54, 57). Briefly, 
plasma was delipidated and glucose was isolated and derivatized to an aldonitril pentace-
tate derivative (245). Organic extraction was used to isolate surfactant lipids in the tra-
cheal aspirates (246), and surfactant PC was recovered by thin layer chromatography 
(278). Isotopic enrichments were measured by mass spectrometry, as described before 
(54). The 13C-enrichments were expressed as atom percent excess (APE), which represent 
the increase in the percentage of 13C atoms in total carbon dioxide from the combusted 
compounds above baseline enrichment (before infusion). Enrichments were corrected for 
the contribution of unlabeled carbon atoms added during derivatization. 
 
Determination of composition and concentration 
Fatty acid composition of surfactant PC and the amount of surfactant PC were determined 
by gas-chromatography (GC) (Hewlett-Packard, 5890 series II, Amstelveen, The Nether-
lands) (100). The concentration of surfactant PC in the epithelial lining fluid (ELF) was 
calculated by correcting for dilution of the ELF during endotracheal suction: dilution fac-
tor = [urea]serum/[urea]supernatant (257). 
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Calculations 
Calculations were performed as described before (54). Time of first appearance (Tapp) is 
defined as the time delay between the start of the isotope infusion and the first appear-
ance of the label in surfactant PC. Time of maximal enrichment (Tmax) is the time where 
maximum enrichment is reached (Emax). Half-life of surfactant PC (T½) was calculated 
from the downslope of the enrichment versus time curve. Fractional synthesis time (FSR) 
of palmitic acid in surfactant PC represents the percentage of the total PC-palmitate pool 
synthesized de novo from plasma glucose per day.  
 
Data analyses 
Data are presented as mean±standard error of the mean (SEM). The non-parametric Mann-
Whitney U-test was applied to compare groups. The Spearman method was used to evalu-
ate correlations between surfactant kinetic parameters, surfactant PC concentration and 
patient characteristics. Significance was accepted at a value of p<0.05. 
 
 
Table 1. Patients characteristics  
 
CDH-ECMO 
n=11 
Control 
n=10 
Gestational age (wk) 38.2±0.8 39.0±0.4 
Birth weight (g) 3077±150 3189±237 
Apgar score at 5 min. 6.4±0.8 7.0±1.5 
Male/Female 7/4 5/5 
Pneumothorax (n) 5 1 
Duration of ventilation (d) 28.3±5.1 25.6±9.9 
Age at start study (h) 42.9±4.5 137.6±45.5* 
Survivors (n) 5 8 
*Significantly different p=0.03. 
 
 
Results 
Seven CDH-ECMO patients were diagnosed prenatally and were born in our hospital, four 
were postnatal referrals. The ECMO of the CDH patients was started 15.1±2.7 hours after 
birth, and had a duration of 226±34 hours. The time on ECMO before the start of the study 
was 27.8±4.2 hours. In five CDH-ECMO patients a pneumothorax was diagnosed, which in 
all cases occurred before the start of ECMO, sometimes even directly after birth. Six of 
the CDH-ECMO patients underwent a surgical repair of the diaphragmatic defect on day 
20±6 of life, and in none of these CDH patients the surgical repair was performed before 
or during the study. All patients were successfully decannulated. The non-survivors in the 
CDH-ECMO group died at 28.2±5.5 days of life, due to rebound pulmonary hypertension 
which was resistant to maximal treatment. Unfortunately, none of the non-survivors un-
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derwent an autopsy, as a consequence lung body weight ratio’s are not available. Two pa-
tients (both patients with hypoxic ischemic encephalopathy) in the control group died be-
cause of severe cerebral damage at day 6, respectively day 15 of life. Clinical characteris-
tics are described in Table 1. We studied two CDH patients who did not require ECMO, one 
was born in our hospital and was included 27.5 hours after birth before surgical repair of 
the defect, the other was diagnosed three days after birth and was included after repair 
of the defect (at 107 hours after birth). 
Ventilatory parameters. Nine of the CDH patients were ventilated with high frequency 
oscillation (HFO) before ECMO treatment, two CDH patients were conventionally venti-
lated. Ventilation and oxygenation characteristics of the CDH patients before the start of 
ECMO were as follows: mean airway pressure (MAP) was 13.5±1.4 mm Hg (18.3±1.9 cm 
H2O), oxygenation index (OI= (MAP x FiO2)/PaO2) was 40.6±8.1, and the alveolar-arterial 
oxygen gradient (AaDO2= PaO2 – [(713 x FiO2)-(PaCO2/0.8)]) was 593.0±10.2 torr (79 kPa). 
The 10 control patients were conventionally ventilated for 26±10 days following surgery or 
because of apneic attacks. These patients had mild ventilatory settings: FiO2: 0.26±0.03, 
MAP: 5.9±0.6 mm Hg (8.0±0.8 cm H2O), ventilatory rate: 31±4/min., positive inspiratory 
pressure (PIP): 14.1±1.3 mm Hg (19.2±1.8 cm H2O), positive end-expiratory pressure 
(PEEP): 3.2±0.1 mm Hg (4.4±0.2 cm H2O). 
 
 
Figure. 13C-enrichment of palmitic acid in surfactant phosphatidylcholine in sequential 
tracheal aspirates 
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Neonates with congenital diaphragmatic hernia on extracorporeal membrane oxygenation (CDH-
ECMO) (closed circles) and control patients (open circles) received a 24-h [U-13C]glucose infusion as 
precursor for phosphatidylcholine-palmitate. Data are expressed as mean and standard error of 
mean of time intervals of 12 and 24 hours, with the 24 hour interval started at 72 hours. 
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Surfactant kinetic parameters. The 13C-enrichment of plasma glucose was in steady 
state (Egluc) in all infants between t=6 and 24 hours, and was similar in both groups 
(2.0±0.1 versus 2.2±0.3, p=0.70). The Figure shows the 13C-glucose incorporation of sur-
factant PC palmitate in sequential tracheal aspirates in the CDH-ECMO patients and con-
trol patients. The control group had a higher maximal enrichment and an earlier time of 
maximal enrichment compared to the CDH-ECMO group, which reflects more and faster 
precursor incorporation in the control group (Table 2). The FSR, calculated from the linear 
increase of each individual patient is significantly lower in the CDH-ECMO patients com-
pared to the control patients (2.4±0.33 versus 8.0±2.4 %/day, p=0.04). The incorporation 
of 13C from the precursor glucose into surfactant PC palmitate in tracheal aspirates (Tapp) 
started somewhat later in the CDH-ECMO patients (18.0±2.6 versus 11.7±1.1 hours, 
p=0.11), which was followed by a later Tmax in the CDH-ECMO patients compared to the 
control patients (69.8±6.6 versus 46.7±3.0 hours, p=0.004). The Emax in the CDH-ECMO pat-
ients was lower than in controls (0.09±0.02 versus 0.18±0.03 APE, p=0.04). The half-life of 
label disappearance from surfactant PC was not different between groups (Table 2). No 
correlation between surfactant kinetic parameters and patient characteristics were found, 
except for surfactant half-life and gestational age which were correlated negatively in the 
CDH-ECMO group (p=0.03).  
 
 
Table 2. Surfactant kinetic parameters and surfactant phosphatidylcholine (PC)  
concentration in epithelial lining fluid (ELF) during the first four days of the study 
 
CDH-ECMO 
n=11 
Control 
n=10 
p-value 
FSR (%/day) 2.4±0.3 8.0±2.4 0.04 
Tapp (h) 18.0±2.6 11.7±1.1 0.11 
Tmax (h) 69.8±6.6 46.7±3.0 0.004 
Emax (APE) 0.09±0.02 0.18±0.03 0.04 
Half-life (h) 69.0±10.3 63.4±10.7 0.79 
Egluc (APE) 2.0±0.1 2.2±0.3 0.75 
PC (mg/ml ELF) 6.6±1.9 12.8±2.6 0.78 
Data are expressed as mean±standard error of mean (SEM). The non-parametric Mann Whitney U-test 
was applied to compare groups. 
 
 
In the two included CDH patients who did not require ECMO treatment the Tapp was 13 
and 26 hours, maximal enrichment was reached at 39 and 43 hours, with a maximal en-
richment of 0.17 and 0.23 APE, followed by a surfactant half-life of 56.8 hours. Surfactant 
half-life could only be measured in one of the two patients due to the early extubation. 
FSR in the two CDH patients not on ECMO was 7 and 14 %/day. PC concentration in ELF 
during the first four days of the study was 3.7 and 7.6 mg/ml. 
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The surfactant PC concentration in ELF during the first four days of the study was equal 
in both groups (Table 2). No correlations were found between the surfactant PC concen-
tration and the surfactant PC kinetic parameters, nor between the surfactant PC concen-
tration and the OI, AaDO2, and the gestational age. 
Surfactant PC concentration in ELF during the first four days of the study was not differ-
ent between the survivors and non-survivors of the CDH-ECMO group (9.5±3.6 versus 
4.5±1.8 mg/ml ELF, p=0.27). There were also no differences in surfactant kinetic parame-
ters between the survivors and non-survivors of the CDH-ECMO group. However, gesta-
tional age was lower in the non-survivors compared to the survivors of the CDH-ECMO 
group (37.1±0.6 versus 39.6±0.5 weeks, p=0.02). 
 
 
Discussion 
In the present study we report a significantly lower rate of surfactant PC synthesis in hu-
man CDH patients who require ECMO compared to control patients. The surfactant PC syn-
thesis was studied in vivo with the use of stable isotopes, by measuring incorporation 
rates of precursor into surfactant PC (2.4±0.3 versus 8.0±2.4 %/day, p=0.04). The time of 
maximal enrichment (Tmax) was reached later in the CDH-ECMO group and these patients 
also had a lower maximal enrichment (Emax) compared to the controls. Surfactant PC half-
life was not different between the two groups. We measured surfactant PC concentration 
in ELF during the first 4 days of the study, which was not significantly different between 
the groups. 
As in the present study, in vitro studies also found decreased PC synthesis (85, 87, 279). 
Type II cell cultures from rat fetuses with severe CDH showed a reduced activity of phos-
phocholine cytidyltransferase, which regulates the de novo synthesis of PC (279). There 
was a tendency of a decreased incorporation of choline into PC in isolated type II cells of 
CDH lambs compared to control lambs (85, 87). In another study in lambs the ipsilateral 
CDH lungs had a lower PC synthesis rate compared to the contralateral lungs (85). Re-
cently, Bohlin et al. measured surfactant synthesis in term infants using 13C-acetate as 
precursor (56). They found a decreased FSR in term infants with severe respiratory failure, 
similar to the FSR of preterm infants with respiratory distress syndrome, suggesting that a 
lower FSR might be reflective of severely injured and dysfunctional lungs. The FSR we 
found in our CDH patients is also similar to the FSR in preterm infants with RDS (~2.7 
%/day), after 13C-glucose infusion as precursor (54).  
Seven CDH-ECMO patients, two control patients, and one CDH patient who did not re-
quire ECMO were also included in another study, in which we calculated total lung surfac-
tant pool size (277). By multiplying the FSR by the pool size, we were able to calculate 
the ‘absolute synthesis rate’ (ASR). The mean ASR of 7 CDH-ECMO patients was 2.7±0.8 
mg/kg/d, which is comparable with the ASR of premature infants (2.7±0.8 mg/kg/d) (63). 
In the two control patients the ASR was 11.2 and 11.5 mg/kg/d, and in the CDH patient 
who did not require ECMO the ASR was 5.7 mg/kg/d. 
Our group recently studied surfactant disaturated PC (DSPC) synthesis and kinetics in in-
fants with CDH who did not require ECMO (57). FSR in CDH patients was not different from 
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control subjects (∼22 versus 17%/day), neither was the Tapp, Tmax and half-life of surfac-
tant. However, the concentration of DSPC in ELF and surfactant protein-A in tracheal aspi-
rates were significantly lower in CDH patients compared to controls. The most plausible 
explanation for the difference in surfactant synthesis is that the CDH infants in the pre-
sent study required ECMO, and therefore have more severely hypoplastic lungs compared 
with CDH patients who do not require ECMO. In fact, in two CDH patients who did not re-
quire ECMO we found a higher FSR of ~11 %/day after infusion of labeled glucose. Also 
these sicker infants require more intensive ventilation before start of the ECMO which may 
cause even more damage of the lungs (129). By comparison, our CDH-ECMO patients were 
ventilated with a MAP of ~13 mm Hg (18 cm H2O) before the start of ECMO, whereas the 
CDH patients who did not require ECMO had a MAP of ~8 mm Hg (11 cm H2O) (57). The 
amount of pulmonary hypoplasia and lung damage due to the resulting vigorous ventilatory 
support could play a role in the differences in surfactant synthesis that we found.  
An alternative explanation of the decreased surfactant synthesis in CDH patients who 
require ECMO is that these patients had severe pulmonary hypertension which necessi-
tated ECMO treatment. It could be speculated that reduced blood flow through the lungs 
due to severe pulmonary hypertension provides less substrate for surfactant synthesis. In 
addition, during ECMO treatment the lung blood flow is also significant lower. Earlier, we 
found an increased surfactant synthesis in premature infants who had a clinical relevant 
persistent ductus arteriosus, a situation which leads to an increased lung blood flow (63). 
Furthermore, ECMO is known to result into increased vascular permeability and cytokine 
release which could influence surfactant kinetics (280). 
From animal studies it is known that physical stretch of the alveoli stimulates surfactant 
synthesis and secretion (235). Physical stretch during ECMO treatment is reduced because 
low ventilatory settings (PIP 9-12 mm Hg) are used as part of the concept of “lung rest”, 
and could possibly decrease surfactant synthesis. However, in a recent study in preterm 
infants we found no difference in surfactant synthesis ventilated with high frequency os-
cillation compared to conventional ventilation, which argues against the influence of 
stretch in vivo on surfactant metabolism (281).  
Another explanation of the different results obtained by Cogo et al. is that these infants 
received [U-13C]palmitic acid instead of [U-13C]glucose we used. As our studies are the 
only one available in literature, it is unknown whether the use of another tracer deter-
mines the difference in results. Alternatively, CDH lungs could utilize other precursors 
(i.e. palmitate) preferentially, and it may be that the de novo synthesized fatty acids are 
a minor contributor to overall surfactant production in CDH lungs. Cogo et al. found lower 
concentrations of DSPC in ELF and SP-A in tracheal aspirates of CDH patients compared to 
controls (57). If a lower concentration of DSPC in ELF of CDH patients reflects a lower sur-
factant pool size, this could be associated with a higher FSR. The concentration of PC in 
ELF in the present study was not different during the first four days between the CDH pa-
tients on ECMO and controls (Table 2). We recently showed that surfactant PC pool size in 
CDH patients requiring ECMO was not decreased when compared with the pool sizes of 
neonates with meconium aspiration syndrome requiring ECMO and neonates who did not 
require ECMO (277). 
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The PC concentration in ELF of the CDH-ECMO patients during the first four days of the 
study was 6.6 mg/ml (Table 2), which is comparable with the data we found earlier in 
CDH patients who were on ECMO (~6.5 mg/ml), and with the results of CDH patients who 
did not require ECMO (~4 mg/ml) (100, 277, 57). In preterm infants, using the same 
method, a lower surfactant PC concentration was found (2.4 mg/ml) (244).  
We found no significant difference of the PC concentration in ELF during the first four 
days of the study between the CDH-ECMO and the control group (p=0.08), which is in 
agreement with our earlier results (100, 277). Lower DSPC concentrations were found in 
human CDH patients who were not on ECMO (57). In comparison, in the lamb model lower 
concentrations of phospholipids and a lower percent of PC in CDH lungs were found com-
pared to normal (84-87). Phospholipids and DSPC concentration were decreased in rats 
with CDH (92, 93).  
Surfactant PC concentration in ELF during the study was not significantly lower in the 
non-survivors of our CDH-ECMO group, though in the literature a correlation between a 
surfactant component and survival have been mentioned (97, 144). SP-A concentrations in 
amniotic fluid were lower in CDH patients who died or required ECMO postnatally (97), 
and a lack of increase in SP-A concentrations was associated with unsuccessful weaning 
from ECMO (144). In our recent study we found that patients who needed a longer ECMO 
treatment had a longer surfactant PC half-life after administration of labeled surfactant 
(277). The non-survivors in the CDH-ECMO group had a shorter gestational age compared 
to the surviors (p=0.02). This may refer to a delayed maturation of the hypoplastic lung to 
play a role in the clinical outcome of CDH.  
A limiting factor of our study is that it is not possible to determine the exact role of 
ECMO treatment on surfactant kinetics. As we already discussed above the lower blood 
flow through the lungs, the low ventilatory pressures, the increased vascular permeability 
and the release of cytokines during ECMO treatment could influence the surfactant syn-
thesis. Another confounder may be that the control patients were significantly older at 
start of the study (~43 versus ~138 hours, p=0.03). This is because it is almost impossible 
to include newborn infants who are ventilated without significant lung disease. Neverthe-
less, we found no correlation between the age at start of the study and the surfactant ki-
netic parameters. In a study in which labeled acetate was given to term controls with and 
without respiratory failure no correlation was found between the age at start of the study 
and the FSR (Personal communication K. Bohlin). These data suggest that the age at start 
of the study is of no importance for the FSR in the age range of our patients. 
In conclusion, the surfactant synthesis in neonates with CDH on ECMO is decreased com-
pared to ventilated control patients. However, surfactant PC concentration in ELF during 
the first four days of the study and surfactant PC pool size was not decreased in CDH pa-
tients who required ECMO (277). We speculate that the severely disturbed morphology of 
the lungs of CDH patients who require ECMO increases the predisposition to develop lung 
damage. We cannot rule out that the amount of ventilatory support before ECMO treat-
ment contributes to the morphological changes of the lung which are reflected into a de-
creased surfactant synthesis in the CDH patient on ECMO.  
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Abstract 
 
Meconium directly inhibits surfactant function. However, the role of meconium on en-
dogenous surfactant synthesis and clearance is not clear. We studied surfactant phos-
phatidylcholine (PC) metabolism in 11 neonates with meconium aspiration syndrome (MAS) 
who required extracorporeal membrane oxygenation (ECMO) with the use of stable iso-
topes. For comparison we studied 10 term neonates ventilated for non-pulmonary indica-
tions, and 6 neonates with persistent pulmonary hypertension (PPHN) who required ECMO. 
All patients received a 24 h [U-13C]glucose infusion as precursor for palmitic acid in surfac-
tant phosphatidylcholine. In the MAS group, the maximal 13C-incorporation in PC was half 
of that in controls (0.09±0.01 versus 0.18±0.03 APE, p=0.027). There was a tendency of a 
lower surfactant synthesis in the MAS group (3.3±0.7%/day) and PPHN group 
(2.6±0.3%/day) compared to controls 8.0±2.4%/day, p=0.058), which was also reflected by 
a significantly lower PC concentration in the MAS group (4.4±2.6 mg/ml) and PPHN group 
(3.6±2.0 mg/ml) compared to controls (12.8±2.6 mg/ml, p=0.01). Endogenously synthe-
sized surfactant had a similar half-life in all groups, ranging from 63 to 98 hours. We con-
clude that in at least the ‘sickest’ meconium aspiration patients who need ECMO, dis-
turbed surfactant synthesis and concentrations play a role in the pathophysiology of MAS.  
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Introduction 
Meconium aspiration syndrome (MAS) is a severe respiratory disorder in the term neonate. 
The exact pathophysiology is not yet clearly understood, but consists of mechanical ob-
struction of the airways by meconium, followed by a sometimes very severe inflammatory 
response and chemical pneumonitis. Aspiration of meconium inhibits surfactant function 
directly, it increases the minimum and maximum surface tension, and lowers the rate of 
the surface spreading of surfactant (130-134).  
Studies about the surfactant concentration and composition in MAS are scarce. Analyses 
of bronchoalveolar lavage (BAL) fluid from 8 infants with MAS receiving mechanical venti-
lation revealed no difference in phospholipid and surfactant protein-A (SP-A) content 
compared to control subjects (143). In MAS patients who required extracorporeal mem-
brane oxygenation (ECMO) surfactant total phospholipids, phosphatidylcholine (PC) and 
SP-A in tracheal aspirates increased during the ECMO treatment (144-146). Cleary et al. 
found decreased SP-A and SP-B levels in the large aggregates of surfactant in a rat model 
of MAS (141). However, phospholipid levels did not change significantly after meconium 
installation in either the lung tissue or BAL of animal models (141, 142).  
The effect of surfactant therapy in neonates with MAS has been studied by several 
groups (6, 8, 152-155). Surfactant therapy showed an improvement in oxygenation and a 
decrease in ECMO requirement. 
To our knowledge, only one study investigated the surfactant metabolism in the pre-
sence of meconium (147). This in vitro study showed that meconium in low concentrations 
(1%) increases the PC secretion by type II cells, but had no effect on surfactant synthesis.  
Surfactant metabolism has never been studied in human neonates with MAS. In fact, the 
presence of a surfactant deficiency in MAS is still a matter of ongoing discussion. We stud-
ied the surfactant PC metabolism in vivo by stable isotopes techniques, in a group of neo-
nates with the severest form of MAS, those who required ECMO. 
 
 
Patients and Methods 
Patients 
The study was performed in the pediatric surgical and neonatal intensive care units of the 
Sophia Children’s Hospital between October 1999 and April 2001. We studied three groups 
of neonates (Table 1): neonates with meconium aspiration syndrome who required veno-
arterial ECMO (n=11), a group of neonates with persistent pulmonary hypertension of the 
newborn (PPHN) who required ECMO (n=6), and a group of ventilated term neonates with-
out significant lung disease (control) (n=10). Patients of the PPHN group required ECMO 
for idiopathic PPHN (n=4), and pneumonia/sepsis (n=2). PPHN was established by cardiac 
ultrasound. The diagnoses of the 10 ventilated control patients were non-pulmonary: 
gastroschisis, cerebral infarction, omphalocele (n=2), anal atresia, thymic cyst, spina 
bifida, pentalogy of Cantrell, and hypoxic ischemic encephalopathy (n=2). Apart from the 
three study groups, we studied two patients with MAS who did not require ECMO. The 
study was approved by the local medical ethical committee and informed consent was 
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approved by the local medical ethical committee and informed consent was obtained at 
start of the study.  
The entry criteria for ECMO were: gestational age ≥34 weeks; birth weight ≥2000 g; me-
chanical ventilation <7 days; and AaDO2 >600 torr (>80 kPa) for 8 hours. During ECMO, ven-
tilatory settings were usually reduced to peak inspiratory pressure of 12-16 cm H2O, posi-
tive end-expiratory pressure of 5-6 cm H2O, respiratory rate of 10-15 breaths/min, and 
FiO2 of 0.25-0.3. 
 
Isotope infusion and sample collection 
All patients received a 24-hour continuous intravenous infusion of [U-13C]glucose (0.17 
mg/kg/min, Campro Scientific, Veenendaal, The Netherlands). The start of the study (t=0) 
was defined by the start of the isotope infusion. Before and during the label infusion, 1 ml 
blood was drawn every 6 h for determination of 13C-enrichment of plasma glucose. Tra-
cheal aspirates were obtained every 4 to 6 h during the time the infant was intubated, 
with a maximum of 2 weeks. The tracheal suctioning was performed during routine pa-
tient care and did not deviate form the normal clinical care.  
 
Analytical procedure 
The plasma and tracheal aspirates were processed as previously described (54, 57). 
Briefly, plasma glucose was isolated and derivatized to an aldonitril pentacetate deriva-
tive (245). Organic extraction was used to isolate surfactant lipids in the tracheal aspi-
rates (246), and surfactant PC was recovered by thin layer chromatography (278). Isotopic 
enrichments were measured by gas chromatography mass spectrometry, as described be-
fore (54). The 13C-enrichments were expressed as atom percent excess (APE). 
 
Determination of composition and concentration 
Fatty acid composition of surfactant PC and the amount of surfactant PC were analyzed on 
a gas-chromatograph (GC) (Hewlett-Packard, 5890 series II, Amstelveen, The Netherlands) 
(100). The concentration of surfactant PC in the epithelial lining fluid (ELF) was calculated 
by correcting for dilution of the ELF during endotracheal suction: dilution factor = 
[urea]serum/[urea]supernatant (257), and is given as a mean value for the first 4 days of study. 
 
Calculations 
We measured the first appearance of 13C in surfactant PC (Tapp), the time of maximal en-
richment (Tmax), the maximum enrichment (Emax), the half-life of surfactant PC (T½), and 
the fractional synthesis time (FSR) of palmitic acid in surfactant PC, which represents the 
percentage of the total PC-palmitate pool synthesized de novo from plasma glucose per 
day (54).  
 
Data analyses 
Data are presented as mean±standard error of the mean (SEM). One-way ANOVA was ap-
plied to compare groups (Post Hoc Tuckey), Spearman correlation test was used to evalu-
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ate correlations between surfactant parameters and patient characteristics. Significance 
was accepted at a value of p<0.05. 
 
 
Table 1. Patients characteristics 
 
MAS 
n=11 
PPHN 
n=6 
Control 
n=10 
Gestational age (wk) 40.2±0.7 38.1±0.9 38.7±0.5 
Birth weight (g) 3345±175 3412±202 3189±237 
Apgar score at 5 min. 6.0±1.0 6.5±1.2 7.0±1.5 
Male/Female 6/5 3/3 5/5 
Time of ventilation (d) 13.8±2.5 16.2±2.8 25.6±9.9 
Age at start study (h) 58.3±8.7 47.8±6.3 137.6±45.5 
Survivors (n) 11 5 8 
Age at start of ECMO (h) 27.9±6.5 16.0±4.3 - 
Duration of ECMO (h) 156±27* 248±28 - 
Oxygenation Index 41±7 40±13 - 
AaDO2 588±17 604±11 - 
Results reported as mean ± standard error of mean (SEM). Oxygenation index (OI=(MAP x FiO2)/PaO2; 
AaDO2, alveolar-arterial oxygen tension difference (AaDO2=PaO2 – [(713 x FiO2)-(PaCO2/0.8)].  
*Significantly different from the PPHN group (p=0.035). 
 
 
Results 
Patients characteristics 
Patients characteristics are depicted in Table 1. Four of the MAS patients on ECMO re-
ceived surfactant treatment as rescue therapy (100 mg/kg Survanta), and one of the four 
surfactant treated infants received two doses of surfactant. Surfactant treatment was 
given before the start of the study. As comparison we studied a group of ventilated neo-
nates without significant lung disease and a group of patients with PPHN who required 
ECMO. Four patients of the PPHN group received surfactant, one of these received two 
doses of surfactant before start of the study. The three groups were comparable with re-
gard to the patients characteristics, except for duration of ECMO, which was longer in the 
PPHN group compared to the MAS group on ECMO (p=0.035). The two additional MAS pa-
tients who did not require ECMO (not in Table 1) were both male and had comparable ges-
tational age and birth weight as the other patient groups. The age at start of the study 
was ~50 hours, and they were ventilated for ~8 days. One of the MAS patients who did not 
require ECMO was treated with two doses of surfactant before the start of the study.  
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Ventilation characteristics 
Seven patients of the MAS group were conventionally ventilated before the start of ECMO, 
four patients were ventilated with high frequency oscillation after failure of conventional 
ventilation. The mean airway pressure (MAP) of the MAS patients pre-ECMO was 20.1±0.6 
cm H2O. All patients of the PPHN group were conventionally ventilated with a pre-ECMO 
MAP of 16.3±1.3 cm H2O. Pre-ECMO Oxygenation index (OI) and alveolar-arterial oxygen 
tension difference (AaDO2) are reported in Table 1. The 10 control patients were conven-
tionally ventilated following surgery or because of apneic attacks. These patients had mild 
ventilatory settings: FiO2: 0.26±0.03, MAP: 8.0±0.8 cm H2O, and a positive inspiratory 
pressure (PIP): 19.2±1.8 cm H2O. The two MAS patients not on ECMO were conventionally 
ventilated with a MAP of 13 and 14 cm H2O, an OI of 12 and 14, and a AaDO2 of 543 and 
573. 
 
Surfactant kinetics 
The 13C-enrichment of plasma glucose (Egluc) was in steady state in all infants between t=6 
and t=24, and was similar in all groups (Table 2). Figure shows the 13C-glucose incorpora-
tion in surfactant PC palmitate in sequential tracheal aspirates in the three study groups. 
The kinetic parameters of surfactant are reported in Table 2. The Tapp was similar in the 
groups and was ~12 hours, followed by a Tmax which was significantly longer in the PPHN-
group compared to controls (p=0.017). From Figure and Table 2 it is also clear that Emax 
was significantly lower in the MAS group compared to controls (p=0.027). The surfactant 
PC half-life was not different between groups. There was a trend to a lower FSR in the 
MAS and PPHN group compared to the control group (p=0.058). The two MAS patients who 
did not require ECMO treatment had the following surfactant kinetic parameters: Egluc 2.4 
and 3.0 APE, Tapp 8 and 16 hours, Tmax in both patients 49 hours, Emax 0.05 and 0.08 APE, 
half-life 43 and 76 hours, and FSR 1.3 and 2.1 %/day. If these two patients were included, 
then the MAS patients had a significantly lower FSR compared to the control group 
(p=0.035). 
The surfactant PC concentration in ELF during the first four days of the study was sig-
nificantly lower in the MAS and PPHN group compared to the controls (p=0.011, Table 2). 
No correlations were found between the surfactant PC concentration and the surfactant 
kinetic parameters, OI, AaDO2, and gestational age. The two MAS patients not on ECMO 
had PC concentrations of 0.9 and 9.5 mg/ml ELF. The patients with a PC concentration of 
9.5 mg/ml received two doses of surfactant before the start of the study. 
In the MAS group the duration of ECMO was shorter in the patients who were treated with 
surfactant before the start of ECMO (p=0.023). This relation between surfactant treatment 
and duration of ECMO was not observed in the PPHN group. 
Fatty acid composition of PC (C14:0: myristic acid ~5%, C16:0: palmitic acid ~63%, 
C16:1ω7 ~3.5%, C18:0 ~7%, C18:1ω9 ~7%, C18:2ω6: linoleic acid ~3%) in tracheal aspirates 
during the first four days was not different between groups. 
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Figure. 13C-enrichment of palmitic acid in surfactant phosphatidylcholine (PC) in sequen-
tial tracheal aspirates 
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MAS patients (closed triangles), control patients (open squares) and PPHN patients (open circles) re-
ceived a 24-h [U-13C]glucose infusion as precursor for PC-palmitate. Enrichment is represented as 
Atom Percent Excess (APE). Data are expressed as mean and standard error of mean (SEM) of time 
intervals of 12 and 24 hours, with the 24 hour interval started at 72 hours. 
 
 
Discussion 
This is the first report on surfactant metabolism in human neonates with MAS who require 
ECMO. With the use of stable isotopes we studied surfactant PC palmitate metabolism in 
vivo in three patient groups. In the MAS patients who required ECMO the maximal enrich-
ment (Emax) was lower compared to controls (Table 2 and Figure). The MAS patients as 
well as the PPHN patients tended to have a lower surfactant synthesis (FSR) compared to 
the controls (p=0.058). The suggestion of a lower surfactant PC synthesis in the ECMO 
groups was reflected by lower PC concentrations in ELF during the first four days of the 
study (~4 mg/ml in MAS and PPHN group versus ~12 mg/ml in controls). Furthermore, if 2 
MAS patients who did not require ECMO were included, then the FSR was significantly 
lower in the MAS group compared to controls (p=0.035). 
 
 
12-24 36-48 60-72 72-96 96-120 144-168 192-216 240-264 
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Table 2. Surfactant kinetic parameters and surfactant phosphatidylcholine (PC)  
concentration in epithelial lining fluid (ELF) during the first four days of the study 
 
MAS 
n=11 
PPHN 
n=6 
Control 
n=10 
p-value 
Egluc (APE) 2.0±0.2 2.0±0.2 2.2±0.3 0.798 
Tapp (h) 12.6±1.5 13.0±2.0 11.7±1.1 0.815 
Tmax (h) 50.4±4.2 64.1±3.4* 46.7±3.0 0.017 
Emax (APE) 0.09±0.01* 0.11±0.01 0.18±0.03 0.027 
FSR (%/day) 3.3±0.7 2.6±0.3 8.0±2.4 0.058 
Half life (h) 68.5±11.8 98.1±27.2 63.4±10.7 0.305 
PC (mg/ml ELF) 4.4±2.6* 3.6±2.0* 12.8±2.6 0.011 
Data are expressed as mean±standard error of mean (SEM). Differences between groups were ana-
lyzed by one-way ANOVA. *Different from controls. 
 
 
In isolated type II cells of rats, meconium in low concentrations (1%) has no effect on 
surfactant PC synthesis, though the secretion of surfactant PC is increased (147). The 
same study showed that higher meconium concentrations were toxic to the cultured type 
II cells, though the effect of these higher concentrations on surfactant synthesis is not 
known. The chemical pneumonitis caused by the aspiration of meconium could influence 
surfactant synthesis by damage to the type II cells. Moreover, the release of cytokines due 
to the inflammation has inhibitory effects on surfactant synthesis (282). 
The PC concentration in ELF during the first four days of the study was decreased in the 
MAS group on ECMO (~4 mg/ml). In animal studies total phospholipid and dipalmitoyl PC 
levels in either lung tissue or bronchoalveolar lavage were not different after meconium 
installation compared to controls (141, 142). In bronchoalveolar lavage from infants with 
MAS who did not receive ECMO, disaturated PC (DSPC) concentration (~2 mg/ml) was not 
different from control patients (143). The lower PC concentration in the present study 
could be explained by more severe lung disease. In MAS patients who required ECMO total 
phospholipid and DSPC concentration in tracheal aspirates were lower at the beginning of 
ECMO, and increased significantly during ECMO treatment (145). Unfortunately, in that 
study no control group was included. In a recent study in which we measured surfactant 
PC pool size in MAS patients who required ECMO, we found no differences in pool size 
compared to CDH patients who required ECMO and non-ECMO patients (277). However, the 
MAS-ECMO patients tended to a lower surfactant PC pool size compared to the two other 
groups (80 versus 118 mg/kg). 
Four MAS patients on ECMO, two control patients, and one MAS patient not on ECMO of 
the present study were also included in another recent study (277), in which we measured 
total lung surfactant PC pool size. In the four MAS patient on ECMO we were able to calcu-
late “absolute synthesis rate” (ASR). By multiplying the FSR by the pool size, we found an 
ASR of 1.3±1.0 mg/kg/d surfactant PC synthesized from glucose. In the two control pa-
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tients, the ASR were higher (11.2 and 11.5 mg/kg/d). The MAS patient who did not receive 
ECMO had an ASR of 7 mg/kg/d, which was not due to surfactant therapy, as this patient 
did not receive any surfactant treatment. ASR in premature infants was calculated to be 
2.7±0.8 mg/kg/d (63). The MAS-ECMO patients seem to have a lower ASR, which means 
that the tendency of a lower FSR, which we found in the present study, is not caused by a 
higher dilution of the precursor due to a higher surfactant PC pool size. 
Besides a suggested disturbed surfactant metabolism, also surfactant inactivation plays 
a role in MAS. Several proteins, lipids and free amino acids can inactivate surfactant in 
several ways (253). In the present study we did not measure surfactant activity by dy-
namic surface pressure measurements, nor did we measure surfactant inhibitors, like al-
bumin in the tracheal aspirates. We analyzed the fatty acid composition of surfactant PC 
in tracheal aspirates during the first four days, which was not different compared to con-
trols. 
We found that MAS patients who were treated with surfactant before the start of ECMO 
had a shorter duration of ECMO compared to non-treated MAS patients. This is similar to 
the findings in a randomized study in ECMO treated patients (146). The clinical efficacy of 
exogenous surfactant therapy in MAS has been suggested by several non-randomized stud-
ies (6, 8, 152, 153) and two randomized controlled trials (154, 155). From these studies it 
could be suggested that surfactant treatment in MAS is most effective when given in the 
early phase of the respiratory failure and at a high dose. 
The question whether the disturbed surfactant metabolism is a result of the underlying 
condition or a consequence of ECMO treatment remains unanswered. It seems clear that 
patients who require ECMO have more damaged lungs compared to patients who do not 
require ECMO treatment. The sick lungs will be even more damaged due to the intensive 
ventilation prior to the ECMO treatment. We studied a group of patients with PPHN who 
required ECMO. These patients also show a trend of a lower FSR compared to the controls, 
which suggests a role of ECMO on surfactant metabolism. However, two patients with MAS 
who did not require ECMO had a FSR in the same range as the ECMO treated patients (1.3 
and 2.1 %/day). In another study, the surfactant PC and SP-A in tracheal aspirates in-
crease in patients on ECMO, suggesting no detrimental effect of ECMO (144-146). 
During ECMO the lung blood flow is lower, and it could be speculated that a reduced 
blood flow through the lungs provides less substrate for surfactant synthesis. We found an 
increased surfactant synthesis in premature infants who had a clinically relevant persis-
tent ductus arteriosus, a situation which leads to an increased lung blood flow (63). From 
animal studies it is known that physical stretch of the alveoli stimulates surfactant synthe-
sis and secretion (235). As physical stretch is low during ECMO treatment due to the low 
ventilatory settings as part of the concept of “lung rest”, this could possibly decrease sur-
factant synthesis. A result of ECMO treatment is an increase in capillary permeability, 
which together with a release of cytokines change surfactant function. This is even more 
plausible in an ECMO population in whom lung damage before ECMO may contribute to 
capillary protein leakage.  
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In summary, infants with MAS have normally developed lungs. Due to the direct effect of 
meconium and the inflammatory response in the lung, surfactant function in MAS is inhib-
ited. In this study a disturbed surfactant synthesis and concentration is suggested at least 
in the sickest MAS patients who required ECMO. Further studies have to reveal the effect 
of ECMO on surfactant metabolism. 
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Abstract 
 
Neonates with inherited surfactant protein-B (SP-B) deficiency develop a lethal respiratory 
insufficiency after birth. Because there are major ultrastructural changes in the SP-B defi-
cient lung, disorganized tubular myelin, lamellar bodies, and SP-C, we expected a se-
verely disturbed surfactant phosphatidylcholine (PC) metabolism. Surfactant PC metabo-
lism was measured in vivo using stable isotopes. Four SP-B deficient infants and 10 con-
trols received a 24 h [U-13C]glucose infusion. One SP-B deficient infant and 5 controls re-
ceived a 24 h [U-13C]palmitic acid infusion. Isotopic enrichment was measured in palmitic 
acid of surfactant PC. Fractional synthesis rate (FSR) of surfactant PC after [U-13C]glucose 
was 4.7±2.4%/day. Maximal enrichment was reached at 48.4±8.3 hours, followed by a half-
life of 65.4±24.8 hours. Controls had similar data. After [U-13C]palmitic acid the FSR was 
65% in SP-deficiency and only 17.0±11.0% in controls. Time of maximal enrichment was 36 
versus 51.0±9.5 hours and half-life was 35.7 versus 43.0±6.0 hours in the SP-B deficient 
patient and controls, respectively. PC content in tracheal aspirates were also not different 
between SP-B patients and controls. Despite lethal respiratory insufficiency, aberrant sur-
factant, and severe structural changes of the lung, the overall surfactant PC kinetics seem 
not disturbed in SP-B deficiency. 
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Introduction 
Surfactant protein B (SP-B) is a hydrophobic peptide with several functions related to al-
veolar surface tension reduction and metabolism of pulmonary surfactant (23). SP-B en-
hances the rate of adsorption and surface spreading of the phospholipids, it plays a role in 
the formation of the surface active layer of surfactant, and in the organization and turn-
over of pulmonary phospholipids. Furthermore, SP-B counteracts the inhibition of surfac-
tant function by plasma proteins, and contributes to the recycling of surfactant from the 
alveolar space (22). In humans the SP-B is encoded by a 9.5 kb gene that contains 11 exons 
on chromosome 2, and is expressed exclusively in the epithelium of the lung (23). Mature 
SP-B is detectable in the human lung after 19 weeks of gestation, and is found in the am-
niotic fluid after 31 to 33 weeks of gestation (179). 
Inherited SP-B deficiency is a lethal disease only identified in term neonates, to date. It 
was first recognized in 1993 by Nogee et al (24), and it is characterized by the absence of 
SP-B, an aberrant form of SP-C (174), and altered phospholipid composition (283). Ultra-
structural studies show disorganized lamellar bodies and absence of tubular myelin (25). 
The most common mutation described to date is a net 2 base-pair insertion at codon 121 
in exon 4 of the SP-B gene (121ins2), causing a frameshift and premature stop signal fol-
lowed by termination of the translation. Also other mutations have been identified result-
ing in total or partial SP-B deficiency (181-187). Clinically, neonates with SP-B deficiency 
present with severe progressive respiratory distress which does not respond to surfactant 
therapy, corticosteroid administration, or extracorporeal membrane oxygenation (ECMO) 
(177). The infants will die in the first few weeks of life, unless a lung transplantation is 
performed.  
Because of the ultrastructural changes in SP-B deficient lungs, the altered surfactant 
phospholipid composition, and the severity of the lung disease, we hypothesized that the 
production and clearance of surfactant phosphatidylcholine (PC) would be disrupted. We 
therefore studied the surfactant PC metabolism in vivo in neonates with a congenital SP-B 
deficiency and in a control group with the use of stable isotopes (54, 64).  
 
 
Methods 
Subjects 
The SP-B deficient infants were included in different neonatal intensive care units; one in-
fant was studied in the Sophia Children’s Hospital in Rotterdam (The Netherlands), one in 
the St. Louis Children’s Hospital (USA), one in the A.Z. Sint-Jan Hospital in Brugge (Bel-
gium), one in the Universitätsklinikum der RWTH Aachen (Germany), and one in the Uni-
versity Hospital of Padua (Italy). The diagnoses of the 15 ventilated control patients varied 
and overall no primary pulmonary anomaly or sign of abnormal lung development was pre-
sent: gastroschisis, cerebral infarction, omphalocele, anal atresia, thymic cyst, spina bi-
fida, pentalogy of Cantrell, and hypoxic ischemic encephalopathy. The study was ap-
proved by the local medical ethical committee and informed consent was obtained at 
start of the study.  
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Isotope infusion and sample collection 
Four SP-B deficient patients and 10 controls received a 24-hour intravenous infusion of [U-
13C]glucose (0.17 mg/kg/min, Campro Scientific, Veenendaal, The Netherlands). One SP-B 
deficient patient and 5 controls received a 24 hour intravenous infusion of [U-13C]palmitic 
acid (Martek Biosciences, Columbia MD), as previously described (64). The start of the 
study (t=0) was defined by the start of the isotope infusion. Before and during the label 
infusion, 1 ml blood was drawn every 6 h for determination of 13C-enrichment of plasma 
glucose or plasma palmitic acid. Tracheal aspirates were obtained every 4 to 6 h during 
the time the infant was intubated, with a maximum of 2 weeks. The tracheal suctioning 
was performed during routine patient care and did not deviate form the normal clinical 
care. Tracheal aspirates were immediately placed at -20°C, until further processing.  
 
Analytical procedure 
The plasma and tracheal aspirates were processed as described before (54, 57). Briefly, 
plasma glucose was isolated and derivatized to an aldonitril pentacetate derivative and 
plasma palmitic acid was derivatized to a methyl-ester (245). Organic extraction was used 
to isolate surfactant lipids in the tracheal aspirates (246), and total surfactant PC was re-
covered by thin layer chromatography (278). In the patients who received labeled palmitic 
acid disaturated PC (DSPC) was purified from tracheal aspirates (54, 57). Isotopic enrich-
ments were measured by gas chromatography mass spectrometry, as described before (54, 
57, 64). The 13C-enrichments were expressed as atom percent excess (APE) when [U-
13C]glucose was administered, and mol percent excess (MPE) when [U-13C]palmitic acid 
was administered.  
 
Determination of composition and concentration 
Fatty acid composition of surfactant PC and the amount of surfactant PC were analyzed on 
a gas-chromatograph (GC) (Hewlett-Packard, 5890 series II, Amstelveen, The Netherlands) 
(100). The concentration was determined by original sample volume and expressed as 
µmol per tracheal aspirate (µmol/TAS). 
 
Calculations  
We measured time of first appearance of enrichment (Tapp), time of maximal enrichment 
(Tmax), maximal enrichment (Emax), and half-life of surfactant (DS)PC (T½). Fractional syn-
thesis rate (FSR) of palmitic acid in surfactant PC represents the percentage of the total 
(DS)PC-palmitate pool synthesized de novo from plasma glucose respectively plasma 
palmitic acid per day (54).  
 
Data analyses 
Data are presented as mean±standard error of the mean (SEM). Differences between 
groups were analyzed by Student T-test. Significance was accepted at p<0.05. 
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Table 1. Clinical parameters of patients 
 13C-Glucose 13C-Palmitic Acid 
 SP-B deficient 
n=4 
Controls 
n=10 
SP-B deficient 
n=1 
Controls 
n=5 
Gestational age (wk) 39.4±0.5 38.7±0.5 40 38.4±2.4 
Birth weight (g) 3435±221 3171±231 3400 2700±600 
Male/Female 3/1 5/5 0/1 3/2 
Age at start study (d) 44.5±15.3 5.4±1.7 30 96.3±73.4 
Surfactant treatment 4/4 0/10 1/1 0/8 
Survivors 1/4 8/10 0/1 4/5 
Data expressed as mean±SEM. 
 
 
Results 
All SP-B deficient patients had a 121ins2 mutation (the most common mutation), and all 
except two died during the neonatal period (at 36±8 days of life). One survivor underwent 
a lung transplantation at four months of age and another one died at the age of 6 months. 
Three patients (all patients with hypoxic ischemic encephalopathy) in the control group 
died at 6, 15 and 25 days of age because of severe cerebral damage. 
Clinical parameters are described in Table 1. All SP-B deficient patients were ventilated 
from birth to death or lung transplantation. One SP-B deficient patient was treated with 
extracorporal membrane oxygenation (ECMO) during 10 days, starting at day 8 after birth. 
This patient was studied during the time he was on ECMO. The 10 control patients who re-
ceived labeled glucose were conventionally ventilated for 26±10 days following surgery or 
because of apneic attacks. These patients had mild ventilatory settings: FiO2: 0.26±0.03, 
mean airway pressure (MAP): 8.0±0.8 cm H2O, ventilatory rate: 31±4, positive inspiratory 
pressure (PIP): 19.2±1.8 cm H2O, positive end-expiratory pressure (PEEP): 4.4±0.2 cm H2O. 
The 5 control patients who received labeled palmitic acid were conventionally ventilated 
for 21.2±10.0 days, with the following settings: FiO2: 0.24±0.3, mean airway pressure 
(MAP): 3.2±0.2 cm H2O. 
The Figure shows the 13C-glucose incorporation of surfactant PC palmitate in sequential 
tracheal aspirates in the SP-B deficient patients and control patients. 13C-enrichments 
were corrected for the mean plasma glucose enrichments of each patient. Both curves 
show the same course of incorporation of the 13C label. We found no significant difference 
in enrichment at each time interval between the SP-B and the control group. The curve of 
the SP-B deficient patients is shorter because in three of the four patients treatment was 
stopped soon after the diagnosis became clear. 
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Figure. 13C-enrichment of palmitic acid in surfactant phosphatidylcholine (PC) in sequen-
tial tracheal aspirates, corrected for plasma glucose enrichment 
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SP-B deficient patients (open triangles) and control patients (closed triangles) received a 24-h [U-
13C]glucose infusion as precursor for PC-palmitate. Data are expressed as median and interquartile 
ranges of time intervals of 12 and 24 hours, with the 24 hour interval started at 72 hours. 
 
 
Table 2 reports the metabolic indices of endogenous surfactant synthesized from glu-
cose. There were no differences in Tmax, T½, and FSR between the SP-B deficient patients 
and the control patients. The incorporation of 13C from the precursor glucose into surfac-
tant PC palmitate in tracheal aspirates started at 9.4±2.7 hours in the control group 
(=Tapp). The Tapp of the SP-B deficient patients could not be calculated reliably. Also the 
metabolic indices of endogenous surfactant synthesized from palmitic acid are shown in 
Table 2. The SP-B deficient patient who received 13C labeled palmitic acid as precursor 
had a FSR of 65%/day, whereas the 5 controls had a FSR of 17.0±11.0%/day. 
Emax corrected for the precursor enrichment (= plasma glucose enrichment) in the pa-
tients who received labeled glucose, was not different between groups (Table 2 and Fig-
ure). The mean plasma glucose enrichment for the 4 SP-B deficient patients was 1.2±0.5 
APE and 2.3±0.4 APE for the 10 control patients (p=0.1). If we did not correct for the 
plasma glucose enrichment Emax was significant lower in the SP-deficient patients com-
pared to the control patients (0.05±0.01 versus 0.18±0.04 APE, p=0.04). This could be ex-
plained by a lower plasma glucose enrichment in SP-B deficient patients possibly due to a 
higher non-labeled glucose administration compared to the control group. 
Mean PC amount in tracheal aspirates of SP-B deficient patients and control patients did 
not reach statistical significance, but the mean value in the SP-B deficient group was 
about 40% of the value of the controls (0.23±0.19 versus 0.62±0.17 µmol/TAS, p=0.22). 
12-24 36-48 60-72 72-96 96-120 144-168 192-216 240-264 
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Fatty acid composition of PC from tracheal aspirates was also not different between the 
two groups, except for stearic acid (C18:0) which was significantly higher in the SP-B defi-
cient group (table 3). Mean DSPC in tracheal aspirates of the SP-B deficient patient who 
received labeled palmitic acid was 0.21 µmol/ml, whereas in the 5 controls mean DSPC 
was 2.3±0.2 µmol/ml.  
 
 
Table 2. Metabolic indices of endogenous surfactant synthesized from glucose and 
palmitic acid 
 13C-Glucose 
 13C-Palmitic Acid 
 SP-B deficient 
n=4 
Controls 
n=10 
p-value SP-B deficient 
n=1 
Controls 
n=5 
4.7±2.4 7.8±2.4 0.46 65.0 17.0±11.0 FSR (%) 
Tmax (h) 48.4±8.3 48.4±8.3 0.81 36.0 51.0±9.5 
Emax (APE/MPE) 0.06±0.03
* 0.10±0.03* 0.39 0.20 0.22±0.05 
Half-life (h) 65.4±24.8 63.4±10.7 0.93 35.7 43.0±6.0 
Tapp (h) - - - 13.9 8.5±2.5 
*Emax is corrected for plasma glucose enrichment (maximum enrichment of surfactant PC palmitate / 
glucose plasma enrichment). No significant differences were found in surfactant kinetic indices be-
tween the two groups. 
 
 
Discussion 
SP-B deficiency leads to a disorganized intracellular structure of the pulmonary type II 
cell, including a lack of mature lamellar bodies and absence of tubular myelin (25, 175). 
Furthermore, surfactant phospholipid composition is altered (283). These structural and 
compositional abnormalities suggest multiple effects on surfactant synthesis, secretion 
and catabolism. We studied the endogenous surfactant PC metabolism in vivo in SP-B defi-
cient human neonates using stable isotopes. SP-B deficient patients who received an infu-
sion of labeled glucose had a FSR of endogenous surfactant PC palmitate of ~4.7 % per 
day, with a maximal surfactant PC palmitate enrichment at ~48 hours, and a half-life of 
disappearance of label of ~65 hours. These data indicate that in SP-B deficient patients 
the PC synthesis from plasma glucose and PC half-life are not markedly different from 
control patients without lung disease. 
This is the first study that describes the surfactant PC metabolism in vivo in human neo-
nates with an inherited SP-B deficiency. Only two studies of the surfactant metabolism in 
SP-B deficiency have been performed, one in animals (190), and one in human lung tissue 
obtained at transplant (194). Our results are comparable with findings in SP-B knock-out 
mice (190). These mice die within minutes after birth, have poorly compliant lungs, and 
express the aberrant SP-C. Ultrastructural examination of the lungs revealed an absence 
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of lamellar bodies and tubular myelin (189). However, phospholipid content in lungs from 
SP-B knockout mice was not altered compared to normal mice. Neither was the incorpora-
tion of labeled choline and labeled palmitic acid in lung saturated PC of SP-B deficient fe-
tuses after injection of the labels in pregnant mice (190). 
Beers et al. investigated the phospholipid content, composition and synthesis in lung tis-
sue and lavage fluid acquired at transplantation or postmortem from 10 SP-B deficient in-
fants (194). They found elevated phosphatidylinositol and percent disaturated PC in lung 
tissue, and decreased levels of phosphatidylglycerol in both lavage and lung tissue com-
pared to normal lungs. As in our study, no difference between SP-B deficient infants and 
controls was found in percentage of palmitic acid in lung lavage. 
 
 
Table 3. The mean concentration of phosphatidylcholine (PC) and the fatty acid composi-
tion of PC in tracheal aspirates (TAS) from the patients who received 13C-glucose 
 
SP-B deficient 
n=3 
Controls 
n=7 
p-value 
PC (µmol/TAS) 0.23±0.19 0.62±0.17 0.22 
C16:0 (%) 61.0±1.1 58.8±4.4 0.75 
C18:0 (%) 17.9±0.7 5.7±1.2 0.0002 
C18:1ω9 (%) 8.3±3.0 10.5±2.9 0.67 
C18:2ω6 (%) 3.6±1.3 4.4±1.1 0.67 
Data are expressed as mean±SEM. C16:0 (palmitic acid), C18:0 (stearic acid), C18:1ω9 (oleic acid), 
C18:2ω6 (linoleic acid). 
 
 
Beers also studied the synthesis of phospholipids by determining the rate of incorpora-
tion into phospholipids after incubation of explanted lung tissue with three different la-
beled lipid precursors: choline, glycerol and acetate (194). The incorporation rate of cho-
line into PC and acetate into phospholipids was increased in lung tissue from SP-B defi-
cient infants compared to lung tissue of infants with chronic lung disease, but was not dif-
ferent when compared to normal lungs. The incorporation rate of glycerol into PC was not 
different between groups. In this study, infants with chronic lung disease who underwent 
lung transplantation were used as comparison because they had undergone the same 
therapeutic interventions as the SP-B deficient patients. The difference in incorporation 
could also be due to a lower surfactant synthesis in patients with chronic lung disease. At 
least, they found no decreased incorporation in SP-B deficient lung tissue. 
We also studied one SP-B deficient patient who received labeled palmitic acid. This pa-
tient had a much higher FSR compared to the 5 control patients (65 % versus ~17.0 %). Un-
fortunately, we only had the opportunity to study one SP-B deficient patient with labeled 
palmitic acid as precursor. This makes it difficult to compare the data with the data of 
the controls. A possible explanation for the high FSR could be a low surfactant pool size in 
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the SP-B deficient patient. This is also suggested by the lower DSPC concentration in tra-
cheal aspirates compared to the controls (0.015 mg/ml versus 0.17 mg/ml). The higher 
FSR could also be due to the kind of label used. Beers et al. showed a higher incorporation 
rate in SP-B deficient tissue when choline and acetate were used, but not when glycerol 
was used as precursor (194). Nevertheless, these additional data show also no impaired 
surfactant synthesis in SP-B deficiency. 
The method we used to study the surfactant metabolism in vivo was first described by 
Bunt et al (54). Surfactant kinetics in preterm infants with respiratory distress syndrome 
after prenatal corticosteroids and postnatal surfactant administration were studied. The 
FSR in these preterm infants was ~2.7 %/day and half-life was ~113 hours. Preterm infants 
seem to have a slower surfactant metabolism compared to our SP-B deficient patients and 
controls. 
Our study has certain limitations. One is that the SP-B deficient patients were signifi-
cantly older at start of the study compared to the control patients (~45 versus ~5 days, 
p=0.001). It would have been more appropriate to include age-matched control patients. 
It is however very difficult to find infants of one or two months of age, without significant 
lung disease, who are ventilated for several days. The control patients in our study were 
included during the first week of life, except two patients who were included at day 11 
and day 18 of life. These two patients also had a higher FSR of ~21 %/day. In a study in 
which labeled acetate was given to term controls with and without respiratory failure no 
correlation existed between the age at start of the study and the FSR (Personal communi-
cation K. Bohlin). From this we suggest that the age at start of the study is of no impor-
tance in relation to the FSR. 
The number of included SP-B deficient patients in the present study is low. But with a 
gene frequency of approximately one 121ins2 mutation per 1000-3000 individuals (284), 
the incidence of a SP-B deficiency is rare. This low incidence of the disease is also the 
reason why our four SP-B deficient infants were studied in four different clinical centers. 
Besides the rarity of the disease it was also difficult to include SP-B deficient neonates in 
the study because in most cases treatment was stopped the moment the diagnosis was 
known.  
In conclusion, although normal lamellar bodies and tubular myelin are absent in inher-
ited SP-B deficiency, the overall surfactant PC palmitate synthesis from plasma glucose 
and its half-life seem not disturbed. Surfactant PC fractional synthesis rate is not de-
creased in SP-B deficient neonates, although no information is available on absolute syn-
thesis. Probably, other factors such as failure in the formation of a surface active film in 
the alveoli, a disturbed recycling and uptake of surfactant, and a disturbed metabolism of 
surfactant proteins contribute to the clinical course of this disease. 
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Summary and interpretation of the studies 
Surfactant metabolism was measured in premature infants and baboons with respiratory 
distress syndrome, and term infants with severe lung disease. Understanding of the me-
tabolism of surfactant is of importance for the development of therapeutic strategies that 
are specific to the mechanism of metabolic disruption. The method employing the safe 
non-radiating stable isotopes to study surfactant metabolism was developed recently by us 
(54, 62). The endogenous surfactant metabolism was studied by a 24-h infusion with the 
stable isotope [U-13C]glucose as a precursor for palmitic acid of surfactant PC. During the 
period of intubation, tracheal aspirates were collected to obtain serial time points to 
measure incorporation of the stable isotope 13C into surfactant PC palmitate. Fractional 
synthesis rate (FSR), which is the percentage of the total surfactant pool synthesized from 
glucose per day, and half-life of endogenous surfactant were calculated.  
In preterm infants with RDS, surfactant metabolism studied with the these methods is 
slow (232). Prenatal corticosteroids and surfactant therapy were found to be stimulating 
for the endogenous surfactant synthesis in preterm infants. Physical stretch is another 
factor which stimulates surfactant synthesis and function (235). During conventional venti-
lation, repetitive alveolar distension stimulates surfactant synthesis and secretion. In con-
trast, during high frequency oscillation (HFO) this alveolar excursion may be limited, 
which could result in a lower surfactant synthesis and secretion. We studied surfactant 
metabolism in premature infants with RDS, randomized for either HFO or conventional 
ventilation (Chapter 3). FSR from glucose did not differ between groups (4.7 versus 
4.2%/day), neither did the half-life of endogenous surfactant (∼79 versus ∼76 hours). The 
infants ventilated with HFO appeared to have more severe lung disease, which could be 
due to the way of randomization at 24 hours of age. Infants who were already receiving 
HFO as part of their routine care continued to receive it, infants on CV at 24 hours were 
randomized to HFO or CV. The fact that we did not detect differences in surfactant me-
tabolism between the two groups could be explained by several reasons. One of these rea-
sons could be the sicker lungs of the infants in the HFO group. However, if a lower surfac-
tant synthesis is expected in the HFO group due to less alveolar stretch, this lower synthe-
sis would be even lower in sicker lungs. It could be that HFO has a protective role on sur-
factant metabolism, because it combats the overexpansion of the alveoli. And, in this way 
may mask the decreased surfactant synthesis due to the severe lung disease. The study 
also showed that premature infants who died of refractory respiratory failure seem to 
have a shorter half-life of endogenous surfactant.  
 
 
We measured surfactant half-lives and pool sizes in very premature baboons during the 
first two weeks of life (Chapter 4). As there is almost no information available about the 
surfactant metabolism during the development of bronchopulmonary dysplasia (BPD), we 
were especially interested in the changes of the surfactant metabolism in the second 
week of life (i.e. during the development of BPD). In this study we administered stable 
isotope labeled dipalmitoylphosphatidylcholine (2H-DPPC, 5 mg/kg) endotracheally in very 
premature baboons on day 5 of life, and on day 8 we administered radioactive labeled 
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DPPC. This made it possible to measure the half-life of exogenous surfactant and surfac-
tant pool size. By using a baboon model, we were able to compare the half-life and pool 
size obtained by our stable isotope method to measurements made with radioactive iso-
topes and direct measurements of pool size at autopsy. The results of this study were 
compared with previous data for surfactant metabolism in similar premature baboons ven-
tilated for 6 days. The half-life of exogenous surfactant and the surfactant pool size did 
not change during the recovery from RDS and the development of BPD in very premature 
baboons. In addition, stables isotopes were shown to be a valid method for studying half-
life of exogenous surfactant and surfactant pool size.  
 
 
The method of administration of 2H-DPPC to measure the half-life of exogenous surfactant 
and surfactant pool size was also used in term neonates with severe lung disease (Chapter 
5). Surfactant PC pool size was ∼73 mg/kg in neonates with CDH who required ECMO. Neo-
nates with MAS who required ECMO had a surfactant PC pool size of ∼50 mg/kg, which was 
not significantly different from the CDH patients. We also studied a varied group of pa-
tients who were not on ECMO, which had a comparable surfactant PC pool size (∼69 
mg/kg). In addition, we measured PC concentrations in epithelial lining fluid (ELF), which 
were similar in all groups. The results of this study showed that the lungs of CDH and MAS 
patients were not surfactant deficient. The half-life of exogenous surfactant was similar in 
all groups (∼24 hours), and a correlation (positive) was found between the half-life and 
the duration of ECMO. From this correlation we speculated that a surfactant pool that is 
replaced by newly synthesized surfactant more rapidly results in a faster improvement of 
the clinical condition and a shorter duration of ECMO. The relation between a shorter 
half-life of surfactant and a faster improvement is in contradiction with what we found in 
chapter 3. However, in chapter 3 we measured the half-life of endogenous surfactant (13C-
glucose), whereas in this study we measured the half-life of exogenous surfactant (2H-
DPPC). We found no correlation between the two half-lives (endogenous versus exoge-
nous), when measured in the same patient. When a plasma precursor (13C-glucose) is used 
to label endogenous surfactant, it takes about 3 days before the maximal enrichment is 
reached and the labeled surfactant is started to disappear. Whereas when exogenous la-
beled surfactant is used as label, the disappearance of the labeled exogenous surfactant 
can directly be measured. In the intermediate 3 days after infusion of the plasma precur-
sor, the surfactant metabolism could have changed. The fact that the half-life of endoge-
nous surfactant is longer can be explained by ongoing synthesis of labeled surfactant from 
intermediate precursor pools (e.g. palmitic acid, acetate). 
The MAS patients who require ECMO have relatively low surfactant pool sizes even 
though five of the seven patients received surfactant treatments that contained more 
than 50 mg/kg PC. However, most surfactant treatments were given in the first 24 hours 
of life, whereas the age of start of the study was ~59 hours. As the half-life of the exoge-
nous surfactant is ~22 hours in the MAS patients, more than 50% of the administered sur-
factant treatment already disappeared by the time the study was started. 
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The endogenous surfactant metabolism was measured in CDH patients (n=11) and MAS pa-
tients (n=11) on ECMO, and compared with ventilated term control patients without sig-
nificant lung disease (n=10) (Chapter 6 & 7). Results and comparison with other patients 
and precursors are shown in Table 1. Surfactant PC synthesis was decreased in CDH pa-
tients on ECMO compared to controls (∼2.4 versus ∼8.0 %/day). The maximal enrichment 
was lower (∼0.09 versus ∼0.18 atom percent excess (APE)), and the time of maximal en-
richment was reached later (∼69 versus ∼47 hours) in CDH patients on ECMO. The half-life 
of endogenous surfactant was similar in both groups (∼65 hours), as was the surfactant PC 
concentration in ELF. These data reflect less surfactant synthesis in the CDH group. 
In the study of the MAS patients, we included a group of term neonates with persistent 
pulmonary hypertension (PPHN) who required ECMO (n=6). In MAS patients on ECMO the 
maximal incorporation of 13C in PC was half of that in controls (∼0.09 versus 0.18 APE). 
And there was a tendency of a lower FSR in the MAS patients (∼3.3 %/day) and PPHN pa-
tients (∼2.6 %/day) compared to controls (∼8.0 %/day), which was also reflected by a 
lower PC concentration in ELF in the MAS (∼4 mg/ml) and PPHN (∼4 mg/ml) patients com-
pared to controls (∼13 mg/ml). The half-life of endogenous surfactant was similar in all 
groups, ranging from 63-98 hours. In conclusion, a disturbed surfactant synthesis and con-
centration is suggested in at least the sickest MAS patients who require ECMO. 
The decreased FSR with the normal surfactant pool size (chapter 5) in CDH patients who 
require ECMO seems contradictionary, but could be explained by the fact that these se-
verely sick patients use other precursors (e.g. palmitic acid) than glucose for the synthesis 
of surfactant. Another explanation could be that CDH patients have originally a normal 
FSR, which however decreases due to damage of type II cells by intensive ventilation. As it 
takes some time before a decreased FSR leads to a decreased surfactant pool size, we did 
not yet find a decreased pool size in the CDH patients. 
 
 
We were able to study the surfactant metabolism in 5 patients with an inherited surfac-
tant SP-B deficiency (Chapter 8). This rare and lethal neonatal lung disease was originally 
described by Nogee et al. (24). The lungs of the SP-B deficient neonate show major ultra-
structural changes, disorganized tubular myelin and lamellar bodies, and pro SP-C, but no 
mature SP-C. Because loss of SP-B has such an impact on the stucture and functioning of 
type II cells of the lung, we expected a severely disturbed surfactant PC metabolism. 
However, we found no difference in surfactant PC metabolism in SP-B deficient patients 
compared to controls (Table 1). Our results are in accordance with studies in SP-B knock-
out mice and in vitro studies in autopsy lungs of SP-B infants (190, 194). In one SP-B defi-
cient patient we used another precursor (13C-palmitic acid instead of 13C-glucose) to study 
the surfactant metabolism. The FSR in this patient, after infusing 13C-palmitic acid was 65 
%/day, which is much higher compared to the FSR from the control patients (∼17 %/day, 
n=5). It could be that the relative contribution of precursors for surfactant synthesis 
changes in states of disease or congenital malformation. CDH patients not on ECMO had a 
similar FSR as control patients after 13C-palmitic acid infusion (∼22 versus ∼17 %/day) (57). 
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However, after 13C-glucose infusion in CDH patients on ECMO, these CDH patients had a 
significant lower FSR from glucose compared to controls (∼2.4 versus ∼8.0 %/day). 
All the SP-B deficient infants received various treatments, including exogenous surfac-
tant administration and dexamethason. From earlier studies it is known that exogenous 
surfactant treatment and dexamethason have stimulating effects on surfactant synthesis 
(63, 244, 262, 285). It is therefore possible that we measured an overestimation of the 
‘actual’ FSR. However, because these SP-B deficient infants were also intensively venti-
lated, the effect of an overestimated FSR due to the treatment with exogenous surfactant 
and dexamethason could be counteracted. 
 
 
Limitations of the studies 
The randomization of the infants to either HFO or conventional ventilation was subopti-
mal. Randomization was started at 24 hours after birth, but infants who already received 
HFO as part of their routine care continued to receive it. Furthermore, the CDH and MAS 
patients were not randomized to receive ECMO treatment, which is ethically not possible. 
Moreover, because infants have to be intubated for at least three days for reliable calcu-
lations of surfactant kinetic parameters, only the sickest infants were included in the 
study.  
As this kind of studies are expensive and laboratory analyses intensive, it is difficult to 
study large series. Especially, inclusion of control patients is difficult, as these patients 
have to be ventilated for at least three days without having significant lung disease. This 
is also the reason why we were not able to include age-matched control infants in the 
study about surfactant metabolism in SP-B deficient patients (Chapter 8). 
We used tracheal aspirates to collect alveolar surfactant PC. Theoretically, a more ac-
curate method could be bronchoalveolar lavage (BAL), but this method cannot be used for 
frequent sampling in the studied population. However, the PC concentrations we meas-
ured in tracheal aspirates of CDH patients on ECMO and control patients did not differ 
from the PC concentrations measured in BAL fluid of CDH patients on ECMO and ventilated 
control patients (100). Furthermore, it is known that the phospholipid composition in tra-
cheal aspirates and BAL are similar, just like the 13C enrichment of palmitic acid of surfac-
tant PC was similar in tracheal aspirates and BAL (262). And as all tracheal aspirates were 
handled similarly in all studies, any accuracy would have occurred in all patient groups 
probably to the same extent. Loss of surfactant during the handling of the tracheal aspi-
rates does not influence the measurement of 13C or 2H enrichment in surfactant PC palmi-
tate. Enrichment is measured by mass spectrometry by direct measurement of the ratio of 
labeled versus unlabeled palmitic acid in surfactant PC. This ratio is not influenced by 
sampling size or loss during preparation. 
In the studies of this thesis we only studied the palmitic acid metabolism of surfactant 
PC. Surfactant PC composes of different components (i.e. glycerol, choline, phosphate, 
and different fatty acids) which probably have different metabolism. Other components of 
surfactant, such as some surfactant proteins are also important for proper functioning of 
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surfactant. However, in none of our studies the metabolism of surfactant proteins was 
studied. 
We used 13C-glucose as precursor to study the metabolism of endogenous surfactant PC 
palmitate (Chapter 3, 6, 7 & 8). Incorporation of 13C molecules derived from labeled 
plasma glucose and palmitic acid was measured. Palmitic acid in the type II cell can also 
be synthesized from other substrates like glycogen, intracellular palmitic acid, ketone 
bodies, glycerol and lactate. The surfactant PC synthesis (FSR) we measured by infusing 
13C-glusose is therefore probably an underestimation. Moreover, calculation of the ‘true’ 
FSR is only possible from the enrichment of the direct precursor, which is acetylCoA. The 
enrichment of acetylCoA in the type II cell cannot be measured, and therefore we calcu-
lated FSR from plasma precursor enrichments. 
Most of our included patients were on ECMO during the study. The exact effect of ECMO 
on the surfactant metabolism could not be distinguished in the present studies. During 
ECMO the lung blood flow is lower, and it could be speculated that a reduced blood flow 
through the lungs provides less substrate for surfactant synthesis. Secondly, as physical 
stretch is low during ECMO treatment due to the low ventilatory settings as part of the 
concept of “lung rest”, this could possibly decrease surfactant synthesis (235). And finally, 
a result of ECMO treatment is an increase in capillary permeability (280), which together 
with a release of cytokines change surfactant function (282, 286). This is even more plau-
sible in an ECMO population in whom lung damage before ECMO may contribute to capil-
lary protein leakage. But overall, it seems clear that patients who require ECMO have 
more damaged lungs compared to patients who do not require ECMO treatment, which 
could be the reason of the disturbed surfactant metabolism. And sick lungs will be even 
more damaged due to the intensive ventilation prior to the ECMO treatment. Unfortu-
nately, we did not have enough CDH and MAS patients who did not require ECMO to use as 
‘control’ for ECMO treatment. In a study by Cogo et al. surfactant metabolism was studied 
in CDH patients not on ECMO (57). After infusion of 13C-palmitic acid they found no differ-
ence in surfactant synthesis compared to control patients. These contradictory results 
could be due to the use of another precursor, to the fact that these infants did not re-
quire ECMO, and therefore had less severe lung disease, or to the influence of ECMO on 
surfactant metabolism. But also in patients who are not on ECMO, the role of the treat-
ment and ventilation before the start of the study on the surfactant metabolism could not 
be elucidated. 
Another important confounder is the use of feeding. The patients were not standardized 
for the start of the parenteral and/or enteral feeding, nor for the composition of the 
feedings. A recent publication suggests an effect of the dietary fatty acid composition on 
pulmonary function (287). Increased unsaturated fatty acids in the diet of critically ill pa-
tients could affect surfactant function detrimentally. Most of the included patients re-
ceived Intralipid as parenteral feeding. Intralipid could be a substrate of surfactant syn-
thesis, and if so, it would dilute the precursor pool and give an underestimation of the 
FSR. 
It is difficult to interpret the half-life of surfactant. The half-life measures the decrease 
in amount of tracer relative to the pool with which it is mixing. In the lung, there are pri-
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marily two pools, the intracellular pool and the alveolar pool. The half-life measurements 
is a composite of the loss of the tracer due to catabolism within the lung and the dilution 
of the tracer due to synthesis of newly unlabeled surfactant. In the newborn lung re-
cycling of surfactant is very efficient and exceeds 90% in animal studies (47, 274). Effi-
cient recycling of surfactant can contribute to a longer surfactant half-life. In our studies 
it was not possible to discriminate between newly synthesized surfactant and recycled 
surfactant. 
The method we used to calculate surfactant pool size (chapter 4 & 5) needs more stan-
dardization. The apparent lung PC pool size was calculated by using the linear regression 
line representing the decay of the log-transformed 2H-enrichment over time. The start and 
the length of the enrichment versus time curve used for pool size calculation is decisive 
for the calculation of the surfactant pool size. We tried to standardize the method in the 
study of the term infants with severe lung disease by defining the start of the curve at 18 
hours after the administration of the label, and the length at four times the half-life of 
each individual curve. The method of surfactant pool size measurement is derived from 
the compartment model which has extensively been described by Jacobs et al (47). Three-
day-old rabbits were injected endotracheally with radioactive labeled DPPC. They de-
scribed a rapid initial fall of the specific activity in the alveolar wash after the delivery of 
the labeled DPPC, followed by a more gradual decay, and finally by a long slow decay. The 
initial rapid phase represents the deposition of the label in the large airways, and the dis-
tribution from the large airways to the alveoli. The second phase corresponds to the dis-
appearance of the label from the alveolar space to the intracellular lamellar bodies. Fi-
nally, the third slow phase reflects the disappearance of the label from the total lung. 
However, in the 2H-enrichment versus time curves of the baboons and the term infants 
with severe lung disease it was difficult to distinguish the two slower phases, which repre-
sent the metabolism of surfactant. Therefore, it was not quite clear what we measured: 
the alveolar surfactant pool, the total surfactant pool, or a mix of both. By extrapolating 
the tracer dilution from measurements beginning 18 hours after tracer administration, we 
probably measuring an estimate of the total lung surfactant pool because of the assump-
tion that recycling will have resulted in mixing of the alveolar and tissue pools by 18 
hours. The fact that we could not distinguish between the two metabolic phases, could 
suggest a disturbance of mixing of the label by recycling between the alveolar and tissue 
pools.  
Measurements of surfactant half-life and pool size by the isotope dilution method (Fick 
principle) are based on several assumptions. One of these assumptions is that the lung is 
in steady state for surfactant metabolism. However, the lungs and surfactant pools are 
likely to be changing as a normal developmental process if for no other reasons. 
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Directions for future research 
As we did not have age-matched control patients to compare with SP-B deficient patients, 
it is relevant to study the effect of age on surfactant metabolism. Two of our control pa-
tients were included at day 11 and day 18 of life, and had a higher FSR of ~21 %/day. 
However, in a study in which labeled acetate was given to term controls with and without 
respiratory failure no correlation existed between the age at start of the study and the 
FSR (56). Surfactant metabolism should be measured in term control patients, shortly af-
ter birth, in the second week, and for example at 3 months of age. 
Moreover, surfactant metabolism could be measured twice in the same patient. Bohlin 
et al. performed two studies 3 weeks apart (at age 24 and 45 days) in one control patient 
(56). They found nearly identical enrichment curves and metabolic indices (FSR 25.4 and 
25.2 %/day, half-life 25.0 and 25.4 hours). To study the course of surfactant metabolism 
during ECMO, a patient who requires ECMO could be studied twice, at the beginning of the 
ECMO run and one week after the start of ECMO, or just after ECMO treatment is ended. In 
this way the effect of ECMO on surfactant metabolism could be studied.  
All our patients were already ventilated for some days before the start of the study. Es-
pecially in sick lungs, ventilation can cause even more damage and may disturb surfactant 
metabolism. A way to measure the effect of CDH on surfactant metabolism without the in-
fluence of therapy or ventilation, is to measure surfactant metabolism in lung tissue ac-
quired postmortem from CDH patients who died at birth. This kind of study was also per-
formed by Beers et al. in lungs from SP-B deficient infants (194). But in that case we have 
to keep in mind that we are studying the worst cases of CDH, in vitro. 
The study of the metabolism of the specific surfactant proteins would contribute to a 
better understanding of the overall surfactant metabolism. The surfactant proteins play a 
critical role in the formation and functioning of the surfactant monolayer as well as in the 
regulation of the surfactant metabolism (16). Decreased SP-A levels have been found in 
tracheal aspirates of human neonates with CDH (57, 99) and infants with pneumonia (209). 
Recently, we were able to demonstrate a secondary SP-B deficiency in MAS patients, ei-
ther caused by degradation of SP-B or by disturbed SP-B metabolism (Personal communica-
tion, F. van Iwaarden, Rotterdam).  
We studied the metabolism of endogenous surfactant PC by using labeled glucose. Our 
data give valuable information but methodological problems remain. As I already pointed 
out in the summary and interpretation of the studies we used plasma enrichments instead 
of direct precursor enrichments to calculate FSR. With the use of multiple isotopomer dis-
tribution analysis (MIDA) it is possible to determine isotopic enrichment of the direct pre-
cursor pool (56, 288). But also this technique does not account for the incorporation of 
unlabeled palmitic acid from plasma into surfactant PC. Furthermore, the use of a more 
direct precursor could be used to reflect more directly surfactant metabolism (e.g. li-
noleic acid, palmitic acid, choline, glycerol). 
Metabolic measurements are just one part of understanding surfactant function. In fu-
ture studies we also should study alterations in surfactant aggregate forms and surfactant 
function, which could be more disturbed even though surfactant metabolic measurements 
are unchanged (289).  
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Samenvatting 
 
Surfactant is een stofje in de longen dat ervoor zorgt dat de longblaasjes (= alveoli) kun-
nen ontplooien bij de inademing en open blijven bij de uitademing. Via de longblaasjes 
wordt zuurstof vanuit de lucht naar de bloedbaan getransporteerd, en koolstofdioxide 
vanuit het bloed via de lucht afgevoerd. Indien er te weinig surfactant in de long aanwezig 
is, zullen de longblaasjes samenvallen en daardoor zal de opname van zuurstof en de af-
gifte van koolstofdioxide ernstig belemmerd worden. Een tekort aan surfactant is de oor-
zaak van het Respiratoir Distress Syndroom (RDS), dat vaak optreedt na de geboorte van te 
vroeg geboren kinderen. 
Surfactant bestaat hoofdzakelijk uit vetten (90%), voornamelijk (70-80%) fosfatidylcholine 
(FC) en eiwitten (10%). Er bestaan 4 surfactant eiwitten, SP-A, SP-B, SP-C en SP-D, met 
ieder een specifieke functie. Surfactant wordt in de type II cel van de long geproduceerd 
en opgeslagen als lamellaire structuren in de cel. Na uitscheiding van surfactant naar het 
longblaasje, vespreidt het zich als een zeer dunne laag over het totale longoppervlak. De-
ze dunne laag verlaagt de oppervlaktespanning tussen lucht en het longblaasje waardoor 
het longblaasje open blijft. Na enkele ademteugen wordt surfactant afgebroken en gro-
tendeels door de type II cel weer opgenomen en hergebruikt, een klein deel wordt afge-
voerd.  
Tijdens het laatste trimester van de zwangerschap is er een geleidelijke toename van de 
hoeveelheid surfactant in de foetale longen. Bij de geboorte worden grote hoeveelheden 
surfactant uitgescheiden in de longblaasjes, zodoende kunnen de longen zich direct na de 
geboorte voldoende ontplooien en kan een adequate gasuitwisseling plaatsvinden. De hoe-
veelheid surfactant in de longen verandert met de leeftijd; naarmate men ouder wordt, 
daalt de hoeveelheid surfactant in de longen. 
Studies in dieren tonen een langzamere aanmaak en afbraak (=metabolisme) van surfac-
tant in pasgeborenen en te vroeg geborenen in vergelijking met oudere dieren. In pasge-
borenen speelt hergebruik (recycling) van surfactant een grote rol, terwijl in oudere die-
ren meer aanmaak van nieuw surfactant plaatsvindt. Het metabolisme van surfactant 
werd recent bestudeerd in te vroeg geboren kinderen met behulp van stabiele isotopen. 
Deze studies toonden ook dat de aanmaak en afbraak van surfactant in deze groep kinde-
ren langzaam verloopt. 
 
Naast RDS, dat voorkomt bij te vroeg geboren kinderen, zijn er een aantal longziekten bij 
pasgeborenen (neonatale longziekten) waarbij een tekort aan surfactant ook een rol zou 
kunnen spelen. Enkele neonatale longziekten, zoals congenitale hernia diafragmatica 
(CDH), meconium aspiratie syndroom (MAS), surfactant proteïne B (SP-B) deficiëntie en 
neonatale pneumonie (= long ontsteking) worden in Hoofdstuk 1 besproken. Het hoofdstuk 
geeft een overzicht van de literatuur over het metabolisme van surfactant in relatie tot 
de bovengenoemde ziektebeelden. 
Neonaten met CDH hebben een gat in het middenrif, dat al vroeg in de zwangerschap is 
ontstaan. Ten gevolge van het defecte middenrif komt een deel van de buikorganen in de 
borstholte te liggen waardoor de long onvoldoende ruimte heeft om zich adequaat te ont-
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wikkelen. Het is echter nog steeds niet duidelijk of deze neonaten met ‘onrijpe’ longen 
ook een tekort aan surfactant hebben.  
Bij MAS is er sprake van aspiratie (= verslikking) van vruchtwater met meconium (= eerste 
ontlasting), waardoor er meconium in de longen terechtkomt. Meconium heeft een rem-
mend effect op de functie van surfactant. Het is echter nog de vraag of er naast deze in-
activatie van surfactant ook een tekort aan surfactant een rol speelt in MAS. 
SP-B deficiëntie is een aangeboren genetische afwijking waarbij er geen SP-B (1 van de 4 
surfactant eiwitten) wordt aangemaakt in de long. Daarnaast is er ook een verstoring van 
de intracellulaire structuren in de type II cel van de long. Het gevolg is dat deze kinderen 
na de geboorte ernstige ademhalingsproblemen krijgen. Kinderen met een SP-B deficiëntie 
zullen overlijden mits er een longtransplantatie zal worden uitgevoerd. De rol van het ge-
netische defect op het metabolisme van surfactant is bestudeerd in muizen, maar studies 
in levende mensen zijn nog niet verricht.  
Een pneumonie in pasgeborenen komt regelmatig voor, met name in te vroeg geboren kin-
deren. Het kan worden veroorzaakt door een bacterie, virus of een schimmel. Studies la-
ten zien dat pneumonie een effect heeft op de functie van surfactant. Tevens daalt de 
concentratie van surfactant in de longen indien er sprake is van een pneumonie. Echter, 
de meeste studies zijn verricht in dieren of volwassen mensen. Over de rol van een neona-
tale pneumonie op het metabolisme van surfactant in pasgeboren kinderen is weinig be-
kend. 
 
Eerder onderzoek van het metabolisme van surfactant in te vroeg geboren kinderen en het 
bovenbeschreven literatuur overzicht hebben aanleiding gegeven tot de vraagstellingen 
die in hoofdstuk 2 beschreven zijn: 
 
1. Heeft beademing met hoge frequentie (high frequency oscillation) een remmend 
of stimulerend effect op de aanmaak van surfactant bij te vroeg geborenen met 
RDS? 
2. Hoe verloopt de aanmaak en afbraak (= metabolisme) van surfactant en de hoe-
veelheid surfactant in de longen (= pool size) gedurende de ontwikkeling van 
bronchopulmonaire dysplasie (= chronische long ziekte die soms ontstaat na RDS)? 
3. Hoeveel surfactant hebben pasgeboren kinderen met verschillende longziekten? 
4. Is het metabolisme van surfactant in pasgeboren kinderen met congenitale hernia 
diafragmatica, pasgeboren kinderen met een meconium aspiratie syndroom en 
pasgeborenen met een surfactant proteïne B deficiëntie verschillend ten opzichte 
van pasgeboren kinderen zonder longziekte? 
 
De meeste kinderen beschreven in dit proefschrift zijn zo ziek dat ze aan een ‘long ma-
chine’ liggen. Dit machine wordt in de studies ‘extracorporeal membrane oxygenation’ 
(ECMO) genoemd. Met behulp van een pomp wordt bloed via een canule uit het kind langs 
een ‘kunst-long’ geleid en van zuurstof voorzien. Na verwarming stroomt het zuurstofrijke 
bloed weer naar het lichaam. Op deze wijze wordt het kind van zuurstof voorzien, wordt 
koolstofdioxide afgevoerd en hebben de zieke longen tijd te herstellen. 
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Het metabolisme van surfactant is bestudeerd met behulp van stabiele isotopen. Stabiele 
isotopen zijn atomen met 1 extra neutron in hun kern, waardoor ze als het ware ‘gemerkt’ 
zijn. Het zijn veilige stoffen, die niet vervallen zoals gebeurd bij radio-actieve isotopen. 
In dit proefschrift hebben we gebruik gemaakt van 2 verschillende soorten stabiele isoto-
pen: het stabiele isotoop van waterstof en het stabiele isotoop van het koolstof-atoom. De 
toediening van deze 2 verschillende isotopen gebeurde op verschillende wijzen. Ten eer-
ste, gelabeld dipalmitoylfosfatidylcholine (= belangrijkste actieve component van surfac-
tant) (2H-DPPC) werd via de luchtpijp toegediend. Na toediening mengt 2H-DPPC zich in 
het longblaasje met het aanwezige ongelabelde surfactant en zal worden opgenomen door 
de type II cel waar menging met het intracellulaire surfactant zal plaatsvinden. Uiteinde-
lijk zal het label geleidelijk uit de longen verdwijnen. Door de verdwijning van het label 
te meten, kan de half-waardetijd van 2H-DPPC en de pool size (totale hoeveelheid) van 
fosfatidylcholine worden berekend. 
De verdwijning van het label (2H) uit de long werd gemeten in trachea-aspiraten. Een tra-
chea-aspiraat wordt verkregen door slijm uit de beademingsbuis te zuigen, iets wat routi-
nematig regelmatig wordt gedaan in beademde kinderen om verstopping van de beade-
mingsbuis te verkomen. Uit het trachea-aspiraat wordt surfactant fosfatidylcholine geïso-
leerd. Met behulp van speciale apparatuur kan de verhouding tussen het gelabelde en on-
gelabelde fosfatidylcholine worden gemeten. 
De andere methode is toediening van stabiele isotopen in de vorm van een 24-uurs infuus 
met [U-13C]glucose, om vervolgens de inbouw van het 13C-isotoop in surfactant te vervol-
gen. Het 13C-isotoop in de glucose wordt door de longen gebruikt om de vetzuren van 
surfactant fosfatidylcholine te maken. Als dit 13C wordt aangetoond in surfactant, dan is 
het surfactant ‘verrijkt’. De snelheid van inbouw en verdwijning van 13C is een maat voor 
de surfactant aanmaak en verdwijning. Eenvoudig gesteld geldt dat hoe meer 13C in 
surfactant fosfatidylcholine gemeten wordt, des te hoger de aanmaak van surfactant 
fosfatidylcholine is. In deze methode werd surfactant fosfatidylcholine eveneens 
geïsoleerd uit trachea-aspiraten. 
 
Eerdere studies toonden dat surfactant therapie na de geboorte en toediening van cortico-
steroïden voor de geboorte van het kind (= prenataal) een stimulerende invloed hebben op 
de eigen (= endogene) productie van surfactant. Fysieke rek van de longblaasjes is ook 
een stimulus voor de surfactant productie. Tijdens normale (= conventionele) beademing 
vindt er herhaaldelijke uitzetting van de longblaasjes plaats. Deze uitzetting zorgt voor 
stimulatie van de productie van surfactant en uitscheiding naar de longblaasjes. Echter, 
tijdens high frequency oscillation (HFO), is de stretch van de longblaasjes veel kleiner. Dit 
zou kunnen resulteren in een verminderde surfactant productie. Het effect van HFO be-
ademing op het surfactant metabolisme in te vroeg geboren kinderen hebben we bestu-
deerd (Hoofdstuk 3). De fractionele synthese snelheid (FSR) van surfactant was niet ver-
schillend tussen de kinderen die conventioneel beademd werden en kinderen die middels 
HFO beademd werden (4.7 versus 4.2%/dag). Een fractionele synthese snelheid van 
4.5%/dag betekent dat ongeveer 4.5% van de totale hoeveelheid surfactant FC per dag uit 
glucose wordt aangemaakt. De half-waardetijd van endogeen surfactant was ook niet ver-
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schillend tussen beide groepen (∼79 versus ∼76 uren). Echter, bij kinderen die te vroeg 
waren geboren en die overleden ten gevolge van respiratoir falen leek de half-waardetijd 
van surfactant korter te zijn. 
 
Hoofdstuk 4 beschrijft een studie in te vroeg geboren bavianen. In deze bavianen is de 
half-waardetijd van surfactant en de ‘pool size’ (= de hoeveelheid surfactant in de longen) 
in de eerste 2 weken na de geboorte bestudeerd. De meeste studies over het metabolisme 
van surfactant zijn uitgevoerd direct na de geboorte. Er is weinig informatie over het me-
tabolisme van surfactant in de weken na de geboorte en/of tijdens de ontwikkeling van 
bronchopulmonale dysplasie (BPD). BPD is een chronisch ziektebeeld van de long dat soms 
ontstaat nadat een te vroeg geboren kind RDS heeft doorgemaakt. De precieze oorzaak 
van BPD is nog onbekend, evenals het antwoord op de vraag of surfactant een rol speelt in 
de ontwikkeling van RDS naar BPD. De te vroeg geboren bavianen kregen 2H-DPPC via de 
luchtpijp op dag 5 na de geboorte en op dag 8 kregen ze radio-actief gelabeld surfactant 
via de luchtpijp toegediend. De half-waardetijd van het toegediende (exogeen) surfactant 
werd berekend en op dag 5 werd tevens een surfactant pool size berekend. De half-
waardetijd verkregen met behulp van de stabiele isotopen methode was vergelijkbaar met 
de half-waardetijd verkregen na toediening van radio-actief surfactant (ongeveer 30 uur), 
en toonde geen verandering in de 2e levensweek. De surfactant pool size op dag 5 was 
vergelijkbaar met de pool size op dag 6 uit een eerdere studie in bavianen en eveneens 
met de pool size bij autopsie op dag 14. Dus, de half-waardetijd en de pool size van sur-
factant veranderen niet in de tweede week na de geboorte tijdens de ontwikkeling van 
BPD.  
 
In hoofdstuk 5 wordt 2H-DPPC toegediend aan pasgeboren kinderen met een ernstige 
longziekte en een normale zwangerschapsduur. Er werden 3 groepen bestudeerd: een 
groep van kinderen met CDH aan ECMO (CDH-ECMO), een groep kinderen met MAS aan 
ECMO (MAS-ECMO) en een groep kinderen met verschillende diagnoses, niet aan ECMO 
(NON-ECMO). De half-waardetijd en de pool size van surfactant waren gelijk in de 3 groe-
pen. Waarschijnlijk hebben kinderen met CDH of MAS aan ECMO geen tekort aan surfac-
tant in hun longen. Daarnaast werd er in deze studie ook een relatie gevonden tussen de 
surfactant half-waardetijd en de duur van ECMO. Kinderen waarbij de hoeveelheid surfac-
tant in de longen sneller vervangen werd (= kortere half-waardetijd), toonden een snelle-
re klinische verbetering en hadden dus een kortere ECMO duur. 
 
Hoofdstuk 6 beschrijft de studie waarin het surfactant fosfatidylcholine metabolisme in 
kinderen met CDH wordt gemeten. Elf kinderen met CDH aan ECMO en 10 controle kinde-
ren (= kinderen die wel beademd werden, maar geen longziekte hadden) kregen geduren-
de 24 uur een infuus met gelabeld glucose. De inbouw van het label in surfactant werd 
vervolgd. De CDH-ECMO kinderen toonden een lagere surfactant aanmaak ten opzichte van 
de controle groep (FSR ~2.4 versus ~8.0%/dag). De surfactant half-waardetijd was in beide 
groepen gelijk (~65 uur). De surfactant fosfatidylcholine concentratie in de longvloeistof 
liet geen significante verschillen zien tussen de 2 groepen (~7 versus ~13 mg/ml). Het feit 
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dat kinderen met CDH wel een lagere productie van surfactant hebben maar geen lagere 
surfactant concentratie in de longen kan op verschillende manieren verklaard worden. Ten 
eerste kan het zo zijn dat hele zieke kinderen andere bouwstoffen in plaats van glucose 
gebruiken voor de productie van surfactant. Wij meten alleen de productie van surfactant 
uit glucose. Een andere verklaring is dat de FSR in kinderen met CDH bij de geboorte nor-
maal is, maar dat de FSR daalt door beschadiging van de type II cel ten gevolge van de in-
tensieve beademing die deze kinderen nodig hebben voordat ze aan ECMO gaan. Omdat 
het enige tijd duurt voordat de verlaagde FSR leidt tot een verlaagde surfactant concen-
tratie in de long, vinden wij nog geen verlaagde pool size in kinderen met CDH aan ECMO. 
 
Het surfactant fosfatidylcholine metabolisme in kinderen met MAS wordt beschreven in 
hoofdstuk 7. In deze studie zijn er behalve 11 kinderen met MAS aan ECMO en 10 controle 
kinderen, ook 6 kinderen met een zogenaamde persisterende pulmonale hypertensie 
(PPHN) aan ECMO, bestudeerd. Deze PPHN groep is een soort ‘controle’ groep om uit te 
sluiten dat de resultaten die we vinden niet het gevolg zijn van behandeling met ECMO. In 
zowel de MAS als de PPHN groep leek er een tendens tot een lagere FSR in vergelijking 
met de controle groep (~3.3 en ~2.6 versus ~8.0%/dag), echter de verschillen waren niet 
significant. De surfactant fosfatidylcholine concentratie in de longvloeistof was wel signi-
ficant lager in de MAS en de PPHN groep ten opzichte van de controle groep (~4 versus ~13 
mg/ml). Het lijkt er dus op dat de kinderen met MAS een verstoord surfactant metabolis-
me en concentratie hebben. Echter het is moeilijk na te gaan in hoeverre dit veroorzaakt 
wordt doordat de kinderen aan ECMO liggen. Behandeling met ECMO zou kunnen leiden tot 
een lagere FSR, doordat tijdens ECMO de bloeddoorstroming van de longen lager is dan 
normaal. Door minder aanvoer van bloed naar de longen, is er minder aanbod van bouw-
stoffen (o.a. gelabeld glucose) voor de productie van surfactant. Tijdens ECMO wordt het 
bloed door een ‘kunst-long’ van zuurstof voorzien en zijn de longen in een ‘rust-toestand’. 
Hierdoor is er tijdens ECMO minder rek van alveoli en daardoor minder surfactant produc-
tie. Een derde verklaring is dat er tijdens behandeling met ECMO een vergrote doorlaat-
baarheid van de bloedvatwand bestaat, waardoor er in de long stoffen kunnen komen die 
de functie van surfactant remmen, of surfactant afbreken. 
 
Hoofdstuk 8 beschrijft het surfactant fosfatidylcholine metabolisme in kinderen met een 
SP-B deficiëntie. SP-B deficiëntie is een ziektebeeld dat nog niet zo lang geleden ontdekt 
is en dat zeldzaam is. Vandaar dat er in deze studie maar 4 kinderen met dit ziektebeeld 
bestudeerd zijn. Ook in deze studie zijn de resultaten vergeleken met die van 10 controle 
kinderen. Er werd geen verschil gevonden in het surfactant fosfatidylcholine metabolisme 
van kinderen met SP-B deficiëntie en dat van controle kinderen. Deze resultaten komen 
overeen met de bevindingen van studies in dieren. Daarnaast hebben we 1 kind met een 
SP-B deficiëntie en 5 controle patiënten in plaats van gelabeld glucose, gelabeld palmi-
taatzuur gegeven. In dit kind werd een hoge FSR gevonden (63 %/dag versus 17 %/dag in 
controle kinderen). Dit zou verklaard kunnen worden door het gebruik van andere bouw-
stoffen voor de aanmaak van surfactant in zieke kinderen.  
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Prof. dr. H.A. Büller en Prof. dr. J.C. de Jongste wil ik hartelijk danken voor de 
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aan de oppositie. Prof. dr. F.W.J. Hazebroek dank ik voor zijn deelname aan de grote 
commissie. 
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interest in my studies and your enthusiasm about doing research, stimulated me. Steven 
Seidner, MD, PhD, dear Steven, thank you for giving me the opportunity to participate in 
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ergeneeskunde. Zonder de hulp van Ingrid Luijendijk was me dat niet gelukt. Ingrid, je 
hebt me wegwijs gemaakt in het wereldje van het lab en alle bloedsamples voor de 
studies bewerkt en geanalyseerd. Samen hebben we onze frustraties gedeeld en ook af en 
toe een lekker recept. Bedankt!  
Verder wil ik Darcos Wattimena bedanken voor zijn kennis van die verschrikkelijk gevoel-
ige apparatuur. Ad de Bruijn wil ik bedanken voor zijn bijdrage aan de ‘surfactant 
meetings’ en de eiwit bepalingen in trachea-aspiraten. Freek van Iwaarden, Freek jij 
bracht wat afleiding in het lab met je ratten operaties en je imposante proefopstellingen 
om surfactant eiwitten te isoleren. Succes verder in Maastricht. 
 
Het Algemeen Klinisch Chemisch Lab van het Sophia wil ik bedanken voor de snelle bepal-
ingen van de ureumconcentratie in de trachea-aspiraten. 
 
Afgelopen jaren hebben enkele studenten me geholpen bij het uitvoeren van de studies en 
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voor de gezelligheid, de goede tips, de borrels, etentjes, de Roparun en de AIO-
weekenden. De groep is inmiddels zo groot geworden dat ik me er niet meer aan waag 
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ASR     Absolute fractional synthesis 
BAL     Bronchoalveolar lavage 
BPD     Bronchopulmonary dysplasia 
CDH    Congenital diaphragmatic hernia 
DPPC    Dipalmitoyl phosphatidylcholine 
DSPC    Disaturated phosphatidylcholine 
ECMO    Extracorporeal membrane oxygenation 
Egluc     Mean plasma glucose enrichment 
Emax     Maximal enrichment 
FSR     Fractional synthesis rate 
GBS     Group B streptococci 
LPS     Lipopolysaccharide 
L/S     Lecithin/Sphingomyelin  
LysoPC   Lysophosphatidylcholine 
MAS     Meconium aspiration syndrome 
PC     Phophatidylcholine 
PE     Phosphatidylethanolamine 
PG     Phospatidylglycerol 
PI      Phosphatidlylinositol 
PPHN    Persistent pulmonary hypertension of the newborn 
RDS     Respiratory distress syndrome 
SP-B    Surfactant protein-B 
Tapp     Time of first appearance 
TAS     Tracheal aspirate 
Tmax    Time of maximal enrichment 
TRH    Thyrotropin-releasing hormone 
 
 

